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ABSTRACT OF THE THESIS

A Thesis on the Detection of Parkinson Disease Rest Tremor
by
Matthew Jonathan Johnson
Master of Science in Electrical Engineering
Washington University in St. Louis, 2014
Research Advisor: Dr. Arye Nehorai, Department Chair

Parkinson Disease (PD) is a debilitating and progressive movement disorder that is
estimated to affect over six million worldwide. One of the most characteristic symptoms of PD is
resting tremor, which involves unintentional and rhythmic muscle oscillations of an afflicted
extremity while the muscles of said extremity are relaxed. This study involved measuring the rest
tremor of 10 PD subjects, 10 Essential Tremor subjects, and 10 healthy control subjects using two
devices. One device was an FDA approved accelerometry system to measure human tremor known
as the TremorometerTM and the other was a consumer three-dimensional camera known as the Leap
MotionTM Controller. The study compares tremor characteristics calculated from both devices to
compare the Leap Motion Controller to the Tremorometer System. The tremor characteristics
obtained from the Leap Motion Controller were also used in an attempt to classify the subjects used
in the study as either PD or non-PD subjects.

x

Chapter 1
Introduction
1.1

Purpose
Parkinson Disease (PD) is a debilitating and progressive movement disorder

that affects over one million people in the United States alone. One of the most
characteristic symptoms of PD is resting tremor, as it has been shown that the
proportion of patients with resting tremor ranged from 69-100% in 3 series of patients
with autopsy-proven PD.1,2,3 Several methods currently exist to quantitatively measure
tremor including accelerometry, electromyography, the spirogram, and most recently
three-dimensional cameras.4
This study involves measuring the rest tremor of 30 human subjects, consisting
of 10 Parkinson’s subjects, 10 Essential Tremor subjects, and 10 healthy control
subjects to classify test subjects as either Parkinson or non-Parkinson. The rest tremor
was measured by recording the three-dimensional position and acceleration of their
index finger while at rest over a set period of time using two devices. The first device,
the TremorometerTM, has 510k clearance by the FDA to measure and quantify tremor
by measuring acceleration in human patients. The second device, the Leap MotionTM
Controller, is a three-dimensional camera that uses two CCD (Charged Coupled Device)
cameras, three infrared Light Emitting Diodes (LEDs), and preprocessing in order to
obtain position data.
The study was split into two sections. The first section, involves comparing the
Leap Motion Controller to the Tremorometer by calculating different tremor
characteristics and comparing them to determine if the two devices are statistically
1

similar. The second part of the study involves using those same characteristics in an
attempt to classify subjects as either Parkinson or non-Parkinson subjects.

1.2

Motivation
Advances in three-dimensional cameras have allowed for more accurate

recordings and can now be used to provide much more accurate measurements in
microdisplacements of upper extremities that are involved in movements such as resting
tremor. The Leap Motion Controller produced by Leap Motion, Inc., has been shown
to be capable of measuring changes in position of 0.2 mm for static setup and 1.2 mm
for a dynamic setup.5 The Leap Motion Controller requires no external sensors or
markers to be attached to the body unlike accelerometry, electromyography, and the
spirogram. One possible disadvantage of having sensors attached to the body is that for
every gram of additional mass a sensor adds, the peak frequency of finger tremor
decreases by approximately 0.85 Hz and can also have an affect the amplitude of
acceleration.6 Therefore the attached sensors may change the characteristics of the
tremor and thus could alter the interpretation of tremor. Attaching sensors to the body
can also be inconvenient, uncomfortable, and provide a margin of error if not done
correctly. Another advantage of the Leap Motion Controller over accelerometry is that
it does not require calibration, eliminating possible errors caused by consistent
recalibration. Unlike electromyography, the Leap Motion Controller is not affected by
interference from electrical sources, mechanical artifacts, stimulus artifacts, and the
electrical activity of muscles that are not of interest. It is for these reasons that the Leap
Motion Controller is of interest and may be a superior method for measuring tremor.

2

Chapter 2
Background
2.1

Parkinson Disease

2.1.1

Prevalence
According to the National Institute of Neurological Disorders and Stroke, at

least 500,000 people suffer from Parkinson Disease (PD) in the United States with
about 50,000 new cases reported annually.7 With more than 22,000 lives lost to PD in
2010, it was claimed to be the 14th leading cause of death in the United States by the
United States Centers for Disease Control and Prevention (CDC).8 As can be seen in
Figure 2.1, the age-adjusted death rate for PD has steadily increased since 1958.

Figure 2.1 Age-adjusted death rates for selected leading causes of death in the United
States between 1958 and 2010. Figure obtained from the CDC.8

3

In fact, it has been projected that the estimate of people with Parkinson’s
(PwPs) in 2005 is expected to double by 2030 in the world’s ten most populous nations
as shown in Figure 2.2.9

Figure 2.2 Projected number of People with Parkinson disease (PwP)
in the most populous nations between 2005 and 2030. Figure obtained
from Dorsey, et al (2007).

2.1.2

Symptoms
Although symptoms can vary significantly between individuals, the primary

motor symptoms involved with Parkinson Disease include: rigidity, postural instability,
bradykinesia and tremor.10
4

Bradykinesia

Bradykinesia refers to slowness of movement and

initially manifests as slowness in performing activities associated with daily living, slow
movement, and reaction times.10,11,12 Similar to other parkinsonian symptoms,
bradykinesia is dependent on the emotional state of the patient and is the Parkinson
characteristic that correlates best with the degree of dopamine deficiency.10,13
Rigidity

Rigidity is described as an increase in resistance while passively

stretching a muscle, causing a feeling of stiffness.14 Rigidity is sometimes accompanied
by the “cogwheel” phenomenon, which is the periodic interruption of rigidity on
passive movement of the limbs.15 Rigidity of the neck and trunk eventually leads to
changes in posture and postural deformities.
Postural Instability

Postural instability usually occurs during the late

stages of PD and typically after the onset of the other motor symptoms.10 It is the most
common cause of falls and the late onset of falls can differentiate PD from other
neurodegenerative disorders like progressive supranuclear palsy (PSP) and multiple
system atrophy (MSA). 10,16
Tremor

Tremor is defined as an involuntary rhythmic oscillation of a

body part. The characteristic tremor of PD, is usually a 3-6 Hz distal resting tremor, but
patients with PD may also exhibit postural and kinetic tremors.17-19 Rest tremor occurs
when a body part is at rest or relaxed while postural tremor occurs when a body part is
maintained at a position against gravity, and kinetic tremor occurs during the movement
of a body part. Rest tremor is such a characteristic feature of Parkinson’s that it has
been shown that the proportion of patients with resting tremor ranged from 69-100%
in three series of autopsy proven PD.1,2,3 In fact, rest tremor is the most common and
most recognizable symptom of PD, and is, by itself, a positive diagnostic criterion for
PD.10,20

5

2.2

Tremor Analysis
New technologies and methods that complement the clinical neurologic

evaluation are becoming more popular and useful by offering objective and quantitative
data that can be analyzed. In fact, difficult medical diagnoses can even be confirmed or
excluded on the basis of these additional tests. Since tremor is one of the most cardinal
symptoms of PD, tremor analysis has become one of the most useful of these new
methods to help differentiate tremor associated with PD from other types of tremor.21
Tremor analysis refers to the method of recording certain identifiable
characteristics of tremor and other involuntary movements through the use of
computers and other hardware. Since tremors are quasi-sinusoidal movements, they can
be approached using a quantitative mathematical analysis.21 Two of the most important
characteristics of tremor in tremor analysis, are the frequency and amplitude. Tremor
frequency refers to the number of oscillations per second and is usually measured in
cycles per second (Hz), while tremor amplitude refers to the degree of linear or angular
displacement of the limb and is typically measured in degrees or millimeters. Tremor
analysis is most useful when the clinical signs are subtle, such as distinguishing between
Parkinsonian tremor and essential tremor.22

2.2.1

Commonly Used Methods
Accelerometry

Accelerometry is accomplished through the use of

accelerometers that measure static or dynamic acceleration forces. Miniature
accelerometers can be attached to the afflicted body part, which are typically the limbs,
and usually do not interfere with voluntary or involuntary movements. Mathematical
integration is needed to determine the displacement of the oscillating body part and to
better perceive the sinusoidal motion of the tremor.21
Electromyography

In electromyography (EMG), typically surface electrodes

are fixed on the flexor and extensor muscles of the limb to measure the electrical
6

activity produced by the muscles involved in the generation of the tremor. However,
EMG activity can also be measured using needle or wire electrodes.23 The EMG signal
should be processed by rectification and integration or smoothing to properly place its
frequency profile into the tremor range.24
Spirogram

Spirograms are less common than the other methods, but are

performed by analyzing a drawing made by the patient of models of Archimedes’
spirals. This method is based on essentially “unraveling” the two-dimensional drawn
spiral to determine kinematic data. This kinematic data is collected in the X, Y, and
pressure axes, which essentially provides a virtual tri-axial recording of data. By
analyzing multiple trials together, tremor characteristics such as frequency, direction,
and amplitude can be detected and quantified.
Optical Systems

Optical systems consist of a light source and an optical

sensor. Some examples of laser-based systems are displacement lasers and velocity
transducing lasers and have been previously used to record kinematic data associated
with tremor in PD.25,26 Other optical systems include vision systems and essentially
involve a sensor and an emitter, such as infrared cameras, which are used in many
commercial motion capture systems.27,28 These vision systems can be used to measure
and record the three-dimensional position of the body part exhibiting tremor with
respect to time and can then be used to calculate velocity, acceleration, and other
characteristic parameters.

2.2.2

Tremorometer
The Tremorometer is an accelerometer-based system produced by FlexAble

Systems, Inc. that has received FDA 510 (k) approval to measure and quantify tremor in
human patients. The system consists of two major components: the TremorScope and
the TremorLab.

7

TremorScope Sensor
The TremorScope sensor has a tri-axial accelerometer that measures in all three dimension
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Figure 2.3 TremorScope. Image obtained from Tremorometer System
Manual.
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Analysis (Advanced) runs the program that lets two sets of readings be compared in many formats
Most of the work in TremorLab is done on the Main screen that consists of controls and indicators. These are
basically grouped into five color-coded categories:
Test Controls (brown) are used to select Protocols, Start the test, Show Tremor and other operations.
Display Controls (gold) select display resolution, type of display and readings mode.
Report Controls (green) setup reports, control the report generation, show the TREM Table results.
File Controls (yellow) include Patient ID, Record ID and other items relating to the report files.
Prompts (blue) have information about running the system and Tutorials.

Main TremorLab
Screen showing
the Controls
and from
Indicators.
Figure2.4 Screenshot
of TremorLab.
Image
obtained
the Tremorometer System
Manual.
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2.2.3

Leap Motion Controller
The Leap Motion Controller, shown in Figure 2.5, is a USB 3D camera that

connects to a computer and is claimed to measure positional data accurate to within
0.01 mm. The device, made by Leap Motion, Inc., is very small with a height of 1.27 cm,
a width of 3.05 cm, a depth of 7.62 cm, and only weighs 45.36 g. The Leap Motion
Controller uses two CCD (Charged Coupled Device) cameras and three infrared LEDs
to obtain depth information. As illustrated in Figure 2.6, on the following page, the
device is capable of detecting a roughly hemispheric area of about 0.23 cubic meters.

Figure 2.5 The Leap Motion Controller. Image
obtained from Leap Motion, Inc.29
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Interaction Area

2 feet above the controller, by 2 feet wide on each side
(150° angle), by 2 feet deep on each side (120° angle)

Figure 2.6 Interaction Area of Leap Motion Controller.
Image obtained from Leap Motion, Inc.29

Output

The Leap Motion Controller is capable of detecting and tracking

hands, fingers, and tools in its field of view. The device captures data one frame at a
time and the rate at which this occurs, or frame-rate, can vary based on the lighting
conditions, but typically occurs at approximately 100 frames per second (fps). The
device is capable of recording the three dimensional fingertip positions, which is done
in millimeters relative to the device’s origin. The Leap Motion Controller follows a
right-handed Cartesian coordinate system, with the origin centered at the top and
middle of the Leap Motion Controller as shown in Figure 2.7. The data from the Leap
Motion Controller is accessible using the Leap SDK and a supported programming
language such as C++, C#, Objective-C, Java, JavaScript, and Python.

Figure 2.7 The Leap Motion Controller righthanded coordinate system. Image obtained from
the Leap Motion Developer Portal.29
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Chapter 3
Methodology
A description of the methodology will include information about the setup
required for the devices used, the subject groups, the recruitment and consent process,
as well as the ethical considerations involved. A more in-depth methodology of the
study can be seen in the attached Protocol, located in the Appendix.

3.1

Device Setup
The two devices that were used in this study were the Tremorometer and Leap

Motion Controller. These devices required an initial setup, which will be described in
this section.

3.1.1

Tremorometer
For the purposes of this study, the Custom module of the TremorLab 2013

Software Program was used. This module allows the user to use the system for custom
controlled tremor experimentation and supports different lengths of recording (from 5
to 180 seconds) as well as custom test protocols.
One custom test protocol was developed for this study, which involved
measuring rest tremor of the index finger of the hand that exhibited the most severe
rest tremor. This protocol consisted of two separate trials, each lasting for thirty
seconds, and was run once for each participant. Once the protocol was run, the data
was labeled to identify the participant number and whether the participant was part of
11

the healthy, Parkinson, or Essential Tremor group. This data was then saved to a
HIPAA compliant secure flash drive for later analysis.

3.1.2

Leap Motion Controller
To use the Leap Motion Controller for the purposes of this study, a stand-alone

Java program was written in order to access and record the positions detected by the
Leap Motion Controller. The Leap Motion Skeletal V2 Beta SDK for Java, obtained
through the Leap Motion Developer Portal, was used in writing the program to provide
more robust hand tracking even if the fingers or hands were partially occluded. The
Leap Motion Java SDK utilizes a standard Jar file for Leap Motion API class definitions
as well as a set of native libraries that allow the Leap-enabled Java program to exchange
data with the Leap Motion Controller. The Eclipse platform was used to write the code
necessary to access and record the data obtained from the device for thirty seconds.
The stand-alone Java program that was written, recorded the position of each
fingertip on the hand that exhibited the most tremor. The code was run twice for each
participant and each time it was run, it saved a separate comma delimited CSV file to a
HIPAA compliant secure flash drive with a filename that identified an arbitrary
participant number, the trial number, and whether the data was from a participant from
the Healthy Control, Parkinson Disease, or Essential Tremor group.
The Leap Motion Controller itself was also attached to the ramp used to
support the participants’ arm during the recordings. It was positioned approximately 6
cm below where the base of the hand rested. The Leap Motion Controller was oriented
such that the Z-axis was vertical and increased in the upward direction; the Y-axis was
parallel with the horizon and increased moving away from the ramp.
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3.2

Subject Selection
There were a total of thirty individuals who participated in this study. These

thirty individuals were divided up into the different groups as follows: 10 patients with
Parkinsonism with tremor based on diagnostic criteria30, 10 patients with Essential
Tremor based on diagnostic criteria31, and 10 healthy subjects. All potential participants
had to be over the age of 18, could be either male or female, could be of any race or
ethnicity, and had to have the ability to give informed consent. A history of stroke,
cerebral palsy, additional neurological disorders, severe upper limb tremor, and
cognitive impairment (A Mini-Mental State Score less than 19) were set as exclusion
criteria for all participants since the possible inclusion of these criteria could negatively
affect the data.

3.3

Subject Recruitment and Consent Process
Participants were recruited from the Movement Disorders Center at

Washington University School of Medicine as well as the Volunteer for Health initiative
of Barnes-Jewish Hospital, an affiliate of the Washington University School of Medicine
with a pool of over 8,000 volunteers. The clinical database in the Washington University
Movement Disorders Clinic follows a large number of patients that met the criteria set
for the study, making it a practical choice for recruitment.
Participants were recruited in person during their clinic visits with their
physician or nurse. If the potential participant expressed interest in the study and fit all
inclusion/exclusion criteria, informed consent materials were provided. A study team
member reviewed the document with the potential participant, which gave the
participant an opportunity to ask questions. Potential participants were then given time
to read the document in its entirety, ask questions, and speak with friends/family
members if they desired. If the potential participants agreed to participate in the study,
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they signed the informed consent, and were offered a signed copy of the consent after
both parties signed the document.

3.4

Study Procedures
All participants, including the control participants, followed the same procedure.

Each participant was measured individually, twice with the Tremorometer and twice
with the Leap Motion Controller. This occurred behind the closed doors of an
examination room. First, a study member taped the accelerometer (from the
Tremorometer system) to the index finger on the hand that they believe to exhibit the
most symptomatic tremor. Each participant then rested their arm on a small slanted
ramp and was asked to relax their fingers and hands. The acceleration of their index
finger was then recorded for 30 seconds, while the participant counted down from 100.
After the first Tremorometer recording, the subject was asked to re-adjust their arm on
the slanted ramp and again relax their fingers. The participant was again asked to count
down from 100 while the 30-second recording takes place for the second time. Once
the second recording was complete, the accelerometer was removed.
The participant was then asked to place the same arm on the small slanted ramp
with their fingers relaxed, this time in front of the Leap Motion Controller. The position
of each finger on the testing hand was then recorded for 30 seconds, while the
participant again counted down from 100. After the first recording with the Leap
Motion Controller, the subject was asked to re-adjust their hand and again place it on
the slanted ramp with their fingers relaxed. Then the second 30-second recording with
the Leap Motion Controller took place, while the participant again counted down from
100. It was estimated that the time commitment for each participant was approximately
10 minutes.
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3.5

Ethical Considerations
Each participant was an adult equal to or greater than 18 years of age and gave

informed consent. To ensure all participants had the ability can give informed consent
all participants had to have a Mini-Mental State Score greater than or equal to 19 and
could not have any serious medical or psychiatric condition.

3.5.1

Risks and Benefits
The potential risks that were determined for the participants were mild and

considered unlikely. The predetermined potential risks included: discomfort from
attempting to hold one hand still, boredom or frustration during the recordings, and
stress if the patient exhibits too severe of upper limb tremor to record the data. In order
to reduce the potential risk to the subjects, a physician was present throughout all
studies.
The two devices that were used in this study, the Leap Motion Controller and
the Tremorometer, met the Food and Drug Administration (FDA) definition of a NonSignificant Risk Device (NSR). This is because neither device was used as an implant,
used in supporting or sustaining human life, was of substantial importance in
diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment
of human health, and neither presented a potential for serious risk to the health, safety,
or welfare of a subject.
The Leap Motion Controller is a consumer three-dimensional camera and was
used in accordance with its purpose: to measure and record hand and finger motions.
The Tremorometer has 510k clearance for measuring and quantifying tremor in human
participants, which was its only use in this study. As a result, it can be concluded that
the use of these devices in the study was safe for all those who participated in the study.
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3.5.2

Early Withdrawal of Subjects
None of the participants chose to or were withdrawn from the study. However,

all of the participants were informed that they could withdraw from the study at any
point and would not be penalized or lose any benefits that they would otherwise qualify
for. In this case, the recordings would end and the data collected from the participant
would have been deleted and not used in the study. Participants could have also been
withdrawn from the study if they had exhibited upper limb tremor that was too severe
to be recorded or if the participant could not spread their fingers enough to be detected
by the Leap Controller. This withdrawal would have been based on the judgment of the
study team member at the time of recording. Any data collected by a subject who had
decided to withdraw or was withdrawn during the recording would not have been used
and would have been deleted.

3.5.3

Confidentiality and Security
In order to protect the confidentiality of the patients, only study team members

had access to the medical record of any of the potential and enrolled subjects. These
records are password protected in the clinical movement disorders database (MARS) of
Washington University in St. Louis, which is HIPAA compliant. This is the clinical
database for which clinical information is entered for all patients seen in the movement
disorders division of neurology. The collected data did not contain any identifiers and
was stored on a LOK-IT Secure Flash Drive, which was automatically encrypted with
military-grade 256-bit AES hardware encryption and is also HIPAA compliant.

16

Chapter 4
Analysis
4.1

Leap Motion Data Conditioning
In order to calculate the necessary characteristics from the data of the Leap

Motion Controller, a preliminary conditioning of the position data was performed. This
position data was conditioned to reduce noise and eliminate errors in order to obtain
the filtered displacement, which was later used to classify the Parkinson subjects. The
displacement was then further conditioned to derive the acceleration, in order to
compare it to the acceleration from the Tremorometer.

Upon collection of the Leap Motion Controller data, it was noticed that the
Leap Motion Controller would not detect the hand unless the hand was moved into the
field of view of the device after the test had begun. Although the code was written so
that no data was recorded until the hand was detected, this still caused the first second
or so of each data set to be recording the subject purposefully moving their hand into a
relaxed position into the view of the Leap Motion Controller. It was determined that
the removal of the first three seconds of the data from each recording was sufficient to
eliminate any intentional movement of placing the hand in view of the Leap Motion
Controller from the data.

4.1.1

Positions
The Leap Motion Controller provides three-dimensional coordinates of position

for each finger in its field of view. The position of the index finger is recorded with
17

respect to the origin of the Leap Motion Controller, which is centered at the top and
middle of the surface of the Leap and is assumed to remain stationary.29 Examples of
these positions can be seen on the following pages for subjects with Parkinson Disease
in Figure 4.1, Essential Tremor in Figure 4.2, and for a Healthy Control in Figure 4.3.
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Figure 4.1 Recorded positions in millimeters with respect to time for each
axis (x,y, and z) of Patient 10, who has Parkinson Disease (PD).
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Figure 4.2 Recorded positions in millimeters with respect to time for each
axis (x,y, and z) of Patient 15, who has Essential Tremor (ET).
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Figure 4.3 Recorded positions in millimeters with respect to time for each
axis (x,y, and z) of Patient 22, who is a Healthy (HE) Control.

4.1.2

Displacements

Student Version of MATLAB

In order to analyze the data from the Leap Motion Controller, displacements of
the positions (Eq. 4.1) and new associated times (Eq. 4.2) were calculated for each axis.
(4.1)
(4.2)
Where:
n is the frame number,
p is the x, y, or z coordinate associate with frame n,
tn+1 is the time associated with frame n+1,
Tn is the new time associated with pn.
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The displacements are indicative of the magnitude of movement in each axis of
the index finger. A comparison between the positions and calculated displacements for
Patient 22 are shown in Figure 4.4. As expected, the increase in oscillations of the
position in the z-axis starting at around 20 seconds can be shown by the increases in
magnitude of the displacements. The displacements were calculated, in part, to eliminate
any large spikes in the position data, which will be discussed next.
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Figure 4.4 A side by side comparison of the positions and displacements for each axis of
Patient 22, who is a Healthy (HE) control.

4.1.3

Spike Removal
Student Version of MATLAB
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Upon inspection of both the position and displacement data it was noticed that
there were occasionally large spikes in the recorded positions and as a result, large
magnitude spikes in the calculated displacements from the Leap Motion Controller.
An example of data containing these spikes can be seen in the position data and
displacement data from Patient 18 with Essential Tremor in Figures 4.5, on the
following page. As expected, a spike can be seen to occur on multiple axes and often
can be seen more easily in one axis than another for both positions and displacements.
It is apparent by observing the y-axis and z-axis positions that there are significant
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spikes around 5 seconds, but these spikes are not as visible in the x-axis. As shown
below, it is much easier to visualize these spikes by observing the displacement data
rather than just observing the position.
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Figure 4.5 The positions and displacements for each axis of Patient 18, who has Essential
Tremor (ET).

The skeletal tracking V2 Beta Version of the SDK that was used in this study
uses an anatomical model of the human hand to track 26 feature points of each hand. If
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one finger is not seen for a frame it is interpolated and considered as curled beneath the
palm or the map of the entire hand is incorrectly recorded for that frame, returning an
incorrect position. Another possible cause of these spikes could be a quick shift in the
arm of the subject during the recording, such as a quick readjustment or a twitch, which
would also return an erroneous position. When this occurs, the data was shown to have
large magnitude spikes in the position, and more visibly in displacement as shown above
in Figure 4.5.
To compensate for this, any displacement with a magnitude of 4 mm or above
was discarded. This value was chosen on the basis that a displacement of 4 mm between
two frames approximately 0.01 milliseconds apart is too large of a magnitude for rest
tremor since the magnitude of displacement from PD subjects has been shown to be
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below 4 millimeters for similar sampling rates of high-amplitude rest tremor.32 Nearly all
of the large magnitude spikes in the data that were larger than 4 millimeters between
two frames were at least several magnitudes larger than 4 millimeters, supporting the
argument that these large magnitude spikes are not a result of abnormally highamplitude tremor, but are incorrect readings. Therefore, it was concluded that
displacement magnitudes greater than 4 mm between two frames on any axis indicated
an incorrect reading and were thus removed from the data set. Eliminating these large
displacement magnitudes from every axis ensured the removal of incorrect readings
from an axis even when incorrect readings were not visible on that axis. Unfortunately,
elimination of these data points does not exclude the possibility that an incorrect finger
or an incorrect finger position could be tracked for several frames before the Leap
Motion Controller returns the correct finger position. However, it was determined that
the elimination of these large magnitude spikes in displacement was a better alternative
than using a median filter since these spikes lasted for a different number of frames in
different data sets. Therefore, in one data set a median filter using a given number of
adjacent data points might work well while the same filter in another data set would not.
A median filter would also face the same issue in that it would also not eliminate the
possibility of an incorrect position reading for several frames. As a result, it was
concluded it would be best to simply set a threshold with a displacement of 4
millimeters between any two frames and remove any large magnitude spikes that were
larger than this threshold.
Figure 4.6, on the following page, shows a side-by-side comparison of the
displacement data for Patient 18 before and after the removal of these large magnitude
spikes. It can be seen that all of the spikes shown were several magnitudes larger than 4
mm and are clearly incorrect recordings. It can easily be seen that after the removal of
these large magnitude spikes, the data is cleaner and more reasonable.
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Spikes Removed in Displacement of Patient 18
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Figure 4.6 A side by side comparison of the displacements with respect to each axis of Patient
18, who has Essential Tremor (ET), before and after the large magnitude spikes were removed.

4.1.4

Euclidean Distance
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Once the spikes were removed from the displacement data, the Euclidean
distance (Eq. 4.3) was calculated between the three-dimensional sampled position and
the origin of the Leap Motion Controller.33 As previously mentioned, the origin of the
coordinate system of the Leap Motion Controller is centered at the top and middle of
the surface of the Leap and is assumed to remain stationary.29 The change in Euclidean
Distance (Eq. 4.4) was calculated for each recorded frame in order to determine the
magnitude of the change in distance of the index finger with the new associated time
(Eq. 4.5).

(4.3)
(4.4)
(4.5)
Where:
n is the frame number,
dn is the Euclidean distance,
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(xn, yn, zn) are the positional coordinates associated with frame n,
dn+1 is the Euclidean distance associated with frame n+1,
tn+1 is the time associated with frame n+1,
Tn is the new time associated with Dn.
Dn is the new Euclidean distance associated with frame n.
This new metric takes into account the magnitude of movement from each axis.
As expected, if the spikes had not been removed they would have had a significant
impact on the change in Euclidean Distance. The impact of the spikes can be seen in
Figure 4.7, where a comparison between the change in Euclidean Distance with and
without spike removal for Patient 18 with Essential Tremor is shown. When the spikes
were removed, the actual magnitude of movement of the index finger can be seen much
more clearly.
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Figure 4.7 A side by side comparison of the change in Euclidean Distance of Patient 18, who
has Essential Tremor (ET), before and after the large magnitude spikes were removed.
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4.1.5

Non-Uniform Sampling
As previously mentioned, the Leap Motion Controller has an inconsistent frame

rate and so the collected data is non-uniform with respect to time. According to the
Shannon sampling theory for non-uniform sampling, a band-limited signal can be
reconstructed from its samples if the average sampling rate satisfies the Nyquist
condition.34 The average sampling rate of the Leap Motion Controller during the study
was approximately 100 Hz, which satisfies the Nyquist condition since the upper limit
of the frequency that is of interest is no more than 25 Hz. As a result, the change in the
Euclidean distance was interpolated with a cubic spine and resampled at a frequency of
half of the average sampling rate, 50 Hz.

4.1.6

Band-pass Butterworth Filter
The magnitudes of the Euclidean distance for the data from the Leap Motion

Controller were then filtered using a 4th-Order band-pass Butterworth Filter. The
Butterworth Filter that was used had a low-pass cutoff frequency of 20 Hz and a highpass cutoff of 2.5 Hz to eliminate frequencies that were not of interest, such as those
due to physiological factors like breathing and heartrate.35 This approximation of the
change in magnitude of displacement after band-pass filtering was used to classify
Parkinson subjects, discussed later.

4.1.7

Savitzky-Golay Filter
A 4th order Savitzky-Golay FIR filter, with a frame size of 11 points, was

implemented in MATLAB using the sgolay function to smooth and perform a 2nd order
differentiation on the band-pass filtered Euclidean distance.36 This allowed for an
approximation of the change in magnitude of the acceleration while removing higher
frequency noise that was amplified from differentiation. In Figure 4.8, the effects of the
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Savitzky-Golay FIR filter can be seen on the magnitude of displacement, change in
velocity, and change in acceleration of Patient 10, with Parkinson Disease.
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Figure 4.8 The displacement, change in velocity, and change in acceleration of Patient 10, who
has Parkinson Disease, with and without the Savitzky-Golay FIR filter.

It can be more clearly seen that the amplification of higher frequency noise is
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greatly reduced when the Savitzky-Golay filter is applied in the frequency domain.
Figure 4.9 shows Welch’s one-sided power spectral density estimate for acceleration
with and without the Savitztky-Golay Filter using a Hanning window, averaging twenty
sections with no overlap for Patient 10, with Parkinson Disease.
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Figure 4.9 Welch’s one-sided Power Spectral Density (PSD) estimate of Patient 10 who has
Parkinson Disease, with and without the Savitzky-Golay FIR filter.
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4.2

Tremorometer Data Conditioning
Since the Tremorometer provides a uniform sampling rate of 100 Hz, the data

from the Tremorometer did not have to be resampled since this rate is sufficient to
analyze the frequencies of interest, those below 25 Hz.

4.2.1

Change in Acceleration
The Tremorometer provides changes in acceleration in three dimensions

measured in milli-g (1/1000th of the acceleration due to gravity), with respect to time
measured in seconds. Examples of these recorded accelerations can be seen on the
following pages for subjects with Parkinson Disease in Figure 4.10, Essential Tremor in
Figure 4.11, and for a Healthy Control subject in Figure 4.11.
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Figure 4.10 Recorded changes in acceleration (milli-g) with respect to time for
each axis (x,y,z) of Patient 10, who has Parkinson Disease (PD).
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Figure 4.11 Recorded changes in acceleration (milli-g) with respect to time for
each axis (x,y,z) of Patient 15, who has Essential Tremor (ET).

100
Student Version of MATLAB

0
−100
0

z−axis (milli−g)

y−axis (milli−g)

x−axis (milli−g)

Change in Acceleration of HE Patient 22

5

10

15
Time (s)

20

25

30

5

10

15
Time (s)

20

25

30

5

10

15
Time (s)

20

25

30

850
800
750
0

−500
−550
−600
0

Figure 4.12 Recorded changes in acceleration (milli-g) with respect to time for
each axis (x,y,z) of Patient 22, who is a Healthy (HE) Control.
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4.2.2

Magnitude of Acceleration
As previously mentioned, the Tremorometer records changes in acceleration in

three different dimensions. These dimensions were used to calculate the total magnitude
of the acceleration shown below, in Equation 4.6.
(4.6)
Where:
n is the frame number,
||an|| is the magnitude of the acceleration associated with
frame n,
(ax, ay, az) are the changes in acceleration in each dimension with
their associated frame n,
An example of the calculated magnitude of acceleration for the three different
axes can be seen in Figure 4.13 for Patient 10 who has Parkinson Disease (PD). It can
be seen that in this case the largest changes in acceleration occur in the y-axis, which
causes the greatest influence on the total magnitude of acceleration. However, it should
be noted that the changes in acceleration from the other axes are also important and
also contribute to the result of the total magnitude of the acceleration.
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Figure 4.13 The accelerations (milli-g) for three axes of Patient 10, who has Parkinson Disease
(PD) and the magnitude of acceleration (milli-g) calculated from the three axes.
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4.2.3

Offset
Although the accelerometer from the Tremorometer system was properly

calibrated before the data was recorded, there was a significant offset in the data. As a
result, the offsets in the data were removed by subtracting the mean value of each data
set from the respective data set. The removal of a large offset can be seen in Figure
4.14, where the magnitude of acceleration for Patient 10, who has Parkinson Disease,
had an offset of approximately 1000 milli-g.
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Figure 4.14 The magnitude of acceleration (milli-g) of Patient 10, who has Parkinson Disease
(PD) with and without the offset.

4.2.4

Band-pass Butterworth Filter
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The magnitudes of acceleration for each trial were also filtered using the same
4th-Order band-pass Butterworth Filter with the same parameters used for the Leap
Motion Controller. Again, the filter had a low-pass cutoff frequency of 20 Hz and a
high-pass cutoff of 2.5 Hz to eliminate frequencies that are not of interest.35

4.2.5

Savitzky-Golay Smoothing
Once the frequencies not pertinent to the study were removed from the data

obtained from the Tremorometer, the data was then smoothed using a Savitzky-Golay
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smoothing filter. The same 4th order Savitzky-Golay FIR smoothing filter, with a frame
size of 11 points that was used for the data from the Leap Motion Controller was used
for the data from the Tremorometer in order to apply the same smoothing filter to the
two devices.

4.3

Frequency Domain Characteristics
Once the data from the Leap Motion and Tremorometer were properly

conditioned, various frequency domain characteristics were calculated. This was done
in order to analyze and compare the derived acceleration data from the Leap Motion
Controller to the acceleration data of the Tremorometer. The derived accelerations
from the Leap Motion Controller, measured in millimeters per second squared, and the
acceleration from the Tremorometer, measured in milli-g, were converted into meters
per second squared. These same frequency domain characteristics were also used in an
attempt to classify Parkinson subjects using the position data obtained from the Leap
Motion Controller in Section 4.16, before the Savitzky-Golay 2nd order differentiation
filter was applied.
The Welch’s one-sided power spectral density estimate was calculated using a
Hanning window averaging twenty sections with no overlap with the necessary
correction factors applied.35 The following frequency domain characteristics were then
determined based on this estimated power spectral density.

4.3.1

Proportional Power between 4-6 Hz
This characteristic quantifies the proportional power that is contained in the

frequency range between 4-6 Hz and quantifies the approximate amount that this range
contributes to the tremor. In typical parkinsonian tremor, it is expected that there is a
significant peak in this range, thus causing a large proportion of the power of the
spectrum to also exist in this range.35 An example of this peak can be seen in Figure
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4.15, which shows a large peak for the accelerations of both the Leap Motion Controller
and the Tremorometer of Patient 10, who has Parkinson Disease. Although the peaks
are seen to have slightly different magnitudes, it is clear that due to these peaks there is a
large proportion of power in the 4-6 Hz range for Patient 10.
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Figure 4.15 The Power Spectral Density (PSD) of Patient 10 with Parkinson Disease (PD). The
large peaks in the 4-6 Hz range cause a large proportion of power to also exist in this range.

As shown in Figure 4.16, it was found that many of the Healthy Controls also
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exhibited a large peak in both the Tremorometer acceleration data and the calculated
accelerations from the Leap Motion Controller. This peak also caused an increase in the
proportional power in the 4-6 Hz range for the Healthy Controls.
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Figure 4.16 The Power Spectral Density (PSD) of Patient 22, a Healthy (HE) Control. The large
peaks in the 4-6 Hz range causes a larger proportion of power to also exist in this range, but the
peaks are less significant and have less power than those in the PD subjects.
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However, the peaks of the Healthy Controls were proportionally smaller with
respect to the power spectrum, than the peaks of the Parkinson subjects. This typically
resulted in a smaller proportional power in the 4-6 Hz range for Healthy Controls than
Parkinson subjects. The peaks from the Healthy Controls also tended to exist at a
higher frequency than those of the Parkinson subjects, again resulting in a decreased
proportional power in comparison to the Parkinson subjects.

4.3.2

Proportional Power between 8-12 Hz
This characteristic quantifies the proportional power that is contained in the

frequency range between 8-12 Hz and quantifies the approximate amount that this
range contributes to the tremor. Since normal physiological tremor is typically
concentrated in the 8-12 Hz range, it was expected that the proportion of power in this
range would be high in the absence of any low-frequency pathological tremor.35 As
mentioned in the previous section, some Healthy Controls did exhibit a peak in the 4-6
Hz range but this peak was proportionally smaller for the Healthy Control subjects than
for the Parkinson subjects, typically resulting in a larger proportional power in the 8-12
Hz range for the Healthy Control subjects than subjects with Parkinson Disease. An
example of this can be seen by visually comparing the proportional power in the 8-12
Hz range for subjects with Parkinson Disease in Figure 4.15 to Healthy Control subjects
in Figure 4.16.

4.3.3

Median Frequency
This characteristic is indicative of the frequency at which there is a median of

the area below the power spectrum, where there exists 50% of the power in the
spectrum above and 50% below this frequency and has previously been used to
characterize tremor.35,36 For power spectrums with one significantly large peak, the
median frequency typically coincides with this peak as shown in Figure 4.17, on the
following page.
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Figure 4.17 The Power Spectral Density (PSD) of Patient 1 with
Parkinson Disease (PD). The large peak in the 4-6 Hz range is
so significant that the median frequency coincides with this
peak, shown by the blue dot.
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4.3.4

Frequency Dispersion
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The frequency dispersion measures the width of an interval centered at the
median frequency that contains 68% of the power in the spectrum and has also been
previously used to characterize tremor.35,36 This characteristic can be used to quantify
the harmonicity of oscillations. Typically, for regular oscillation such as parkinsonian or
essential tremor the dispersion bandwidth is small due to a large peak while irregular
tremors like physiological tremor, which usually have several peaks, tend to have a larger
dispersion.35,38
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Figure 4.18 The Power Spectral Density (PSD) of Patient 3 with Parkinson Disease (PD) and
Patient 30, a Healthy (HE) Control. As shown by the blue bars, the frequency dispersion for the
subject with PD is narrower than that of the Healthy Control. The blue dot indicates the median
frequency.
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Figure 4.18, on the previous page, illustrates the difference in frequency
dispersions by comparing Patient 3, with Parkinson Disease, and Patient 30, a Healthy
Control, using the Tremorometer. The lower end of the frequency dispersion for
Patient 3 is shown by the blue bar at 3.91 Hz, the blue bar at 5.08 Hz shows the upper
end, and the median frequency is marked by a blue dot at 4.29 Hz. Whereas Patient 30
has a frequency dispersion with a lower end of 5.47 Hz, an upper end of 10.16 Hz, and
a median frequency of 7.43 Hz. As shown, this results in a much more narrow
frequency dispersion for Patient 3 who has Parkinson Disease, than Patient 30 who is a
Healthy Control.

4.3.5

Peak Frequency between 0-25 Hz
This characteristic indicates the frequency of the highest peak power in the

estimated power spectrum and also has been used to characterize tremor.35 It was
expected that the frequency of this peak would be lower for typical parkinsonian
tremor, typically between 4-6 Hz, and was expected to be higher for Healthy Controls,
while subjects with Essential tremor would exist throughout the spectrum. Although
this was not the case for all subjects, an example of a higher peak frequency in a Healthy
Control subject compared to a Parkinson subject with a peak in the 4-6 Hz range, can
be seen in Figure 4.18.

4.3.6

Peak Power between 0-25 Hz
The peak power between 0-25 Hz is indicative of the power at the highest peak

in the estimated spectrum. It was expected that this peak would be larger for those with
visible high-amplitude tremor, and significantly lower for Healthy Control subjects. This
in seen by comparing the peak power of a subject with Parkinson Disease in Figure 4.15
to the peak power of a Healthy Control subject in Figure 4.16.
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4.3.7

Proportional Power of Peak between 0-25 Hz
The proportional power of the peak between 0-25 Hz represents the proportion

of power in the peak frequency of the estimated spectrum. It was expected that this
peak would be larger for those with visible high-amplitude tremor such as Parkinson
subjects and Essential Tremor subjects, and significantly lower for Healthy Control
subjects.

4.3.8

Total Power between 0-25 Hz
This characteristic is indicative of the total power of the tremor that exists in the

0-25 Hz range of the estimated spectrum. Those with high-amplitude tremor were
expected to exhibit a larger value than those with low-amplitude or no visible tremor.
This can be in Figure 4.18, where the magnitude of the area under the power spectrum
for a Parkinson subject, Patient 3, is much larger than that of a Healthy Control, Patient
30.
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Chapter 5
Results
5.1

Device Comparison
In order to compare the Leap Motion Controller to the Tremorometer, first the

characteristics were tested in order to determine if the devices could be considered
repeatable across trials. Once it was shown that both devices were not statistically
different across trials, the two devices were compared. To do this, the trials and subject
groups were combined for each device and a statistical analysis was performed to
compare the resulting characteristics from each device. Then, a statistical analysis was
performed separately on each subject group, again with combined trials, to determine if
there was a difference in characteristics between devices for each subject group.

5.1.1

Repeatability
To determine the repeatability of each device, a statistical analysis was

performed across trials for each device on each characteristic. It was found that for both
devices, the distributions of each characteristic for both trials did not follow a normal
distribution as was expected.36,39 Therefore, the two trials for each device were first
compared directly using the following nonparametric methods: the Wilcoxon Signed
Ranks Test and the Sign Test.
The Wilcoxon Signed Ranks Test was used as a two-sided test for the null
hypothesis that the differences between trials come from a distribution with zero
median. The Sign Test was also used to test the hypothesis that the differences in the
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trials had a distribution with zero median against the alternative that the distribution did
not have zero median. Again, the test failed to reject the null hypothesis of zero median
in the differences of the trials for both devices for all, but one characteristic. The only
null hypothesis that was rejected was the Peak Frequency between 0-25 Hz for the Leap
Motion Controller using the Sign Test. The Wilcoxon Signed Ranks Test, however, did
not reject the null hypothesis that the Peak Frequency between 0-25 Hz for the Leap
Motion Controller between trials had a distribution with a zero median. The results of
these two tests can be seen in Tables 5.1 and 5.2. Those characteristics with highlighted
p-values are shown to have no significant difference between trials.

Table 5.1 The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference
between the two trials of the Leap Motion Controller. Highlighted p-values indicate that there
was no significant difference.
Leap%Motion%Controller%
Differences%between%Trial%1%and%Trial%2
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

Wilcoxon%Signed%Ranks%Test
Z
p%value

/0.072
/0.751
/0.671
/0.688
/1.435
/0.504
/1.08
/0.956

0.943
0.453
0.502
0.491
0.151
0.614
0.28
0.339

Z

Sign%Test
p%value

0
/0.183
/
/0.588
/
/0.548
/1.278
/0.913

1
0.855
0.523
0.556
0.023
0.584
0.201
0.361

Table 5.2 The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference
between the two trials of the Tremorometer. Highlighted p-values indicate that there was no
significant difference.
Tremorometer'
Differences'between'Trial'1'and'Trial'2
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Power*of*peak*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

Wilcoxon'Signed'Ranks'Test
Z
p'value

/1.45
/0.278
/0.409
/0.258
/0.653
/1.162
/0.792
/0.442
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0.147
0.781
0.682
0.797
0.514
0.245
0.428
0.658

Z

Sign'Test
p'value

/0.548
/0.183
/
/
/
/0.913
/0.183
/0.183

0.584
0.855
1
1
1
0.361
0.855
0.855

The differences between trials were also tested to determine if they followed a
normal distribution. To do so, a Kolmogorov-Smirnov One-Sample Test with Lilliefors’
Significance and a Shapiro-Wilk Test was run to test the null hypothesis that the
differences in characteristics between trials for each device come from standard normal
distributions against the alternative that they do not, at the 0.05 significance level. The
results are shown in Table 5.3 and Table 5.4 on the next page, where highlighted pvalues indicate that the null hypothesis was not rejected and that the distribution was
assumed to follow a normal distribution. As shown, not all characteristics were revealed
to follow a normal distribution. However, for those characteristics that were shown to
follow a normal distribution by just one of the normality tests, a one-sample t-test was
performed.
A one-sample t-test was used to test the null hypothesis that the differences in
the trials come from normal distributions with means equal to zero and unknown
variance for those characteristics that were assumed to follow a normal distribution
from the normality tests. The alternative hypothesis was that the distributions of the
differences in trials do not have means equal to zero. The results for the one-sample t
test can be seen below, in Table 5.3 below and Table 5.4 on the following page, with
highlighted p-values again indicating that there was no significant difference in the
means of the two trials.
Table 5.3 The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, ShapiroWilk Test, and t-test for the differences between trials for the Leap Motion Controller.
Highlighted p-values for the Kolmogorov-Smirnov Test and the Shapiro-Wilk Test suggest that
the characteristic follows a normal distribution. Highlighted p-values for the t-test indicate that
there was no significant difference in the means of the two trials.

Leap%Motion%Controller%
Differences%between%Trial%1%and%Trial%2
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*
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Normality
Kolmogorov< Shapiro<
Smirnova
Wilk

0.052
0.200
0.112
0.200
0.000
0.000
0.013
0.000

0.007
0.235
0.424
0.497
0.001
0.000
0.005
0.000

t<test%
t

p%value

0.065
/1.098
0.767
/0.518
/
/
/
/

0.949
0.281
0.449
0.608
/
/
/
/

Table 5.4 The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, ShapiroWilk Test, and t-test for the differences between trials for the Tremorometer. Highlighted pvalues for the Kolmogorov-Smirnov Test and the Shapiro-Wilk Test suggest that the
characteristic follows a normal distribution. Highlighted p-values for the t-test indicate that
there was no significant difference in the means of the two trials.

Tremorometer'

Normality
Kolmogorov8 Shapiro8
Smirnova
Wilk

Differences'between'Trial'1'and'Trial'2
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Power*of*peak*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

5.1.2

0.026
0.2
0.006
0.2
0
0
0.119
0

0.095
0.637
0.123
0.304
0.002
0
0.036
0

t8test
t

p'value

/1.868
0.244
0.356
/0.476
/
/
/1.161
/

0.072
0.809
0.725
0.638
/
/
0.255
/

Combined Subject Groups
Both trials and all subject groups were combined for each device and the

differences between devices were calculated. Similar to the analysis between trials, the
two devices were first compared directly using nonparametric methods. Again, the
Wilcoxon Signed Ranks Test and Sign Test were used to test the null hypothesis that
the differences between devices come from a distribution with a zero median. The
results of the tests are shown in Table 5.5, where highlighted p-values indicate that the
differences between the devices were not significant.
Table 5.5 The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference
between the Leap Motion Controller and the Tremorometer. Highlighted values indicate that
there was no significant difference.

Differences)between)
Leap)Motion)Controller)and)Tremorometer
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

Wilcoxon)Signed)Ranks)Test
Z
p)value

/2.591
/2.952
/2.397
/2.756
/1.328
/4.483
/6.729
/2.812
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0.010
0.003
0.017
0.006
0.184
0.000
0.000
0.005

Sign)Test
Z
p)value

/1.678
/2.969
/2.806
/2.649
/0.530
/5.035
/7.359
/2.969

0.093
0.003
0.005
0.008
0.596
0.000
0.000
0.003

The differences between the two devices were then tested to determine if they
followed a normal distribution. The Kolmogorov-Smirnov One-Sample Test with
Lilliefors’ Significance and Shapiro-Wilk Test were run to test the null hypothesis that
the differences in characteristics between the two devices come from a standard normal
distributions against the alternative that they do not, at the 5% significance level. The
results of these tests can be seen in Table 5.6, where highlighted p-values indicate that
the null hypothesis was not rejected and that the differences were assumed to follow a
normal distribution. The one-sample t-test was then performed on those characteristics
that were assumed to follow a normal distribution. This test was run in order to test the
null hypothesis that the differences in the devices come from normal distributions with
means equal to zero and unknown variance. The results for the one-sample t test are
shown in Table 5.6, with highlighted p-values indicating that there was no significant
difference in the means of the difference between the two devices.
Table 5.6 The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, ShapiroWilk Test, and t-test for the difference between the Leap Motion Controller and the
Tremorometer. Highlighted p-values for the Kolmogorov-Smirnov Test and the Shapiro-Wilk
Test suggest that the characteristic follows a normal distribution. Highlighted p-values for the ttest indicate that there was no significant difference in the means of the two trials.

Differences)between))
Leap)Motion)Controller)and)Tremorometer
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

41

Normality
Kolmogorov: Shapiro:
Smirnova
Wilk

0.069
0.007
0.065
0.200
0.082
0.000
0.017
0.000

0.034
0.003
0.070
0.098
0.258
0.000
0.004
0.000

t:test)
t

p)value

/2.919
/
2.083
2.745
1.170
/
/
/

0.005
/
0.042
0.008
0.247
/
/
/

5.1.3

Separate Subject Groups
To compare the differences between the two devices, the same series of

statistical analyses that were performed for all subjects in the previous section were also
performed for each subject group. The results of the Wilcoxon Signed Ranks Test and
the Sign Test are shown in Table 5.7 for the Parkinson Group, Table 5.8 for the
Essential Tremor Group, and Table 5.9 for the Healthy Control Group. Following the
same convention as before, highlighted p-values indicate that the differences between
the devices were not significant for that characteristic.

Table 5.7 The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference
between the Leap Motion Controller and the Tremorometer for the Parkinson Group.
Highlighted values indicate that there was no significant difference.

Table 5.8 The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference
between the Leap Motion Controller and the Tremorometer for the Essential Tremor Group.
Highlighted values indicate that there was no significant difference.

42

Table 5.9 The results of the Wilcoxon Signed Ranks Test and the Sign Test for the difference
between the Leap Motion Controller and the Tremorometer for the Healthy Control Group.
Highlighted values indicate that there was no significant difference.

Healthy(Control(Group:(Differences(between( Wilcoxon(Signed(Ranks(Test
Sign(Test
Leap(Motion(Controller(and(Tremorometer
Z
p(value
Z
p(value
Proportional*Power*between*4/6*Hz*
/0.747
0.455
/0.671 0.502
Proportional*Power*between*8/12*Hz*
0.149
0.881
0.671 0.502
Median*Frequency*
0.412
0.681
1.118 0.264
Frequency*Dispersion
1.250
0.211
0.918 0.359
Peak*Frequency*between*0/25*Hz*
0.112
0.911
0.671 0.502
Peak*Power*between*0/25*Hz*
/2.763
0.006
/3.354 0.001
Proportional*Power*of*Peak*between*0/25*Hz*
/3.920
0.000
/4.249 0.000
Total*Power*between*0/25*Hz*
/1.045
0.296
/2.012 0.044

The differences between the two devices for each group were then tested to
determine if they followed a normal distribution using the Kolmogorov-Smirnov OneSample Test with Lilliefors’ Significance and Shapiro-Wilk Test. A one-sample t-test was
performed on those characteristics that were assumed to follow a normal distribution.
The results of the these tests are shown on the following pages in Table 5.10 for the
Parkinson Group, Table 5.11 for the Essential Tremor Group, and Table 5.12 for the
Healthy Control Group. Again, following the same convention as before, highlighted pvalues for the normality tests indicate that the differences were assumed to follow a
normal distribution and a highlighted p-value for the t-test indicates that there was no
significant difference in the means of the difference for that characteristic between the
two devices. P-values with an asterisk for the Kolmogorov-Smirnov indicate that the
value was a lower bound of the true significance.
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Table 5.10 The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, ShapiroWilk Test, and t-test for the difference between the Leap Motion Controller and the
Tremorometer for the Parkinson Group. Highlighted p-values for the Kolmogorov-Smirnov Test
and the Shapiro-Wilk Test suggest that the characteristic follows a normal distribution. P-values
with an asterick indicate the value is ta lower bound of the true significance. Highlighted pvalues for the t-test indicate that there was no significant difference in the means of the two
trials.
Normality

Parkinson2Group:2Differences2between2Leap2
Kolmogorov(
Motion2Controller2and2Tremorometer2
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

t(test2

Smirnov

Shapiro(Wilk

0.200 *
0.200 *
0.200 *
0.200 *
0.077
0.000
0.200 *
0.000

0.776
0.673
0.841
0.581
0.105
0.000
0.647
0.000

t

p2value

1.835
/0.916
/0.322
/1.117
0.195
/
7.114
/

0.082
0.371
0.751
0.278
0.848
/
0.000
/

Table 5.11 The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, ShapiroWilk Test, and t-test for the difference between the Leap Motion Controller and the
Tremorometer for the Essential Tremor Group. Highlighted p-values for the KolmogorovSmirnov Test and the Shapiro-Wilk Test suggest that the characteristic follows a normal
distribution. Highlighted p-values for the t-test indicate that there was no significant difference
in the means of the two trials.

Normality
Essential2Tremor2Group:2Differences2between2
Kolmogorov(
Leap2Motion2Controller2and2Tremorometer2

Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*
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Smirnova

Shapiro(Wilk

0.200 *
0.200 *
0.078
0.200 *
0.200 *
0.000
0.200 *
0.000

0.058
0.987
0.159
0.073
0.136
0.000
0.195
0.000

t(test2
t

p2value

2.341
/7.435
/4.493
/2.278
/3.037
/
8.577
/

0.030
0.000
0.000
0.034
0.007
/
0.000
/

Table 5.12 The results of the Kolmogorov-Smirnov Test with Lilliefors’ Significance, ShapiroWilk Test, and t-test for the difference between the Leap Motion Controller and the
Tremorometer for the Healthy Control Group. Highlighted p-values for the KolmogorovSmirnov Test and the Shapiro-Wilk Test suggest that the characteristic follows a normal
distribution. Highlighted p-values for the t-test indicate that there was no significant difference
in the means of the two trials.

Normality

Healthy2Control2Group:2Differences2between2
Kolmogorov(
Leap2Motion2Controller2and2Tremorometer2
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

5.2

t(test2

Smirnova

Shapiro(Wilk

0.200 *
0.144
0.009
0.139
0.018
0.000
0.200 *
0.000

.438
.093
.010
.406
.009
.000
.266
.000

t

p2value

1.034
0.013
/

0.314
0.990
/

/1.585

0.129

/
/
/
/
11.767 0.000
/
/

Classification of Parkinson Subjects
To classify Parkinson Subjects, the band-pass filtered displacement data of the

Leap Motion Controller from Section 4.1.6 were used. Only the Healthy Control group
and the Parkinson Disease group were used in the classification of Parkinson subjects,
due to the statistical differences found between devices that are discussed later in
Section 6.1.3. Also based on the statistical differences between devices for the
Parkinson and Healthy Control groups, only six of the eight characteristics were used to
classify the Parkinson subjects. These six characteristics were used for both supervised
and unsupervised learning and include: Proportional Power between 4-6 Hz,
Proportional Power between 8-12 Hz, Median Frequency, Frequency Dispersion, Peak
Frequency between 0-25 Hz, and the Total Power between 0-25 Hz. For unsupervised
learning, a K-means cluster analysis was performed to determine how well underlying
patterns or groupings in the characteristics separated the subjects. For supervised
learning, a Support Vector Machine (SVM) was used to train and classify the Parkinson
subjects.
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5.2.1

K-means Cluster Analysis
To determine how well underlying patterns and groupings in the characteristics

separated subjects into their respective groups, K-means cluster analysis was used to
partition the subjects into 2 clusters. First both trials from both subject groups were
combined and normalized. Then the K-means cluster analysis was performed using the
city-block distance measure, where each centroid was the component-wise median of
the points in that cluster. Since the true clinical diagnosis for each subject was known,
the validity of the clustering was verified by comparing the true diagnosis to the cluster
results. The results for each subject can be seen in Table 5.13, where Cluster 2 was
chosen to be representative of the Parkinson group and Cluster 1 was representative of
the Healthy group. The green highlight indicates a correct classification and a red
highlight indicates an incorrect classification. It was found that there were 9
misclassifications out of the 40 subjects, an error rate of 0.225.
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Table 5.13 The results of the K-means
cluster analysis using the city-block
distance measure for the Parkinson
Disease (PD) Group and Healthy
(HE) Control Group.
Patient'Group Subject
1
2
3
4
5
PD
6
7
8
9
10
21
22
23
24
25
HE
26
27
28
29
30
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Trial
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2

Cluster
2
2
2
2
2
2
1
2
1
1
2
2
1
1
2
1
1
1
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1

5.2.2

Support Vector Machine
In an attempt to classify Parkinson subjects, the binary support vector machine

(SVM) classifier function fitcsvm within MATLAB was used. Both trials from the two
subject groups were combined, normalized and labeled with their respective class. The
default parameters of the function were used to train the classifier using a linear kernel
for the six standardized predictors. Once trained, the model was cross-validated using
the leave-one-out method and the cross-validation loss of the model was calculated
using the function kfoldLoss, which was found to be 0.2. This SVM classifier was then
tuned by adjusting the box constraint and kernel scale parameters to optimize this
performance estimation. The best parameters for the kernel scale and the box
constraints were found to be 0.1 and 1, respectively. The tuned SVM classifier was again
cross-validated using the leave-one-out method and the new cross-validation loss was
recalculated to be 0.15. The predicted response for the cross-validated classification
model was then calculated and the resulting predicted class labels are shown in Table
5.14. Again, the green highlight indicates a correct classification and a red highlight
indicates an incorrect classification.
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Table 5.14 The predicted response for
the
tuned
cross-validated
SVM
classification model for the Parkinson
Disease (PD) Group and Healthy (HE)
Control Group.
Patient'Group Subject
1
2
3
4
5
PD
6
7
8
9
10
21
22
23
24
25
HE
26
27
28
29
30
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Trial
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2

SVM'Model
PD
PD
PD
PD
PD
PD
HE
PD
HE
HE
PD
PD
HE
HE
PD
PD
PD
PD
PD
PD
PD
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE
HE

Chapter 6
Discussion and Conclusion
6.1

Device Comparison
To compare the Leap Motion Controller to the Tremorometer, several analyses

were performed. First each device was tested to determine if the trials were statistically
different or if they could be repeatable, then statistical analyses of the differences
between devices for all subject groups were performed, and finally statistical analyses of
the differences between devices for each separate subject group was presented. A
discussion and the conclusions drawn from the results of these analyses are presented in
this section.

6.1.1

Repeatability
The first step in comparing the two devices was to determine if they provide

characteristics that could be repeatable. It was found that the Leap Motion Controller
and Tremorometer were both shown to not statistically different across trials for all
characteristics, which suggest that the devices could be repeatable. This is supported by
results of the Wilcoxon Signed Ranks Test, which indicated that there were no
significant differences between trials. The results of the Sign Test also indicated that
there were no differences between trials for all characteristics in the Tremorometer and
all but one characteristic in the Leap Motion Controller, the Peak Frequency between 025 Hz. However, it can be argued that the Wilcoxon Signed Ranks Test was a stronger
indicator since it took into account the magnitudes and signs of the observations rather
than just the signs. As a result, if there was a discrepancy between the results of the
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Wilcoxon Signed Ranks Test and the Sign Test, the results of the Wilcoxon Signed
Ranks Test were used to determine statistical difference. Since the Wilcoxon Signed
Ranks Test suggested that there was no significant difference between trials for the Peak
Frequency between 0-25 Hz for the Leap Motion Controller, it was concluded that this
characteristic was also not different between trials for the Leap Motion Controller. The
difference between trials were also tested for normality to see if a more powerful
parametric test, such as the t-test, could also be used to determine if there was a
statistical difference between the trials for each device. The results of the t-test
supported the results of the Wilcoxon Signed Ranks Test, where all those characteristics
shown to follow a normal distribution were shown to not be statistically different
between trials for either device. As a result, the results of the t-test also support the
argument that the two devices could be repeatable for measuring all eight characteristics
and that the two trials are not statistically different for either device. In conclusion, it
was found that the two devices could be considered repeatable for the purposes of this
study.

6.1.2

Combined Subject Groups
The results of combining subject groups and comparing the devices revealed

that characteristics for the two devices were statistically different for all but one
characteristic. The only characteristic that was shown to not be statistically different
between devices from the Wilcoxon Signed Ranks Test and Sign Test was the Peak
Frequency between 0-25 Hz. This result was confirmed by the t-test, which indicated
that out all of the characteristics that were shown to possibly follow a normal
distribution by the normality tests, the only one that was not significantly different was,
in fact, the Peak Frequency between 0-25 Hz. The end results of the relevant statistical
tests are summarized on the following page in Table 6.1 where the characteristics
highlighted in green indicate that they are not statistically different between devices,
while a red highlight indicates that the characteristic is statistically different between
devices. In conclusion, only the Peak Frequency between 0-25 Hz was shown to not be
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statistically different between the Leap Motion Controller and Tremorometer when
testing the combined subject groups.
Table 6.1 Summary of characteristics that are not
statistically different between devices for the
combined subject groups. Green indicates not
statistically different. Red indicates statistically
different.
!Combined!Subject!Groups:!!!Summary!of!characteristics!
not!statistically!different!between!devices!
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak%Frequency%between%0125%Hz%
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

Initially this was a little discouraging, but it is also very important to note. The
statistical differences are most likely due to the consequences of pre-processing of the
data previously mentioned in Chapter 4. When comparing the Leap Motion to the
Tremorometer, the displacement data from the Leap Motion Controller had to be
differentiated to calculate acceleration and was then filtered to eliminate the
amplification of the high frequency noise. The differentiation and filtering likely affected
many of the characteristics that depended on the power in the higher frequencies, such
as the Total Power between 0-25 Hz. This most likely resulted in the distortion of many
of these characteristics resulting in a statistical difference between devices. It is also
possible that upon calculating the Welch’s one-sided power spectral density estimate
with the Hanning window averaging twenty sections, the shape of the power spectral
density for some of the trials were not preserved and could influence some of these
resulting characteristics such as the Median Frequency and Frequency Dispersion.
Unfortunately, some of these pre-processing issues were very difficult to avoid because
the data from each trial would have to be conditioned individually, which would be
incredibly time-consuming and could introduce bias into the results since the study was
not blinded. Several methods to improve the pre-processing of the data are discussed in
more detail in the Future Works Section.
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6.1.3

Separate Subject Groups
Once it was found that there was only one characteristic that was not

significantly different between devices for all subject groups, the groups were separated
and reexamined to determine if there were any differences for particular groups. The
trials were combined per subject group due to the small sample size of each group. A
summary of the conclusions drawn from the results can be seen on the following pages
in Table 6.2 for the Parkinson group, Table 6.3 for the Essential Tremor group, and
Table 6.4 for the Healthy Control group. In the summaries, characteristics highlighted
in green indicate that they were not statistically different between devices, while
characteristics with a red highlight indicate that they were statistically different between
devices.
Parkinson Group

The results of the Wilcoxon Signed Ranks Test indicated

that there was no significant difference between devices for the majority of
characteristics. The only two characteristics that were shown to be statistically different
between devices were the Peak Power between 0-25 Hz and the Proportional Power of
Peak between 0-25 Hz. The results of the t-test were shown to support these results for
those characteristics that were shown to follow a normal distribution. It was therefore
concluded that all of the characteristics were shown to not be statistically different
between devices except for Peak Power between 0-25 Hz and Proportional Power of
Peak between 0-25 Hz for the Parkinson group.
Table 6.2 Summary of characteristics that are not
statistically different between devices for the Parkinson
subject group. Green indicates not statistically
different. Red indicates statistically different.

!Parkinson!Subject!Group:!!!Summary!of!characteristics!
not!statistically!different!between!devices!
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak%Power%between%0-25%Hz%
Proportional%Power%of%Peak%between%0-25%Hz%
Total*Power*between*0/25*Hz*
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Essential Tremor Group

The Essential Tremor group, however, only had

two characteristics that were not statistically significant based on the results of the
Wilcoxon Signed Ranks Test. These two characteristics were the Proportional Power
between 4-6 Hz and Frequency Dispersion. It was noted that these two characteristics
were also not statistically different for the Healthy Control group and the Parkinson
Group, suggesting that these characteristics may be most similar between devices for
the different groups. The Essential Tremor group was also shown to have many of the
characteristics follow a normal distribution, but the t-test revealed that all of these
characteristics were also shown to be statistically different between devices. Therefore, it
was found that all of the characteristics were concluded to be statistically different
between the Tremorometer and Leap Motion Controller for the Essential Tremor
group.
Table 6.3 Summary of characteristics that are not
statistically different between devices for the Essential
Tremor subject group. Green indicates not statistically
different. Red indicates statistically different.
Essential)Tremor)Subject)Group:))Summary)of)
characteristics)not)statistically)different)between)devices)
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak*Power*between*0/25*Hz*
Proportional*Power*of*Peak*between*0/25*Hz*
Total*Power*between*0/25*Hz*

Healthy Control Group

The Wilcoxon Signed Ranks Test for the Healthy

Control Group indicated that there were no significant differences between devices for
most of the characteristics. Similar to the Parkinson group, the only two characteristics
that were shown to be statistically different between devices were the Peak Power
between 0-25 Hz and the Proportional Power of Peak between 0-25 Hz. Again like the
Parkinson group, the t-test supported the results from the Wilcoxon Signed Rank Test
for the normally distributed. It was concluded that all of the characteristics were shown
to not be statistically different except for Peak Power between 0-25 Hz and
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Proportional Power of Peak between 0-25 Hz for the Healthy Control group, which
were the same results as the Parkinson group.
Table 6.4 Summary of characteristics that are not
statistically different between devices for the Healthy
Control subject group. Green indicates not statistically
different. Red indicates statistically different.
!Healthy!Control!Groups:!!!Summary!of!characteristics!not!
statistically!different!between!devices!
Proportional*Power*between*4/6*Hz*
Proportional*Power*between*8/12*Hz*
Median*Frequency*
Frequency*Dispersion
Peak*Frequency*between*0/25*Hz*
Peak%Power%between%0-25%Hz%
Proportional%Power%of%Peak%between%0-25%Hz%
Total*Power*between*0/25*Hz*

It is clear that the results for the Parkinson group and Healthy Control group
agree, where the same six characteristics are shown to not be statistically different
between devices. This supports the claim that for these six characteristics, the two
devices are not statistically different. However, these six characteristics were revealed to
not be statistically similar for the Essential Tremor group. The statistical differences in
the characteristics measured from the Essential Tremor group could be due to the
nature of the disorder. It is known that the amplitude of Essential Tremor tends to be
fairly variable and thus changes in the amplitude of the tremor between device
recordings may have influenced the results, especially since many of the characteristics
depend on the amplitude of this tremor. Another possibility for the statistical difference
in characteristics for the Essential Tremor group is that during the pre-processing of the
data, such as during the differentiation and filtering of the displacement data from the
Leap Motion Controller, the characteristics unique to subjects with Essential Tremor
were more greatly affected than the Parkinson and Healthy Control subjects. Similarly,
upon calculating the Welch’s one-sided power spectral density estimate using a Hanning
window with an average of twenty sections, the shape of the power spectral density for
the Essential Tremor subjects could have been more distorted than the Healthy Control
subjects or the Parkinson subjects due to features unique to Essential Tremor.
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6.2

Classification of Parkinson Subjects
Due to the statistical differences in characteristics between devices for the

Essential Tremor group, only the Healthy Control and Parkinson groups were used for
the classification of Parkinson subjects. Likewise, only those six characteristics that were
not shown to be statistically different between the Leap Motion Controller and the
Tremorometer were used as features to classify the Parkinson subjects. Again, those six
characteristics were Proportional Power between 4-6 Hz, Proportional Power between
8-12 Hz, Median Frequency, Frequency Dispersion, Peak Frequency between 0-25 Hz,
and the Total Power between 0-25 Hz. Since these characteristics were not statistically
different by device for the Healthy Control group and Parkinson group, it was assumed
that the characteristics provided by the Leap Motion Controller were correct and that
they would be the most useful features to classify the Parkinson subjects.

6.2.1

K-means Cluster Analysis
The K-means Cluster analysis, as a method of classifying Parkinson subjects

from Healthy Control subjects, was found to be fairly successful. It was found that
there were 9 misclassifications out of the 40 subjects, an error rate of 0.225. To evaluate
the performance of the classification, a confusion matrix was created and is shown in
Table 6.5. The label True Positive represents the subjects that were from the Parkinson
group, True Negative represents the subjects that were from the Healthy Control group,
the label Predicted Positive represents the subjects that were classified as Parkinson
subjects, and the Predicted Negative label represents the subjects that were classified as
Healthy Control subjects.
Table 6.5 The confusion matrix for the K-means cluster analysis
as a means of classification.

Predicted Positive
Predicted Negative

True Positive
12
8
56

True Negative
1
19

Based on the confusion matrix, the accuracy, sensitivity, and specificity were
calculated and are shown in Table 6.6. The precision is indicative of the percentage of
the positive cluster labels that were correct, the recall/sensitivity represents the
percentage of True Positive subjects that were correctly clustered, the specificity
represents the percentage of True Negative subjects that were correctly clustered, and
the accuracy represents the percentage of the clustering that were correct. The overall
accuracy for classifying Parkinson subjects from Healthy Control subjects using Kmeans Clustering was found to be 77.5%.
Table 6.6
The precision, recall/sensitivity,
specificity, and accuracy to evaluate the K-means
cluster analysis as a means of classification.

K-means Clustering
Precision
92.3%
Recall/Sensitivity
60%
Specificity
95%
Accuracy
77.5 %

A visualization of the K-means cluster analysis was also created for several of
the characteristics and can be seen in Figure 6.1 on the following page. Blue data points
indicate the data that were classified into Cluster 1 and red data points are those that
were classified of Cluster 2. The data points labeled with an asterisk are diagnosed
Parkinson Disease subjects and the data points labeled by a circle are Healthy Controls.
Those points labeled with an “X” represent the centroid of the cluster. This figure
allows for a better visualization of the performance of the K-means cluster analysis in
terms of classifying the Healthy Controls and Parkinson subjects. It also allows one to
visually compare the characteristics of individual subjects per subject group. It can be
seen that some of the Parkinson subjects exhibited a higher Proportion of Power
between 4-6 Hz as expected and it is hypothesized that these Parkinson subjects had
visible or high-amplitude tremor. This is supported by the fact that the same Parkinson
subjects had a much higher Proportional Power of Peak between 0-25 Hz than other
Parkinson subjects. However, other Parkinson subjects were shown to have a lower
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Proportional Power between 4-6 Hz that were more similar to the Healthy Controls.
This most likely indicates that these subjects did not exhibit any visible high amplitude
tremor and were possibly being treated using Deep Brain Stimulation (DBS) or were
taking medications to suppress the severity of the tremor.

Normalized K−means Cluster analysis for
Proportional Power between 4−6 Hz and Proportional Power between 8−12 Hz

Normalized K−means Cluster analysis for
Median Frequency (Hz) and Frequency Dispersion (Hz)

1
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Cluster 1: HE Subjects
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Centroids of Clusters
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Figure 6.1 The K-means cluster analysis for several characteristics. The data points in blue
represent Cluster 1, the red data points represent Cluster 2. The data points labeled with an
asterisk are Parkinson Disease (PD) subjects and those labeled with a circle are Healthy (HE)
Controls. The points labeled with an “X” represent the centroid of the cluster.
Student Version of MATLAB

Student Version of MATLAB
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6.2.2

Support Vector Machine
The original SVM classifier was also found to be fairly successful in classifying

the Parkinson subjects. When cross-validated using the leave-one-out method, the
misclassification rate was calculated to be 0.2, which was slightly better than the error
rate of 0.225 from the K-means cluster analysis. However, once the SVM classifier was
tuned, the misclassification rate was reduced from 0.2 down to 0.15. To evaluate the
performance of this classification the confusion matrix was created and the accuracy,
sensitivity, and specificity were calculated and can be shown in Table 6.7 and Table 6.8,
respectively. The same labels used in the K-cluster analysis confusion matrix were used
for the SVM confusion matrix. As shown, the precision, recall/sensitivity, and accuracy
were all higher for the tuned SVM classifier than for the K-means clustering, while the
specificity remained the same. The resulting overall accuracy of the tuned SVM classifier
for classifying Parkinson subjects from Healthy Controls was found to be 85%.

Table 6.7 The confusion matrix for the predicted response of
the cross-validated SVM classification model

True Positive True Negative
Predicted Positive
15
1
Predicted Negative
5
19

Table 6.8 The precision, recall/sensitivity,
specificity, and accuracy for the tuned SVM
Classifier.

SVM Classifier
Precision
93.75%
Recall/Sensitivity
75%
Specificity
95%
Accuracy
85%
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6.3

Concluding Remarks
In conclusion, the study was fairly successful in comparing the Leap Motion

Controller to the Tremorometer. All eight characteristics were found to not be
statistically different across trials for either device, suggesting that both devices may be
repeatable. It was concluded that when comparing the differences between devices for
the combined subject groups, only the Peak Frequency between 0-25 Hz was found to
not be statistically different. This suggests that the Leap Motion Controller may be
capable of obtaining the same Peak Frequency between 0-25 Hz as the Tremorometer
for subjects with Parkinson Disease, subjects with Essential Tremor, and Healthy
subjects. However, for all other characteristics, the characteristics between devices were
shown to be statistically different. These statistically different characteristics could be
attributed to the pre-processing of the Leap Motion Controller displacement data that
was performed to obtain acceleration. When the devices were compared within each
subject group, evidence was found that the Leap Motion Controller could be capable of
obtaining the same Proportional Power between 4-6 Hz, Proportional Power between
8-12 Hz, Median Frequency, Frequency Dispersion, Peak Frequency between 0-25 Hz,
and Total Power as the Tremorometer in Parkinson subjects as well as Healthy Control
subjects. However, it was found that the Leap Motion Controller did not obtain similar
characteristics to the Tremorometer for the Essential Tremor subjects. This could also
be attributed to the pre-processing of the data, where perhaps characteristics unique to
subjects with Essential Tremor were more greatly affected than the Parkinson and
Healthy Control subjects. It has also been shown that some accelerometers do not
correspond well to the data obtained from devices that record displacement, except for
cases of high-amplitude tremors even though the devices that measure displacement are
shown to be fairly precise.32 Possible improvements to the pre-processing methods are
discussed in the next section. It was noted that in subjects with high-amplitude tremor,
consisting of a very large peak with small frequency dispersion, the resulting
characteristics of the Tremorometer and Leap Motion Controller were very similar. The
power spectral density estimate of such a subject can be seen in Figure 4.15.
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Although only Parkinson subjects and Healthy Controls were used for
classification, the study was still successful in that Parkinson subjects were accurately
differentiated from the Healthy Controls. The Proportional Power between 4-6 Hz,
Proportional Power between 8-12 Hz, Median Frequency, Frequency Dispersion, Peak
Frequency between 0-25 Hz, and the Total Power between 0-25 Hz were all used as
features for classification, based on the results of the statistical differences between the
Leap Motion Controller and Tremorometer for the Parkinson and Healthy Control
groups. The K-means cluster analysis, as a method of classification, was found to have
an accuracy of 77.5%, while the tuned cross-validated SVM classifier was found to have
an accuracy of 85%. It should be noted that another SVM classifier was also trained
using all eight characteristics and while the results are not mentioned in this study, it was
interesting to find that using all eight decreased the overall accuracy even after tuning.
This suggests that perhaps the Peak Power between 0-25 Hz and the Proportional
Power of Peak between 0-25 Hz are either not good predictors or are not consistent
across recordings. Although not perfect, the SVM classifier reported in this study was
more successful in classifying Parkinson subjects than simply using K-means clustering.
Based on these results, it can be concluded that overall the study was successful in
classifying Parkinson subjects from Healthy Control subjects.

It is important to keep in mind that not all of the Parkinson and Essential
Tremor subjects displayed high-amplitude tremor. Many of the subjects were likely
taking medication or undergoing Deep Brain Stimulation (DBS) that could have greatly
suppressed their tremor. This would most likely detriment the accuracy of the
classifications, making it much more difficult to discern subjects Parkinson from
Healthy Controls. Methods to account for cases where patients are undergoing
treatment for their disorder are mentioned in Future Works.
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6.4

Future Works
In future works, it would be interesting to investigate a variety of different

methods to go about comparing the Leap Motion Controller with the Tremorometer to
measure human tremor. It is suggested that rather than performing two separate trials
with the two devices individually, to perform one trial with the two devices
simultaneously as done in other similar studies.32 This would ensure that the same
tremor was recorded rather than tremor from the same individual at two different
points in time. Since tremor can significantly vary at different times, especially for those
with movement disorders, it would be ideal to perform the recordings of both devices
simultaneously. It is also recommended that postural tremor be recorded rather than
rest tremor, since it is less likely that the Leap Motion Controller will incorrectly record
the index finger. This is because if the hand is outstretched, fingers are more spread
apart than they would be at rest. When the Leap Motion Controller can distinguish
individual fingers as is the case when fingers are more spread apart, it is much more
likely to obtain an accurate recording of the index finger. It would also be useful to
implement the confidence level method, available in the Leap Motion Skeletal V2 Beta
SDK for Java, in the code used to record the Leap Motion data. This method rates how
well the internal hand model fits the observed hand and would be useful to ensure that
the recordings are as accurate as possible.
It is suggested that to improve the pre-processing of the data an alternative
approach be taken to estimate the spectra on the data. One method is to blind the study
to eliminate bias and pre-process each tremor signal individually, applying different
filters and windowing to best estimate the power spectral density. This would eliminate
the possibility of distorting the shape of power spectral density estimate by applying the
same filtering and windowing to all tremor signals. Another method would be an
adaptive approach specifically for tremor, such as the one suggested by Timmer, Lauk,
and Deuchl (1996).40 In future works, a Kalman Filter could also be implemented during
the pre-processing of data.
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Although not performed in this study, it would have been interesting to
determine how well the Parkinson subjects could be classified, if the Essential subjects
had been included in the classifications. Likewise, it would also be interesting to
determine if abnormal tremors could be correctly classified out of the Healthy Control
subjects, Parkinson subjects, and Essential Tremor subjects. It is also suggested that
more subjects and possibly more trials be recorded in future works. This would increase
the power of the study and add more validity to the results. It would also be beneficial
to include the UPDRS score at the time of the recording, recorded by a clinician. This
would provide better true indication of the severity of tremor and determine if similar
scores can be derived based on the tremor measurements and characteristics.
Comments as to whether the subjects are currently taking medication or if they are
undergoing treatment for the tremor would also be useful as this could greatly affect the
presence of tremors characteristic to Parkinson Disease and Essential Tremor. The
identification and calculation of more potential features could also prove to be useful
along with an implementation of a feature selection algorithm to identify the most
deterministic features that could be used in the classification. Although only one
unsupervised and one supervised learning methods were implemented in this study, it is
suggested that others alternatives may provide better results.
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HE

ET

PD

Group

Patient,#
Patient,1
Patient,2
Patient,3
Patient,4
Patient,5
Patient,6
Patient,7
Patient,8
Patient,9
Patient,10
Patient,11
Patient,12
Patient,13
Patient,14
Patient,15
Patient,16
Patient,17
Patient,18
Patient,19
Patient,20
Patient,21
Patient,22
Patient,23
Patient,24
Patient,25
Patient,26
Patient,27
Patient,28
Patient,29
Patient,30

Leap,Motion,Controller

Proportional,Power, Proportional,Power, Median,
between,426,Hz
between,8212,Hz
Frequency
0.7181570035
0.0472306237 5.4687500000
0.4947000445
0.1291474835 5.2734375000
0.2980546584
0.2445159130 7.0312500000
0.2405096657
0.2161678332 6.8359375000
0.1631542914
0.3975438530 7.8125000000
0.4642429866
0.1526389050 5.2734375000
0.1993629960
0.2907351146 7.6171875000
0.2294078394
0.0857420869 6.4453125000
0.2782662495
0.1706351751 6.6406250000
0.8664971798
0.0130729994 5.4687500000
0.4492106237
0.1509763903 5.8593750000
0.1577596424
0.3141549332 7.4218750000
0.3069229043
0.2284947613 6.8359375000
0.0894941535
0.4218977353 8.5937500000
0.2270704149
0.2740067836 7.4218750000
0.1952019109
0.3699577811 7.6171875000
0.5531137431
0.0913712348 4.8828125000
0.2916076405
0.2318319385 7.0312500000
0.7485727751
0.0551000471 5.4687500000
0.1659828701
0.3567683078 8.0078125000
0.1544260485
0.3628848014 7.8125000000
0.1813730349
0.3269018050 7.8125000000
0.2150431901
0.3606779267 7.4218750000
0.1886958859
0.2751234323 7.4218750000
0.2176676811
0.2449474607 7.0312500000
0.2451203075
0.2035588432 7.0312500000
0.2650411409
0.2949235404 7.2265625000
0.1619924416
0.2621745987 7.2265625000
0.1725084907
0.2771882823 7.4218750000
0.2392638320
0.2715170543 7.2265625000

Frequency,
Max.,Freq.,
Power,of,max,peak, Proportional,Power,of,max, Total,Power,
Dispersion
between,0225,Hz between,0225,Hz
peak,between,0225,Hz
between,0225,Hz
1.5625000000
5.4687500000
0.0434327267
0.1290748761
0.3364924918
4.1015625000
4.4921875000
0.0003676964
0.0749635096
0.0049050048
4.4921875000
7.8125000000
0.0030371635
0.0460977407
0.0658853004
4.1015625000
6.4453125000
0.0002238201
0.0489406647
0.0045732951
4.1015625000
8.3984375000
0.0000308012
0.0480111523
0.0006415423
4.2968750000
4.8828125000
0.0000544361
0.0552591733
0.0009851046
4.6875000000
7.6171875000
0.0000045072
0.0448777466
0.0001004334
1.9531250000
6.4453125000
0.0010366307
0.1014832527
0.0102147956
4.6875000000
6.6406250000
0.0003823943
0.0587869870
0.0065047446
0.9765625000
5.4687500000
0.0093628096
0.1571659048
0.0595727783
3.9062500000
5.4687500000
0.0010214495
0.0530777732
0.0192443918
4.2968750000
6.6406250000
0.0000357453
0.0503869034
0.0007094174
4.1015625000
5.8593750000
0.0000497057
0.0460581611
0.0010791934
6.6406250000
9.1796875000
0.0000533025
0.0379320387
0.0014052104
6.2500000000
6.0546875000
0.0000252048
0.0358130730
0.0007037865
4.2968750000
8.7890625000
0.0000075499
0.0437546751
0.0001725518
3.3203125000
4.2968750000
0.0010548434
0.0945189689
0.0111601236
4.1015625000
7.4218750000
0.0000486863
0.0457390080
0.0010644364
1.3671875000
5.4687500000
0.0000858662
0.1363013110
0.0006299736
4.8828125000
8.0078125000
0.0000104345
0.0425931411
0.0002449802
4.2968750000
7.4218750000
0.0001839410
0.0404951487
0.0045422973
5.4687500000
7.2265625000
0.0000142447
0.0372290115
0.0003826245
4.1015625000
8.7890625000
0.0000009170
0.0429225280
0.0000213647
4.4921875000
7.6171875000
0.0000000439
0.0409468275
0.0000010713
4.1015625000
6.6406250000
0.0000269410
0.0465143448
0.0005791975
4.2968750000
7.0312500000
0.0000029076
0.0487437486
0.0000596504
4.4921875000
6.0546875000
0.0000040320
0.0380669009
0.0001059183
3.7109375000
6.8359375000
0.0000021822
0.0476682942
0.0000457790
3.7109375000
7.6171875000
0.0000011647
0.0514818016
0.0000226241
4.2968750000
7.2265625000
0.0000136872
0.0429820638
0.0003184406

Trial,1

Appendix A

Data
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HE

ET

PD

Group

Patient,#
Patient,1
Patient,2
Patient,3
Patient,4
Patient,5
Patient,6
Patient,7
Patient,8
Patient,9
Patient,10
Patient,11
Patient,12
Patient,13
Patient,14
Patient,15
Patient,16
Patient,17
Patient,18
Patient,19
Patient,20
Patient,21
Patient,22
Patient,23
Patient,24
Patient,25
Patient,26
Patient,27
Patient,28
Patient,29
Patient,30

Leap,Motion,Controller

Proportional,Power, Proportional,Power, Median,
Frequency,
Max.,Freq.,,,,,,,,,,,,, Power,of,max,peak, Proportional,Power,of,
Total,Power,
between,426,Hz
between,8212,Hz
Frequency
Dispersion
between,0225,Hz between,0225,Hz
max,peak,between,0225,Hz between,0225,Hz
0.3866780
0.2547928
6.0546875
4.4921875
4.4921875
0.0024710
0.0512100
0.0482522
0.5665100
0.1694586
5.0781250
4.2968750
4.4921875
0.0014137
0.0750748
0.0188308
0.3284396
0.2223000
5.8593750
5.2734375
4.1015625
0.0016435
0.0614806
0.0267327
0.5973380
0.1523724
5.6640625
3.3203125
5.4687500
0.0003087
0.1018742
0.0030300
0.1692995
0.3030152
7.6171875
4.8828125
8.0078125
0.0000146
0.0389984
0.0003756
0.3963620
0.2268910
5.8593750
4.2968750
5.2734375
0.0000329
0.0417853
0.0007880
0.1364188
0.4065515
8.0078125
4.1015625
8.5937500
0.0000000
0.0426615
0.0000005
0.1971898
0.2307805
6.8359375
2.9296875
6.4453125
0.0005174
0.0645624
0.0080147
0.1396266
0.3631385
7.8125000
3.9062500
8.5937500
0.0002238
0.0445346
0.0050253
0.8411838
0.0504775
5.4687500
1.1718750
5.2734375
0.0235972
0.1549630
0.1522761
0.5321935
0.1811619
5.8593750
3.9062500
5.2734375
0.0043053
0.0840130
0.0512460
0.2185071
0.3334472
7.6171875
5.0781250
5.8593750
0.0000570
0.0344488
0.0016554
0.2199938
0.2571104
7.2265625
3.3203125
7.8125000
0.0000285
0.0504597
0.0005657
0.1652737
0.4081493
8.2031250
3.7109375
8.7890625
0.0000100
0.0577935
0.0001737
0.2378957
0.3410756
7.0312500
5.0781250
8.5937500
0.0000045
0.0343813
0.0001301
0.2388584
0.2811318
7.4218750
4.1015625
7.6171875
0.0000103
0.0430237
0.0002391
0.4346800
0.2083881
5.4687500
4.4921875
4.2968750
0.0045889
0.0590021
0.0777756
0.2334817
0.2297407
7.0312500
4.1015625
7.4218750
0.0000358
0.0456488
0.0007838
0.6476124
0.1217374
5.6640625
2.9296875
5.4687500
0.0000930
0.1126020
0.0008262
0.1879533
0.3037330
7.6171875
4.8828125
7.8125000
0.0000125
0.0421922
0.0002957
0.2357107
0.3092422
7.4218750
4.4921875
7.0312500
0.0000306
0.0406616
0.0007536
0.2190216
0.2697444
7.2265625
4.2968750
7.2265625
0.0000043
0.0394765
0.0001089
0.2326085
0.2933525
7.4218750
4.2968750
7.6171875
0.0000006
0.0414202
0.0000135
0.1804642
0.2863243
7.4218750
3.9062500
7.2265625
0.0000000
0.0460995
0.0000006
0.2094146
0.2362635
7.0312500
4.4921875
6.4453125
0.0000660
0.0488348
0.0013524
0.2030863
0.2584315
7.0312500
5.6640625
6.6406250
0.0000032
0.0379260
0.0000837
0.2469855
0.1840417
6.6406250
3.1250000
6.4453125
0.0000022
0.0592849
0.0000379
0.3194359
0.2088927
6.4453125
4.6875000
5.6640625
0.0000002
0.0339593
0.0000046
0.1677264
0.2928681
7.4218750
4.8828125
6.8359375
0.0000030
0.0474759
0.0000641
0.2488117
0.2304057
7.0312500
4.1015625
7.0312500
0.0000164
0.0423286
0.0003872

Trial,2
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ET

PD

Group

Proportional,Power, Proportional,Power, Median,
Patient,# between,426,Hz
between,8212,Hz Frequency
Patient,1
0.662898756
0.168711689 4.687500000
Patient,2
0.598708708
0.041206669 5.859375000
Patient,3
0.603574990
0.099730454 4.296875000
Patient,4
0.200416926
0.223835262 7.031250000
Patient,5
0.427382952
0.071385421 6.250000000
Patient,6
0.769274566
0.052440394 4.687500000
Patient,7
0.133203839
0.539032386 8.984375000
Patient,8
0.132804073
0.088745389 7.031250000
Patient,9
0.111090504
0.486497466 8.984375000
Patient,10
0.856480613
0.049093251 5.468750000
Patient,11
0.440837050
0.007496057 6.250000000
Patient,12
0.334350383
0.060918288 6.250000000
Patient,13
0.281706898
0.146672397 6.250000000
Patient,14
0.175563722
0.246762788 7.421875000
Patient,15
0.293197811
0.057819167 3.906250000
Patient,16
0.197490222
0.317474247 7.031250000
Patient,17
0.469121036
0.022960473 3.906250000
Patient,18
0.535055303
0.039717415 4.687500000
Patient,19
0.698532632
0.061161957 5.468750000
Patient,20
0.214809747
0.027644876 6.250000000
Patient,21
0.046460959
0.482540121 10.546875000
Patient,22
0.393938815
0.090553381 6.250000000
Patient,23
0.086193223
0.619810808 10.156250000
Patient,24
0.104563646
0.471636612 8.203125000
Patient,25
0.537190568
0.071672869 5.468750000
Patient,26
0.329238115
0.180133950 6.250000000
Patient,27
0.416266623
0.155343413 6.250000000
Patient,28
0.165489671
0.185577894 7.031250000
Patient,29
0.143306524
0.203487739 7.031250000
Patient,30
0.195691573
0.317210594 7.421875000

Tremorometer
Frequency, Max.,Freq.,
Power,of,max,peak, Proportional,Power,of,max, Total,Power,
Dispersion
between,0225,Hz between,0225,Hz peak,between,0225,Hz
between,0225,Hz
5.078125000
4.687500000
0.036190135
0.216915850
0.166839228
1.953125000
5.468750000
0.000202818
0.169117390
0.001199267
1.171875000
4.296875000
0.164428372
0.309310018
0.531597041
3.515625000
7.031250000
0.000245489
0.107785480
0.002277539
2.343750000
6.250000000
0.000148334
0.145017124
0.001022869
1.562500000
4.687500000
0.002134835
0.259918587
0.008213415
5.078125000
9.765625000
0.000004536
0.072984526
0.000062152
1.562500000
7.031250000
0.018245964
0.236032695
0.077302496
5.859375000
9.375000000
0.000009133
0.084547253
0.000108016
0.781250000
5.468750000
0.016967712
0.314015256
0.054034627
1.171875000
6.250000000
0.391771640
0.327519836
1.196176364
1.953125000
6.250000000
0.000149092
0.182422641
0.000817263
7.031250000
6.250000000
0.000211253
0.091412917
0.002310936
6.250000000
7.812500000
0.000005242
0.094668952
0.000055371
3.515625000
3.125000000
0.001655713
0.147906440
0.011194252
3.906250000
6.250000000
0.000043695
0.136789286
0.000319424
1.953125000
3.906250000
0.008292007
0.252589049
0.032828008
2.734375000
4.687500000
0.001112017
0.131615526
0.008448965
1.953125000
5.468750000
0.006764987
0.246581717
0.027435057
1.171875000
6.250000000
0.000532856
0.275212948
0.001936155
4.687500000 12.890625000
0.000010694
0.105050090
0.000101791
3.515625000
6.250000000
0.000016691
0.126398975
0.000132049
4.687500000 10.546875000
0.000015012
0.118718511
0.000126451
3.906250000
8.593750000
0.000006063
0.112506066
0.000053884
2.734375000
5.078125000
0.000055770
0.133051771
0.000419154
5.468750000
5.078125000
0.000018288
0.083628360
0.000218679
3.515625000
6.250000000
0.000054379
0.155648448
0.000349365
3.515625000
6.640625000
0.000012222
0.132450290
0.000092270
3.515625000
7.031250000
0.000013207
0.115649225
0.000114196
4.687500000
6.250000000
0.000061296
0.087032386
0.000704287

Trial,1
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PD

Group

Patient,#
Patient,1
Patient,2
Patient,3
Patient,4
Patient,5
Patient,6
Patient,7
Patient,8
Patient,9
Patient,10
Patient,11
Patient,12
Patient,13
Patient,14
Patient,15
Patient,16
Patient,17
Patient,18
Patient,19
Patient,20
Patient,21
Patient,22
Patient,23
Patient,24
Patient,25
Patient,26
Patient,27
Patient,28
Patient,29
Patient,30

Tremorometer
Proportional,Power, Proportional,Power, Median,
between,426,Hz
between,8212,Hz Frequency
0.672684755
0.125659997 5.078125000
0.740809573
0.040821762 5.468750000
0.785542175
0.072113082 4.687500000
0.123395765
0.332569135 7.812500000
0.818808549
0.045136177 5.078125000
0.601312849
0.065782174 5.468750000
0.141014515
0.380886791 7.812500000
0.270259334
0.116383007 6.640625000
0.174836735
0.436066139 9.375000000
0.889474743
0.026171007 5.468750000
0.435521257
0.011900603 6.250000000
0.240003446
0.084143894 6.250000000
0.416674237
0.145688404 5.859375000
0.127661723
0.294982599 7.421875000
0.198891718
0.111229977 3.906250000
0.190778343
0.306046388 7.421875000
0.781076071
0.054919637 5.078125000
0.539575483
0.081689772 5.859375000
0.872798552
0.019882996 5.468750000
0.258204641
0.075945087 6.250000000
0.042471298
0.619398511 9.765625000
0.325283551
0.134054200 6.250000000
0.095406612
0.530434064 9.375000000
0.065260770
0.511429598 8.203125000
0.527634234
0.037593928 5.859375000
0.312016209
0.123756980 6.250000000
0.298518598
0.161869906 6.250000000
0.351185158
0.136624223 6.250000000
0.229695761
0.178013521 6.640625000
0.307553821
0.248029242 6.640625000

Frequency, Max.,Freq.,
Power,of,max,peak, Proportional,Power,of,max, Total,Power,
Dispersion
between,0225,Hz between,0225,Hz peak,between,0225,Hz
between,0225,Hz
5.078125000
5.078125000
0.042454450
0.217732992
0.194982578
1.562500000
5.078125000
0.000459365
0.221044653
0.002078145
0.781250000
4.687500000
0.224973326
0.301747400
0.745567436
5.078125000
7.421875000
0.000146220
0.094384801
0.001549157
1.171875000
5.078125000
0.000357140
0.295756194
0.001207544
2.343750000
5.468750000
0.001466413
0.195781302
0.007489995
3.906250000
7.421875000
0.000017251
0.113996048
0.000151325
2.734375000
6.640625000
0.012028742
0.177248317
0.067863556
8.984375000
9.375000000
0.000007120
0.083807400
0.000084949
1.171875000
5.468750000
0.114978839
0.304763733
0.377271878
1.171875000
6.250000000
0.533550869
0.308139000
1.731524829
2.343750000
6.640625000
0.000152531
0.179026673
0.000851982
7.031250000
5.078125000
0.000133047
0.099205287
0.001341101
5.468750000
7.812500000
0.000006130
0.110641640
0.000055405
5.078125000
3.125000000
0.000591167
0.163376138
0.003618383
4.296875000
6.250000000
0.000024683
0.105240203
0.000234537
1.171875000
5.078125000
0.220200250
0.235908204
0.933413075
2.734375000
5.468750000
0.000221490
0.161731859
0.001369482
0.781250000
5.468750000
0.008210326
0.353016893
0.023257591
1.562500000
6.250000000
0.000266671
0.239389483
0.001113959
4.296875000 10.156250000
0.000008286
0.094722091
0.000087478
4.687500000
6.250000000
0.000018182
0.162381277
0.000111967
5.468750000 10.156250000
0.000008339
0.077629240
0.000107415
3.125000000
8.593750000
0.000008212
0.123719237
0.000066374
1.953125000
5.468750000
0.000185313
0.182420525
0.001015852
3.515625000
6.250000000
0.000028807
0.128544254
0.000224099
3.906250000
6.250000000
0.000084659
0.201496013
0.000420146
4.687500000
5.859375000
0.000005748
0.103101113
0.000055748
3.515625000
6.250000000
0.000039739
0.123046528
0.000322957
3.906250000
5.859375000
0.000107824
0.099847389
0.001079882
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Appendix B
IRB Application
Tremor Detection
PI:
Matthew Johnson
IRB ID #: 201404034

Project Details
I. Demographics
I.1
I.2
I.3
I.4
I.7

Project Title:
Detection of Parkinson Disease Rest Tremor
Short Title (required):
Tremor Detection
Project is primarily:
Biomedical
Do you want the IRB to give this project
Regular (expedited or full board) review
Enter the estimated date you will be ready to begin
recruiting participants or collecting data for this project.
04/2014
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I.8

Provide a short summary of the purpose and procedures of
the study proposed in this IRB application.
•

•

•

DO NOT include information on studies not proposed
in this application. (If your source of support
proposal describes multiple aims, refer to the
information button for an example on how to
complete this question.)
Use LAY terminology only. This must be easily
understandable by IRB community members and
nonscientists.
DO NOT cut and paste technical abstracts from
source of support applications that may not be
understood by a general audience.

The main purpose of this study is to determine whether it is
possible to predict, with reasonable accuracy, if a patient has
Parkinson Disease based on their rest tremor. The rest tremor
will be measured by recording the three-dimensional position
and acceleration of their index finger while at rest over a set
period of time. This will be done using two devices. The first
device, the Tremorometer, uses a three-dimensional
accelerometer(a device that measures changes in acceleration)
and has 510k clearance by the FDA to measure and quantify
tremor by measuring acceleration and calculating tremor
statistics in human patients. The second device, the Leap
Motion Controller, is a three-dimensional camera that uses
two CCD (Charged Coupled Device) cameras and three
infrared LEDs to obtain position data. Tremor statistics
obtained and calculated from both devices will be compared to
determine if data obtained from the Leap Motion Controller
are substantially equivalent to that obtained from the
Tremorometer. The data obtained from the Leap Motion
Controller will then be used to determine the characteristic
features of rest tremor in Parkinson Disease and then be used
to create an algorithm that can predict whether a patient has
Parkinson disease.
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I.9

Specify your research question(s), study aims or hypotheses
(do not indicate "see protocol")
Hypothesis 1: The Leap Motion Controller can be used in
place of a triaxial accelerometer to record rest tremor in
Parkinson Disease.
Aim 1: Determine whether the Leap Motion Controller can be
used to obtain similar tremor statistics as those obtained from
a triaxial accelerometer (Tremorometer).
Hypothesis 2: The data obtained from the Leap Motion
Controller can be used to identify characteristic features of rest
tremor in Parkinson Disease that will distinguish PD patients
from patients with Essential Tremor.
Aim 2: Determine whether patients with rest tremor in
Parkinson disease can be identified when compared to patients
with Essential Tremor, using the positional data collected by
the Leap Motion Controller.

I.10

Background and significance and/or Preliminary studies
related to this project.
(do not indicate "see protocol")
Parkinson Disease (PD) is a debilitating and progressive
movement disorder that affects over one million people in the
United States alone. One of the most characteristic symptoms
of PD is resting tremor, as it has been shown that the
proportion of patients with resting tremor ranged from 69100% in 3 series of patients with autopsy-proven PD[1,2,3].
Several methods currently exist to quantitatively measure
tremor including accelerometry, electromyography, the
spirogram, and most recently three-dimensional cameras [4].
Advances in three-dimensional cameras have allowed for
more accurate recordings and can now be used to provide
much more accurate measurements in microdisplacements of
upper extremities that are involved in movements such as
resting tremor. One such three-dimensional camera is the Leap
Motion Controller, produced by Leap Motion, Inc. The device
is a small USB three-dimensional camera that utilizes two
CCD (Charged Coupled Device) cameras and three infrared
LEDs to obtain depth information, and is capable of
measuring changes in position to within 0.01 mm, and requires
no external sensors or markers unlike accelerometry,
electromyography, and the spriogram. The advantage of
having no sensors attached to the body is that the mass of the
sensors decrease the peak frequency of finger tremor by
approximately 0.85 Hz for every gram of additional mass with
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no solid data for its effects on the amplitude of acceleration
[5]. Therefore the attached sensors may change the
characteristics of the tremor, thus altering interpretation of
tremor. Unlike accelerometers, the Leap Motion Controller
does not require calibration eliminating possible errors caused
by recalibrating. Unlike electromyography, the Leap Motion
Controller is not affected by interference from electrical
sources, mechanical artifacts, stimulus artifacts, and the
electrical activity of muscles that are not of interest. This is
why the Leap Motion Controller is of interest and may be
superior in measuring tremor.
I.11

Literature cited / references (if attaching a grant or protocol
enter N/A).
1. Hughes AJDaniel SELees AJ The clinical features of
Parkinson's disease in 100 histologically proven cases. Adv
Neurol. 1993;60595- 599
2. Louis EDKlatka LALiu YFahn S Comparison of
extrapyramidal features in 31 pathologically confirmed cases
of diffuse Lewy body disease and 34 pathologically confirmed
cases of Parkinson's disease. Neurology. 1997;48376- 380
3.Rajput AHRozdilsky BAng L Occurrence of resting tremor
in Parkinson's disease. Neurology.1991;411298- 1299
4. Wenzelburger, R., Raethjen, J., Löffler, K., Stolze, H.,
Illert, M. and Deuschl, G. (2000), Kinetic tremor in a reach-tograsp movement in Parkinson's disease. Mov. Disord., 15:
1084–1094.
5. Stiles RN, Randall JE; Mechanical factors in human tremor
frequency; J Appl Physiol 1967;23(3):324-30

I.12

Select up to three key words below that best describe this
research study:
• Engineering
• Electrical
• Investigational Devices
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II. Research Team
II.1

The Principal Investigator of this study is:
Graduate student/Medical Student
Do you want to add a team member who is a WUSTL
faculty, student or staff member?
Yes
Do you want to add a team member who is not a WUSTL
faculty, student or staff member?
No

II.3

II.4

II.Team Members
5
WUSTL Team Members
Role

Name

E-mail

Consent
Process
Involvement

Department

Contact

General
Engineering

Yes

Yes

Electrical &
Systems
Engineering

Yes

No

Neurology

Yes

Yes

Neurology

Yes

Yes

PI

Matthew Johnson,
Biomedical
Engineering, BS

johnson.m@wustl.edu

School Of
Engineering
And
Applied
Science

FS

Arye Nehorai,
PHD

nehorai@ese.wustl.edu

School Of
Engineering

Scott Norris,
MD, BA
Mwiza Ushe,
MD, MA-

WUSTL
COI

College

School Of
Medicine
School Of
Medicine

norriss@npg.wustl.edu
ushem@neuro.wustl.edu

Name
Matthew Johnson, Biomedical Engineering, BS
Arye Nehorai, PHD
Scott Norris, MD, BA
Mwiza Ushe, MD, MA-

Financial Interests
none
none
none
none

Non-WUSTL Team Members
Name
Name

Institution

Location

FWA

Role

DHHS

Contact

Nothing found to display
Financial Interests
Nothing found to display
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WUSTL
COI

Consent Process
Involvement

III. Source(s) of Support
III.1

Source(s) of Support
Type

Source

Grant
Title

Name of
PI on
Grant

Status

Status
Description

No Support

* new source name

IV. Waiver of Consent
IV.1

Are you requesting a waiver of informed consent
(participants will not be given any oral or written
information about the study prior to their participation)?
No

V. Other Institutional Reviews/Requirements
V.1

Do you or a family member have within the past twelve
months or anticipate having within the next twelve months
any financial interests in the company/organization
providing support for this research or from a
company/organization that owns or licenses the drug,
device, or intellectual property being utilized in this
research?
Name
Matthew Johnson, Biomedical Engineering, BS
Arye Nehorai, PHD
Scott Norris, MD, BA
Mwiza Ushe, MD, MA-

V.4

V.5

Financial Interests
none
none
none
none

Do any of the objectives of this study involve the diagnosis,
prevention, screening, evaluation, treatment or support of
cancer patients?
No
Are more than 30% of the patients involved in this study
likely to have an active cancer diagnosis?
No
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V.7

V.10

V.12

Will any subject be asked to undergo a radiation therapy
procedure (including external beam therapy, brachytherapy,
or radiopharmaceutical therapy)?
No
Does your study involve the administration of
radiopharmaceuticals (radioactive drugs) for research
purposes?
No
Will any participant be asked to undergo any of the
following:
•

a standard radiology procedure involving ionizing
radiation (includes X-rays, fluoroscopy, DEXA, CT)

•

a standard nuclear medicine examination with FDAapproved radioactive drugs (including bone scans,
radionuclide ventriculogram (RVG or MUGA),
myocardial perfusion imaging, FDG-PET)

OR

V.17

• DO NOT include MRI or ultrasound
No
Will the study involve any of the following activity at WUSM
or any BJC hospitals, even if subjects or their insurance will
not be billed for the item or service, and regardless of the
study funding source (including studies with departmental
or no funding)?
•

•

V.18

V.19

Procedures, tests, examinations, hospitalizations, use
of Pathology services, use of clinic facilities or
clinical equipment, or any patient care services,
including services conducted in the Clinical
Research Unit; or
Physician services or services provided by nonphysicians who are credentialed to bill (ARNPs,
Physician Assistants, etc.)

Yes
Does this project involve administration of recombinant
DNA (gene therapy) or microorganisms?
No
Does this study involve the use of human embryonic stem
cells or human induced pluripotent stem cells?
No
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V.20

V.21

V.22

V.23

V.24

V.25

V.26

Does this study involve research in which a human embryo
or embryos are destroyed, discarded, or knowingly subjected
to risk of injury or death greater than that allowed for
research on fetuses in utero?
No
Will you be utilizing participants, data or tissue from the
Memory & Aging Project (MAP) or Alzheimer's Disease
Research Center (ADRC)?
No
Is the PI of this study a BJH Registered nurse or a staff
member of Patient Care Services (Pharmacy, PT/OT/,
Respiratory, Rehabilitation, and Social work)?
No
Will any portion of this project be conducted in any Center
for Applied Research Sciences Units, Clinical Research Unit
(CRU), Clinical Trials Unit (CTU) and/or the Pediatric
Research Unit (PCRU)?
No
Will this research be performed in the Neonatal Intensive
Care Unit (NICU)?
No
Is this research being conducted in the Emergency
Department?
No
Are you recruiting or screening patients in the Emergency
Department?
No

VI. Participants
VI.1

VI.2
VI.3
VI.4

How many adult participants do you expect to consent for
this project?
30
What is the age of the youngest adult participant?
18.0
What is the age of the oldest adult participant?
No age limit
How many minor participants do you expect to consent for
this project?
0
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VI.7

Describe EACH of your participant populations
•
•

Include description of any control group(s)
Specify the Inclusion/Exclusion criteria for EACH
group

Study patient groups:
1) 10 patients diagnosed with Parkinsonism with tremor
Inclusion criteria:
a. age greater than or equal to 18
b. male or female
c. any race or ethnicity
d. physician confirmed Parkinsonism, with tremor as a
symptom, based on diagnostic criteria (Calne DB, Snow BJ,
Lee C. Criteria for Diagnosing Parkinson's Disease. Annals of
Neurology 1992; 32:S125-S127.)
e. ability to give informed consent
Exclusion criteria:
a. History of stroke, seizure, cerebral palsy, or additional
neurological diagnosis
b. Severe upper limb tremor
c. Any serious medical or psychiatric condition
d. Age less than 18
e. Cognitive impairment (Mini-Mental State Score <19)
2)10 patients diagnosed with Essential Tremor
Inclusion criteria:
a. age greater than or equal to 18
b. male or female
c. any race or ethnicity
d. physician confirmed essential tremor based on diagnostic
criteria (Bain P, Brin M, Deuschl G, Elble R, Jankovic J,
Findley L, Koller B, Pahwa R. Criteria for the diagnosis of
essential tremor. Neurology 2000;54(Suppl. 4):57.)
e. ability to give informed consent
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Exclusion criteria:
a. History of stroke, seizure, cerebral palsy, or other major
psychiatric illness
b. Severe upper limb tremor
c. Any serious medical or psychiatric condition
d. Age less than 18
e. Cognitive impairment (Mini-Mental State Score <19)
3) 10 normal control subjects
Inclusion criteria:
a. age greater than or equal to 18
b. male or female
c. any race or ethnicity
d. ability to give informed consent

VI.8

VI.9

Exclusion criteria:
a. History of stroke, seizure, cerebral palsy, or other major
psychiatric illness
b. Severe upper limb tremor
c. Any serious medical or psychiatric condition
d. Age less than 18
e. Cognitive impairment (Mini-Mental State Score <19)
Describe why you believe there is a sufficient number of
potential participants available to meet your recruitment
goals.
Over one million people in the United States suffer from
Parkinson disease alone. The clinical database in the
Washington University Movement Disorders Clinic follows a
large number of patients with Parkinsonism with tremor as a
symptom as well as patients with Essential Tremor.
Therefore, the 10 subjects with Parkinsonism with tremor and
the 10 subjects with Essential Tremor required for this study
represents a very small proportion of the potential participants
within this database. 10 healthy control subjects will be
recruited among the spouses or from the Volunteer for Health
initiative of Barnes-Jewish Hospital and Washington
University School of Medicine's Research Participant
Registry with a pool of over 8000 volunteers.
Describe how you will have access to each of your study
populations in sufficient number to meet your recruitment
goals.
Participants with Parkinsonism and Essential Tremor will be
recruited from the Movement Disorders Center at Washington
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VI.10

VI.13

VI.16

VI.21
VI.24

University School of Medicine. Healthy control subjects will
be recruited among their spouses or from the Volunteer for
Health initiative of Barnes-Jewish Hospital, an affiliate of the
Washington University School of Medicine with a pool of
over 8000 volunteers.
Choose the appropriate description of the disease/condition
under study (for example consider race, ethnicity, gender,
socioeconomic status etc.)
The disease/condition under study is represented equally
throughout the population
Will participants provide any information about their
relatives or another person (third party)?
No
Will any individual(s), other than the participant, provide
you with information about the participant (e.g. proxy
interviews)?
No
Do you plan to recruit/enroll non-English speaking people?
No
Do you propose to enroll any of the following in this study
as participants?
•
•
•
•

VI.26
VI.27
VI.28

VI.34

Employee of the PI or employee of a research team
member
Individual supervised by PI or supervised by member
of research team
Individual subordinate to the PI or subordinate to
any member of the research team
Student or trainee under the direction of the PI or
under the direction of a member of the research team

No
Is this project about pregnant women?
No
Will this project involve fetuses?
No
Does this project involve adult participants who may be
incompetent or have limited decision-making capacity on
initial enrollment into the study?
No
Does this project involve participants whose capacity to
consent may change over the course of the study?
No
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VI.38

Does this project involve prisoners as participants?
No

VII.A. Basic Project Information
VII.A.1

VII.A.2
VII.A.4
VII.A.5
VII.A.6
VII.A.7

VII.A.8

VII.A.9

Is there a separate, written protocol that will be submitted in
addition to this IRB New Project form? (Note: a grant
application is not considered to be a protocol)
Yes
Who initiated/provided the protocol?
WUSTL Investigator
Protocol#:
Protocol Version#:
Protocol Date:
Provide a list of the amendments for this study (this may be
left blank if none). Any amendments previously listed should
not be removed.
Amend. #
Amend. Date
Nothing found to display
Where will project procedures take place (check all that
apply)?
• Barnes Jewish Hospital (BJH)
• Washington University School of Medicine (WUSM)
Is this project also being conducted by other researchers at
their own sites (e.g. a multi-site collaborative project)?
No
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VII.B. Drugs/Devices
VII.B.1

Does this project involve any of the following:
•
•
•
•

VII.B.2

VII.B.9
VII.B.11

VII.B.15

VII.B.20

VII.B.21

VII.B.22

VII.B.23

VII.B.24

clinical intervention
pharmacologic intervention
therapeutic intervention
physiology studies (e.g. studying the functions of
organs, tissues, or cells)

Yes
Does this project involve any substance ingested, injected, or
applied to the body?
No
Are any contrast agents used for any purpose in this study?
No
Does this project involve a drug washout (asking participant
to stop taking any drugs s/he is currently taking)?
No
Will any participants receive a placebo in this study when, if
they were not participating, they could be receiving an FDAapproved treatment for their condition?
No
Does this project involve testing the safety and/or efficacy of
a medical device?
Yes
Describe in detail procedures in place for maintaining device
shipment and receipt records:
N/A since the devices are currently marketed and currently on
hand.
Who will be responsible for maintaining these shipment and
receipt records?
N/A
Describe in detail procedures in place for tracking use and
disposition of devices described in this study:
N/A
Who will be responsible for maintaining these use and
disposition tracking records?
N/A
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VII.B.25

VII.B.26

VII.B.27

VII.B.31

VII.B.33

Describe in detail procedures in place to limit access to
authorized study personnel for the storage, control, and
dispensing of the investigational devices.
N/A
Is the device FDA-approved for the way it will be used in this
study?
No
Is there an IDE (Investigational Device Exemption) for this
device in this research project?
No
Indicate the appropriate FDA status you and/or the sponsor
are requesting for the use of this device in this study.
Non-Significant Risk (NSR) device/software
Provide a detailed rationale for why this device meets the
FDA definition of a Non-Significant Risk Device (NSR)
The Leap Motion Controller meets the FDA definition of a
Non-Significant Risk Device (NSR) because:
1. It is not an implant
2. It will not be used in supporting or sustaining human life
3. Is not for a use of substantial importance in diagnosing,
curing, mitigating, or treating disease, or otherwise preventing
impairment of human health
4. It does not present a potential for serious risk to the health,
safety, or welfare of a subject
The Leap Motion Controller is a consumer three-dimensional
camera and will be used in accordance with its purpose: to
measure and record hand and finger motions.
The Tremorometer meets the FDA definition of a NonSignificant Risk Device (NSR) because:
1. It is not an implant
2. It will not be used in supporting or sustaining human life
3. Is not for a use of substantial importance in diagnosing,
curing, mitigating, or treating disease, or otherwise preventing
impairment of human health
4. It does not present a potential for serious risk to the health,
safety, or welfare of a subject
The Tremorometer has 510k clearance for measuring and
quantifying tremor in human participants, which will be its
only use in this study.
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VII.B.34

Provide a summary of prior investigations with this device.
Prior investigations with the Leap Motion Controller
Mauser, Stanis & Burgert, Oliver. (2014, Feb. 12) Touch-Free
GestureBased Control of Medical Devices and Software
Based on the Leap Motion Controller. In J.D Westwood, S.
W. Westwood, and L. Felländer-Tsai, eds. Medicine Meets
Virtual Reality 21: NextMed/MMVR21. Paper presented at
21st NextMed/MMVR conference, Manhattan Beach,
California. (pp. 265-270) Vol. 196. IOS Press, 2014.
F. Weichert, D. Bachmann, B. Rudak, D. Fisseler
Analysis of the accuracy and robustness of the leap motion
controller
Sensors, 13 (5) (2013), pp. 6380–6393
http://dx.doi.org/10.3390/s130506380
I. Tarnanas, W. Schlee, M. Tsolaki, R. Müri, U. Mosimann, T.
Nef
Ecological validity of virtual reality daily living activities
screening for early dementia: longitudinal study
JMIR Serious Games, 1 (1) (2013)
http://dx.doi.org/10.2196/games.2778 e1, 1–13
Guna J, Jakus G, Pogačnik M, Tomažič S, Sodnik J. An
Analysis of the Precision and Reliability of the Leap Motion
Sensor and Its Suitability for Static and Dynamic Tracking.
Sensors. 2014; 14(2):3702-3720.
Taha Khan, Dag Nyholm, Jerker Westin, Mark Dougherty, A
computer vision framework for finger-tapping evaluation in
Parkinson's disease, Artificial Intelligence in Medicine,
Volume 60, Issue 1, January 2014, Pages 27-40, ISSN 09333657, http://dx.doi.org/10.1016/j.artmed.2013.11.004.
(http://www.sciencedirect.com/science/article/pii/S093336571
3001565)
Prior investigations with the Tremorometer
Aasef G. Shaikh, Kenichiro Miura, Lance M. Optican, Stefano
Ramat, Robert M. Tripp and David S. Zee, “Hypothetical
membrane mechanisms in essential tremor”, Journal of
Translational Medicine, 2008, 6:68
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Aasef G. Shaikh, H. A. Jinnah, Robert M. Tripp, Lance M.
Optican, Stefano Ramat, Frederick A. Lenz, David S. Zee,
“Irregularity distinguishes limb tremor in cervical dystonia
from essential tremor”, Journal Neurology, Neurosurgery,
Psychiatry, (2008), 79, 187-189; originally published online
14 Sep 2007, doi: 10.1136/JNNP.2007.131110
Aasef G. Shaikh, Kenichiro Miura, Lance M. Optican, Stefano
Ramat, R. John Leigh, David S. Zee, “A new familial disease
of saccadic oscillations and limb tremor provides clues to
mechanisms of common tremor disorders”, Brain (2007), 130,
3020-3011
S. M. Bowyer, K. Mason, B. Weiland, J. E. Moran, G. L.
Barkley, N. Tepley, “Localization of Motor Cortex by MEG
Using a Tremorometer”, International Congress Series,
Elsevier (2007) doi: 10.1016/j.ics.2007.02.001
Khalafalla O. Bushara, Taimur Malik, Rupert E. Exconde,
“The Effect of Levetiracetam on Essential Tremor”,
Neurology 2005; 64;1078-1080; doi:
10.1212/01.WNL.0000154596.21335.2E
Michael P. Caligiuri, Robert M. Tripp, “A portable hand-held
device for quantifying and standardizing tremor assessment”,
Journal of Medical Engineering and Technology (2004),
28(6):254-262
Michael P. Caligiuri, Robert M. Tripp, “The
TremorometerTM: A Portable Instrument for Quantifying
Hand Tremor”, Biol Psychiatry Abstr (2000), 47:142S
VII.B.35

VII.B.37

VII.B.38

Have there been any prior IRB reviews (at WUSTL or
elsewhere) and/or determinations made with regard to this
device?
No
Has the FDA made an assessment of risk with regard to this
device?
Yes
Has this device/software been approved by the FDA for
another indication or in another form from its use in this
project?
No
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VII.C. Genetic Research
VII.C.1

Does this project involve any research on genes or genetic
testing/research?
No

VII.D. Recruitment & Consent
VII.D.1

Check all materials/methods that will be used in recruiting
participants (you will need to attach copies of all materials
at the end of the application):
• Existing Registry/database , Describe
Washington University Movement Disorders
electronic medical record (MARS) clinical database.
This is the clinical database for which clinical
information is entered for all patients seen in the
movement disorders division of neurology. We may
utilize the Washington University School of Medicine
Research Participant Registry powered by the
Volunteer for Health to recruit normal control
subjects.

•

PHI
o

Use of any information available to the
researchers or their colleagues because this
person is a patient OR use of any
information considered to be Protected
Health Information (PHI) OR review of
patient/clinic records , Describe source of
records

We will review patient records in the Washington
University Movement Disorders electronic
medical record clinical database (MARS) to
identify potential participants.
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•

VII.D.2

VII.D.3

VII.D.4

VII.D.5

VII.D.6

VII.D.7

Referral from colleague , Describe

Physician colleagues within the division of Movement
Disorders at Washington University School of
Medicine will be verbally notified of the ongoing
study. If they evaluate a patient in clinic that fits
inclusion criteria, they may provide potential
participants with contact information for the research
team or direct them directly to the testing room on the
day of study.
List the individual data elements you will need to access/use
from the patient or clinic records to identify potential
participants for recruitment
1. Definite diagnosis of Parkinsonism or Essential Tremor
2. Mini-mental Status Exam
3. Information regarding examination findings with regard to
tremor (i.e. whether present, degree of severity, etc).
Describe why you could not practicably recruit participants
without access to and use of the information described above
The above information is critical inclusion/exclusion criteria
which must be confirmed from the medical record.
Describe why you could not practicably obtain authorization
from potential participants to review their patient or clinic
records for recruitment purposes.
Without knowing the definite diagnosis and medical history
of a patient, it is not possible to identify appropriate subjects
to recruit based on specific inclusion criteria.
Describe plans to protect the identifiers from improper use
or disclosure
Only study team members will have access to the medical
record of any potential and/or enrolled subjects. These records
are password protected in the clinical movement disorders
database (MARS) which is HIPAA compliant. Any data
collected will not contain any identifiers, except for what is
mentioned in the inclusion and exclusion criteria for each
group and will only be stored on a LOK-IT Secure Flash
Drive, which is automatically encrypted with military-grade
256-bit AES hardware encryption, which is HIPAA
compliant.
Describe plans to destroy identifiers at the earliest
opportunity consistent with conduct of the research
There will be no need to utilize any identifiers in this study.
Does the research team agree that the requested information
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VII.D.8

VII.D.9

VII.D.10

VII.D.12

VII.D.13

VII.D.14

will not be reused or disclosed to any other person or entity,
except as required by law, for authorized oversight of the
study, or for other research for which the use or disclosure
of the requested information would be permitted by the
HIPAA Privacy Rule
Yes
Will a member of the research team discuss the study with
the participant in person prior to the participant agreeing to
participate?
Yes
Describe the physical location where the consent process
will take place:
Meetings with participants will occur in the following
location within the Washington University School of
Medicine:
1) The movement disorder clinic in the lower level of
McMillan Building. The study will be performed behind
closed doors in an examination room.
Will a member of the research team discuss the study with
the participant by phone prior to the participant agreeing to
participate?
No
Who will be involved in the consent process (including
review of consent document, answering participants'
questions)?
Consent Process
Name
Involvement
Matthew Johnson,
Yes
Biomedical Engineering, BS
Arye Nehorai, PHD
No
Scott Norris, MD, BA
Yes
Mwiza Ushe, MD, MAYes
Check all materials that will be used to obtain/document
informed consent:
• Consent Document
Does the study include any form of deception (e.g.,
providing participants with false information, misleading
information, or withholding information about certain study
procedures)?
Examples:
•

Procedure includes a cover story that provides a
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•

•
•

•

VII.D.25

VII.D.28

VII.D.29

VII.D.30

VII.D.34

VII.D.36

plausible but inaccurate account of the purposes of
the research.
Participants will be provided with false information
regarding the particular behaviors of interest in the
research.
Procedures include a confederate pretending to be
another participant in the study.
Participants will be told that the research includes
completion of a particular task, when in fact, that
task will not be administered.
Study is designed to introduce a new procedure (or
task) that participants are not initially told about.

No
Are you requesting a waiver of documentation of consent
(either no participant signature or no written document)?
No
Before the participant gives consent to participate are there
any screening questions that you need to directly ask the
potential participant to determine eligibility for the study?
Yes
List any screening questions you will directly ask the
potential participant to determine eligibility.
1. What is your current age?
2. Have you every been diagnosed with any serious medical
or psychiatric conditions?
Will you keep a screening log or other record that would
include information on people who do not consent to
participate in the study?
No
After the participant agrees to participate (signs consent),
are there any screening procedures, tests, or studies that
need to be done to determine if the participant is eligible to
continue participating?
No
Discuss how much time a potential participant will have to
agree to consider participation and whether or not they will
be able to discuss the study with family/friends before
deciding on participation.
The potential participant will have as much time as necessary
(or until completion of the project, whichever comes first) to
consider participation in the study. They will be allowed to
discuss the study with family/friends before deciding on
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VII.D.37

VII.D.38

participation.
How long after the participant agrees to participate do study
procedures begin?
The study procedure can begin as soon as the participant signs
the consent form.
Provide a description of the enrollment and consent process
for adult participants
•
•
•

•

Describe each study population separately including
control population
Include when recruitment and consent materials are
used
Use THIRD person active voice. For example, "the
principal investigator will identify potential
participants, the study coordinator will discuss the
study with participants over the telephone and
schedule the first study visit, etc..."
Describe the steps that will be taken by the research
team to minimize the possibility of coercion or undue
influence during the consent process

Ten subjects with clinical diagnostic criteria for
Parkinsonism, 10 subjects with clinical diagnostic criteria for
Essential Tremor, and 10 normal control subjects will be
enrolled in this study. The study team will identify potential
participants from the clinical database in the movement
disorder clinic at WUSM. Patients will be recruited in person
in the movement disorder clinic at WUSM during clinic visits
with their physician or nurse. The study team member will
determine the capacity of the potential participant to consent
for her/himself during initial contact and ask screening
questions to determine if the potential participant fits the
inclusion/exclusion criteria for the study. If the subject
expresses interest in the study and is deemed to fit all
inclusion/exclusion criteria, informed consent materials will
be provided to the patient. A study team member will review
the document with the potential participant to answer any
questions or explain any unclear points. Potential participants
will be given time to read the document in its entirety, ask
questions, and speak with friends/family members if they so
desire. Study participants will sign the informed consent, and
will be offered a signed copy of the consent after both parties
sign the document.
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VII.E. Methods
VII.E.1
VII.E.3

VII.E.5

VII.E.6

Will participants be randomized?
No
Will any questionnaires, surveys, or written assessments be
used to obtain data directly from participants in this study?
No
Does this project involve creating any audiotapes,
videotapes, or photographs?
No
Provide a detailed description in sequential order of the
study procedures following the consent process - DO NOT
cut and paste from the Consent Document.
Describe study populations separately if they will be
participating in different procedures - include CONTROL
population if applicable.
DESCRIBE:
•
•
•
•

What participants will be asked to do/what happens
in the study (in sequential order)
The time period over which procedures will occur
The time commitment for the participant for
individual visits/procedures
Long-term followup and how it occurs

All participants, including the control participants, will follow
the same procedure. Each participant will be measured twice
and be measured individually. First, the participant will be
asked to allow a study member to affix with tape the
accelerometer (from the Tremorometer system) to the index
finger on the hand that they believe to exhibit the most
symptomatic tremor. The participant will then be asked to
place said hand on a small slanted box and asked to spread
their fingers so that no fingers are touching another finger.
The participant will again be asked to allow their fingers to
relax and drape over the edge of the box, still ensuring that
their fingers are not touching each other. Once the participant
has their hand in a comfortable position, they will be verbally
alerted that the measurement will start and be asked to silently
countdown from 100. After 30 seconds, the participant will be
verbally alerted that the measurement is over and the
accelerometer will be removed. The participant will then be
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VII.E.7

VII.E.9

asked to again place the same hand on the small slanted box,
this time in front of the Leap Motion Controller. The
participant will again be asked to attempt to spread their
fingers so that no fingers are touching another finger and then
allow their fingers to relax and drape over the edge of the box,
ensuring that their fingers are still not touching one another.
Once the participant has their hand in a comfortable position,
they will be verbally alerted that the measurement will start
and be asked to silently countdown from 100. After 30
seconds, the participant will be alerted that the measurement
is over. Once complete, the participant will be finished and
thanked for their time. It is estimated that the time
commitment for the individual visit will be approximately 10
minutes, which includes a short explanation of the study along
with recordings of the individual participant. There will be no
attempt at a long-term followup. Each participant will be
given an option to be contacted with the results of the study,
once the study is complete.
Will you attempt to recontact participants who are lost to
follow-up?
No - followup is not required in this study
Will participants be provided any compensation for
participating in this study?
No

VIII. Risks
VIII.1

What are the risks to participants including
- emotional or psychological
- financial
- legal or social
- physical?
1. Attempting to hold one hand still in one position may be
uncomfortable.
2. Participants may become uncomfortable, frustrated, or
bored during the recording.
3. Participants may become stressed if they exhibit too severe
of upper limb tremor to record the data.
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VIII.2

What have you done to minimize the risks?
•

VIII.3

If applicable to this study ALSO include:
o How you (members of your research team at
WUSTL) will monitor the safety of individual
participants.
o Include a description of the availability of
medical or psychological resources that
participants might require as a consequence
of participating in this research and how
referral will occur if necessary (e.g.
availability of emergency medical care,
psychological counseling, etc.)

To reduce the risks to the subjects, a physician will be present
throughout all studies. Confidentiality will be maintained in
accordance with applicable state and federal laws and all
study data will be identified only by a code number.
Personally identifying data will not be recorded or collected.
Does this study have a plan to have an individual or
committee review combined data from all participants on a
periodic basis (such as summary or aggregate safety and/or
efficacy data)?
No

IX. Benefits
IX.1

IX.2

What are the direct benefits to the participant (do not
include compensation)?
There is no direct benefit to participants.
What are the potential benefits to society in terms of
knowledge to be gained as a result of this project?
This study may help provide a better understanding of the
characteristic features of rest tremor in Parkinsonism. It may
also provide a better alternative method to record and measure
rest tremor that may aid in the differentiation of Parkinsonism
from Essential Tremor.
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X. Privacy & Confidentiality
X.1

Describe your plans to protect the privacy interests of the
participants during the conduct of the study including:
•
•

•

•

How will you provide a private setting during the
recruitment process
How will you provide a private setting for the consent
process including an opportunity for the participant
to ask questions privately
Describe how interventions occur in a private setting
and/or how information will be collected using
methods that protect the participant's privacy.
Discuss why the information collected during the
study is necessary to the conduct of the study and
does not unnecessarily invade the rights of
participants to privacy of their personal information.

The potential subjects will be escorted into a separate
examination room with closed doors in the clinic, after seeing
their physician. The potential subjects will be given the
opportunity to ask questions privately within the examination
room.

X.2

The acceleration information collected using the
Tremorometer and the position information collected using
the Leap Motion Controller is necessary because it serves as a
quantitative representation of tremor, which is needed for this
study. This quantitative data is needed in order to compare the
Leap Motion Controller and the Tremorometer for measuring
tremor. It is also needed in order to identify, calculate, and use
features of rest tremor that are characteristic of subjects with
Parkinson Disease. The collection of this data does not invade
the rights of participants to privacy of their personal
information because the data being collected is not
identifiable and cannot be used to identify the patient. The
data will be used to extract underlying characteristics that are
unique to their group (Parkinson Disease participants,
Essential Tremor participants, healthy participants) and are
not unique to the participants themselves.
Are you collecting or using the Social Security Number of
any participants for any purpose?
No
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X.4

How will information/data be collected and stored for this
study (check all that apply):
• Electronic records (computer files, electronic
databases, etc.) - The data that will be recorded will be
fully de-identified and will not include names, dates of
birth, or clinic numbers. The only data that will be
recorded will be the positional and acceleration data of
the fingers for each subject and whether or not they
have Parkinsons Disease. This data will only be saved
on a LOK-IT Secure Flash Drive, which is
automatically encrypted with military-grade 256-bit
AES hardware encryption. This level of encryption is
HIPAA compliant and ensures that the data is
unreadable if the flash memory were to be physically
accessed.

X.5

Do the confidentiality protections indicated above allow only
members of the research team to access identified
data/specimens?
Yes

XI. Data Analysis
XI.1

Provide a summary of the analysis methods you will use,
including, if applicable, the data points or outcomes you will
analyze.
Tremorometer:
All participants will use the Tremorometer system, which will
record the three-dimensional acceleration of one finger of the
patient over a set period of time. This acceleration data will
then be analyzed by the software included in the system to
provide the frequency and intensity of the tremor.
Leap Motion Controller:
All participants will use the Leap Motion Controller, which
will record the three-dimensional position of the one finger of
the patient over a set period of time. This raw position data
will then be analyzed using MATLAB in order to calculate
the tremor frequency as well as the intensity of the tremor.
These calculations will then be compared to those obtained
from the Tremorometer system. The position data will further
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be used to calculate other characteristics of tremor that will be
used as features in creating an algorithm to predict whether a
patient has Parkinson's disease.
XI.2

Provide the rationale or power analysis to support the
number of participants proposed to complete this study.
In a previous study entitled the Effect of deep brain
stimulation on amplitude and frequency characteristics of rest
tremor in Parkinson's disease by Beuter et al (2001), 8
Parkinsons subjects were used to determine some of the same
characteristics that will also be calculated in this study.
Likewise, in The dynamics of resting and postural tremor in
Parkinson's disease by Vaillancourt et al (2000), 8 Parkinsons
subjects and 8 healthy subjects were used to again obtain the
time and frequency structure of tremor. Similarly, in a study
that used a 3D motion analysis system to measure tremor, 6
Parkinson subjects were used (A novel quantitative method
for 3D measurement of Parkinsonian tremor by Rajaraman et
al. 1999). Based on these previous studies, we will recruit 10
healthy subjects, 10 Parkinsons subjects, and 10 Essential
Tremor subjects. We expect that the number of participants
will provide enough data to adequately examine tremor and to
provide enough characteristic features involved in the rest
tremor of Parkinsonism to create a predictive algorithm.

XII. Future Research
XII.1

XII.3

XII.4

Do you wish to keep any information about participants
involved with this research project so that other researchers
outside the current study team may contact them for future
research?
No
Does this project involve storing any data for future
research?
Yes – contribution for future use is mandatory for
participation in the study
Does this project involve storing any tissues or specimens for
future research?
No
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INFORMED CONSENT DOCUMENT
Project Title:

Detection of Parkinson Disease Rest Tremor

Principal Investigator:

Matthew Johnson

Research Team Contact:

Matthew Johnson: (561) 906-1671

This consent form describes the research study and helps you decide if you want to participate. It
provides important information about what you will be asked to do during the study, about the risks and
benefits of the study, and about your rights as a research participant. By signing this form you are
agreeing to participate in this study.
• If you have any questions about anything in this form, you should ask the research team for
more information.
• You may also wish to talk to your family or friends about your participation in this study.
• Do not agree to participate in this study unless the research team has answered your
questions and you decide that you want to be part of this study.
WHAT IS THE PURPOSE OF THIS STUDY?
This is a research study. We invite you to participate in this research study because you: have been
diagnosed with Parkinson Disease and have tremor as a symptom, have been diagnosed with Essential
Tremor, or are healthy with no symptoms of tremor.
The purpose of this research study is to create an algorithm that will predict, with reasonable accuracy, if
a patient has Parkinson Disease based on their rest tremor. To create this algorithm, rest tremor data will
be collected by recording the three-dimensional position and acceleration of the index finger using two
different devices. The first device, the Tremorometer, uses a three-dimensional accelerometer (a device
that measures changes in acceleration) and is cleared by the FDA to measure and quantify tremor by
measuring acceleration and calculating tremor statistics in human patients. The second device, the Leap
Motion Controller, is a three-dimensional camera that can obtain position data and is considered
investigational, which means that it has not been approved by the U.S. Food and Drug Administration.
The data collected and analyzed by the Tremorometer will be compared to that of the Leap Motion
Controller to determine whether the Leap Motion Controller can be used to obtain similar results as the
Tremorometer. The data from the Leap Motion Controller will be analyzed and used to create an
algorithm that can predict whether a patient has Parkinson Disease. It is hypothesized that the Leap
Motion Controller will provide similar results as the Tremorometer and that the data from the Leap
Motion Controller can be used to create a reasonably accurate algorithm that can identify a patient with
Parkinson Disease from a patient with Essential Tremor or a healthy patient.
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WHAT WILL HAPPEN DURING THIS STUDY?
The study will occur in an examination room behind closed doors in the movement disorders clinic
within the Washington University School of Medicine. The data that will be recorded will consist of the
position and acceleration of your fingers over time and whether you have Parkinson Disease, Essential
Tremor, or are healthy with no symptoms of tremor.
You will first be asked to allow a study member to tape a small sensor (the accelerometer from the
Tremorometer system) to your index finger on the hand that you exhibit the most symptomatic tremor.
You will then be asked to place said hand on a small slanted box and be asked to spread your fingers so
that no fingers are touching another finger. You will then be asked to allow your fingers to relax and
drape over the edge of the box, still ensuring that your fingers are not touching. Once your hand is in a
comfortable position, you will be warned that the recording will start and be asked to silently countdown
from 100. After 30 seconds, you will be told that the recording is over and the sensor will be removed.
You will then be asked to place the same hand on the small slanted box in front of the Leap Motion
Controller (a small three-dimensional camera that tracks hand and finger movements and has not yet
been used to measure hand or finger tremors.) You will again be asked to allow your fingers to relax and
drape over the edge of the box, still ensuring that no fingers are touching another finger. Once your hand
is in a comfortable position, you will be told that the recording will begin and be asked to silently
countdown from 100. After 30 seconds, you will be told that the recording is over and the you will be
finished with your participation in the study.
Will you save my samples or research data to use in future research studies?
As part of this study, we are obtaining tremor data (in the form of position and acceleration over time)
from you. By agreeing to be part of this study you give up any property rights you may have in the
tremor data. We would like to use your tremor data for other research projects in the future. These future
studies may provide additional information that will be helpful in understanding Parkinson's Disease,
but it is unlikely that what we learn from these studies will have a direct benefit to you. It is possible that
your tremor data might be used to develop tests, treatments or cures. There are no plans to provide
financial compensation to you should this occur. If you agree, this means we will store your tremor data
and may use it for studies going on right now as well as studies that are conducted in the future.
I would also like your permission to share your tremor data with other investigators doing research in
similar fields such as other diseases where tremor is a common symptom. These investigators may be at
Washington University or at other research centers. We may also share you research data with large
data repositories (a repository is a database of information) for broad sharing with the research
community. If your individual research data is placed in one of these repositories only qualified
researchers, who have received prior approval from individuals that monitor the use of the data, will be
able to look at your information.
Your tremor data will be stored without your name or any other kind of link that would enable us to
identify which data are yours. Therefore, if you give permission to store and use your tremor data, it
will be available for use in future research studies indefinitely and cannot be removed.
Page 2 of 7
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HOW MANY PEOPLE WILL PARTICIPATE?
Approximately 30 people will take part in this study conducted by investigators at Washington
University.
HOW LONG WILL I BE IN THIS STUDY?
If you agree to take part in this study, your involvement will last for approximately 10 minutes.
WHAT ARE THE RISKS OF THIS STUDY?
You may experience one or more of the risks indicated below from being in this study. In addition to
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this
study.
Less Likely / Less Common
Mild
•
•
•

Risk 1: Attempting to hold one hand still in one position may be physically uncomfortable.
Risk 2: Become fatigued, frustrated, or bored during the recording.
Risk 3: Become stressed if you exhibit too severe of upper limb tremor to record the data.

One risk of participating in this study is that confidential information about you may be accidentally
disclosed. We will use our best efforts to keep the information about you secure, and we think the risk
of accidental disclosure is very small. Please see the section in this consent form titled “How will you
keep my information confidential?” for more information.

WHAT ARE THE BENEFITS OF THIS STUDY?
You will not benefit from being in this study.
However, we hope that, in the future, other people might benefit from this study because the study may
help provide a better understanding of the characteristic features of rest tremor in Parkinsonism as well
as provide a better alternative to record and measure rest tremor that may aid in the differentiation of
Parkinsonism from Essential Tremor.
WILL IT COST ME ANYTHING TO BE IN THIS STUDY?
You will not have any additional costs for being in this research study. You and/or your
medical/hospital insurance provider will remain responsible for your regular medical care expenses.

Page 3 of 7
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WILL I BE PAID FOR PARTICIPATING?
You will not be paid for being in this research study.
WHO IS FUNDING THIS STUDY?
This study is not being funded.
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY?
Washington University investigators and staff will try to reduce, control, and treat any complications
from this research. If you feel you are injured because of the study, please contact the investigator at
(561) 906-1671 and/or the Human Research Protection Office at (314) 633-7400 or 1-(800)-438-0445.
Decisions about payment for medical treatment for injuries relating to your participation in research will
be made by Washington University. If you need to seek medical care for a research-related injury, please
notify the investigator as soon as possible.
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL?
We will keep your participation in this research study confidential to the extent permitted by law.
However, it is possible that other people such as those indicated below may become aware of your
participation in this study and may inspect and copy records pertaining to this research. Some of these
records could contain information that personally identifies you.
• Government representatives, (including the Office for Human Research Protections) to complete
federal or state responsibilities
• The U.S. Food and Drug Administration
• People who use the Washington University School of Medicine's Research Participant Registry
or the clinical movement disorders database (MARS)
• Hospital or University representatives, to complete Hospital or University responsibilities
• Information about your participation in this study may be documented in your health care records
and be available to your health care providers who are not part of the research team.
• Washington University’s Institutional Review Board (a committee that oversees the conduct of
research involving human participants.) The Institutional Review Board has reviewed and
approved this study.
To help protect your confidentiality, we will have you escorted into a separate examination room with
closed doors in the clinic, after seeing your physician. The data that will be recorded will be fully deidentified and will not include your name, date of birth, clinic number, or any other identifiable
information. The only data that will be recorded will be the positional and acceleration data of your
finger and whether or not you have Parkinson Disease. This data will only be saved on a LOK-IT Secure
Flash Drive, which is automatically encrypted with military-grade 256-bit AES hardware encryption.
This level of encryption is HIPAA compliant and ensures that the data is unreadable if the flash memory
were to be physically accessed. If we write a report or article about this study or share the study data set
with others, we will do so in such a way that you cannot be directly identified.
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Are there additional protections for my health information?
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this
research, you must give the research team permission to use and disclose (share) your PHI for the study
as explained in this consent form. The research team will follow state and federal laws and may share
your health information with the agencies and people listed under the previous section titled, “How will
you keep my information confidential?”.
Once your health information is shared with someone outside of the research team, it may no longer be
protected by HIPAA.
The research team will only use and share your information as talked about in this form. When possible,
the research team will make sure information cannot be linked to you (de-identified). Once information
is de-identified, it may be used and shared for other purposes not discussed in this consent form. If you
have questions or concerns about your privacy and the use of your PHI, please contact the University’s
Privacy Officer at 866-747-4975.
Although you will not be allowed to see the study information, you may be given access to your health
care records by contacting your health care provider.
If you decide not to sign this form, it will not affect
• your treatment or the care given by your health provider.
• your insurance payment or enrollment in any health plans.
• any benefits to which you are entitled.
However, it will not be possible for you to take part in the study.
If you sign this form:
• You authorize the use of your PHI for this research
• Your signature and this form will not expire as long as you wish to participate.
• You may later change your mind and not let the research team use or share your information
(you may revoke your authorization).
• To revoke your authorization, complete the withdrawal letter, found in the Participant section
of the Human Research Protection Office website at http://hrpo.wustl.edu (or use the direct
link: http://hrpohome.wustl.edu/participants/WithdrawalTemplate.rtf) or you may request
that the Investigator send you a copy of the letter.
o If you revoke your authorization:
! The research team may only use and share information already collected for
the study.
! Your information may still be used and shared if necessary for safety reasons.
! You will not be allowed to continue to participate in the study.
IS BEING IN THIS STUDY VOLUNTARY?
Taking part in this research study is completely voluntary. You may choose not to take part at all. If
Page 5 of 7
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you decide to be in this study, you may stop participating at any time. If you decide not to be in this
study, or if you stop participating at any time, you won’t be penalized or lose any benefits for which you
otherwise qualify.
What if I decide to withdraw from the study?
You may withdraw by telling the study team you are no longer interested in participating in the study or
you may send in a withdrawal letter. A sample withdrawal letter can be found at http://hrpo.wustl.edu
under Information for Research Participants.
Will I receive new information about the study while participating?
If we obtain any new information during this study that might affect your willingness to continue
participating in the study, we’ll promptly provide you with that information.
Can someone else end my participation in this study?
Under certain circumstances, the researchers might decide to end your participation in this research
study earlier than planned. This might happen because in our judgement you are exhibiting upper limb
tremor too severe to be recorded or if you have too much trouble keeping your fingers separated during
the recording.
WHAT IF I HAVE QUESTIONS?
We encourage you to ask questions. If you have any questions about the research study itself, please
contact: Matthew Johnson, (561) 906-1671. If you experience a research-related injury, please contact:
Dr. Arye Nehorai, (314) 935-5565.
If you have questions, concerns, or complaints about your rights as a research participant, please contact
the Human Research Protection Office, 660 South Euclid Avenue, Campus Box 8089, St. Louis, MO
63110, (314) 633-7400, or 1-(800)-438-0445 or email hrpo@wusm.wustl.edu. General information
about being a research participant can be found by clicking “Participants” on the Human Research
Protection Office web site, http://hrpohome.wustl.edu. To offer input about your experiences as a
research subject or to speak to someone other than the research staff, call the Human Research
Protection Office at the number above.

This consent form is not a contract. It is a written explanation of what will happen during the study if
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study.
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Your signature indicates that this research study has been explained to you, that your questions have
been answered, and that you agree to take part in this study. You will receive a signed and dated copy
of this form.
Do not sign this form if today’s date is after EXPIRATION DATE: 05/26/15.
__________________________________________
(Signature of Participant)

_______________________________
(Date)

____________________________________________
(Participant's name – printed)

Statement of Person Who Obtained Consent
The information in this document has been discussed with the participant or, where appropriate, with the
participant’s legally authorized representative. The participant has indicated that he or she understands
the risks, benefits, and procedures involved with participation in this research study.
__________________________________________
(Signature of Person who Obtained Consent)

_______________________________
(Date)

___________________________________________
(Name of Person who Obtained Consent - printed)
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A Introduction
A1 Study Abstract
This study is exploratory in nature and its purpose is to attempt to classify, with
reasonable accuracy, if a subject can be classified as a Parkinson or non-Pakinson
subject based on their rest tremor. The rest tremor will be measured by recording the
three-dimensional position and acceleration of their index finger while at rest over a set
period of time. This will be done using two devices. The first device, the Tremorometer,
uses a three-dimensional accelerometer (a device that measures changes in
acceleration) and has 510k clearance by the FDA to measure and quantify tremor by
measuring acceleration and calculating tremor statistics in human patients. The second
device, the Leap Motion Controller, is a three-dimensional camera that uses two CCD
(Charged Coupled Device) cameras and three infrared LEDs to obtain position data.
Tremor statistics obtained and calculated from both devices will be compared to
determine if data obtained from the Leap Motion Controller are statistically similar to the
data obtained from the Tremorometer. The data obtained from the Leap Motion
Controller will then be used to determine the characteristic features of rest tremor in
Parkinson Disease and be used to classify subjects used in the study as Parkinson or
non-Parkinson subjects.

A2 Primary Hypothesis
The primary hypothesis is that the positional data from the Leap Motion Controller will be
statistically similar to that of the Tremorometer, showing that the Leap Motion Controller
has the potential to accurately quantify and record tremor. It is also hypothesized that
the position data from the Leap Motion Controller can be used to identify characteristic
features of rest tremor in Parkinson Disease that can be used to classify subjects as
either Parkinson Disease or non-Parkinson Disease subjects.

A3 Purpose of the Study Protocol
The purpose of the protocol is to be used by all study team members as the approved
procedures for conduct of the study.

B Background
B1 Prior Literature and Studies
Parkinson Disease (PD) is a debilitating and progressive movement disorder that affects
over one million people in the United States alone. One of the most characteristic
symptoms of PD is resting tremor, as it has been shown that the proportion of patients
with resting tremor ranged from 69-100% in 3 series of patients with autopsy-proven
PD.1,2,3 Several methods currently exist to quantitatively measure tremor including
accelerometry, electromyography, the spirogram, and most recently three-dimensional
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cameras4. This study involves the use of accelerometry as well as a three-dimensional
camera.

B2 Rationale for this Study
Advances in three-dimensional cameras have allowed for more accurate recordings and
can now be used to provide much more accurate measurements in microdisplacements
of upper extremities that are involved in movements such as resting tremor. One such
three-dimensional camera is the Leap Motion Controller, produced by Leap Motion, Inc.
The device is a small USB three-dimensional camera that utilizes two CCD (Charged
Coupled Device) cameras and three infrared LEDs to obtain depth information, and is
capable of measuring changes in position to within 0.01 mm, and requires no external
sensors or markers unlike accelerometry, electromyography, and the spriogram. One
advantage of having no sensors attached to the body is that the mass of the sensors
decrease the peak frequency of finger tremor by approximately 0.85 Hz for every gram
of additional mass, and also effect the amplitude of acceleration.5 Therefore the attached
sensors may change the characteristics of the tremor, thus altering interpretation of
tremor. Attaching sensors to the body can also be inconvenient, uncomfortable, and
provide a margin of error if not done correctly. Another advantage of the Leap Motion
Controller over accelerometry is that it does not require calibration eliminating possible
errors caused by consistent recalibration. Unlike electromyography, the Leap Motion
Controller is not affected by interference from electrical sources, mechanical artifacts,
stimulus artifacts, and the electrical activity of muscles that are not of interest. It is for
these reasons that the Leap Motion Controller is of interest and may be superior in
measuring tremor.

C Study Objectives
C1 Primary Aim
The primary aim of the study is to determine whether the Leap Motion Controller can be
used to obtain similar tremor statistics as those obtained from a triaxial accelerometer
(Tremorometer).

C2 Secondary Aim
The secondary aim is to determine whether patients with rest tremor in Parkinson
disease can be classified differently when compared to patients with Essential Tremor,
using positional data collected by the Leap Motion Controller.

C3 Rationale for the Selection of Outcome Measures
The rationale for the selection of outcome measures is that the outcome measures are
able to provide characteristic features of tremor such as peak frequency and amplitude,
which are typically used when describing and quantifying tremor. The Tremorometer
provides measurements of acceleration over time and the Leap Motion Controller
provides measurements of position over time, both of which can provide the typical
characteristics used in measuring and quantifying tremor.
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D Study Design
D1 Overview or Design Summary
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A total of thirty (30) subjects will be recruited for participation in this study and will
consist of: 10 subjects diagnosed with Parkinsonsim with tremor, 10 subjects diagnosed
with Essential Tremor, and 10 normal healthy control subjects. These subjects will be
recruited in person through the Washington University Movement Disorders electronic
medical record (MARS) clinical database, among the spouses of the subjects, and from
the Volunteer for Health initiative of Barnes-Jewish Hospital. If the potential participant
expresses interest in the study and is deemed to fit all inclusion/exclusion criteria,
informed consent materials will be provided to the subject. A study team member will
review the study and the informed consent materials with the potential participant, and
provide the participant an opportunity to ask any questions or request further
elaboration. If the potential participant agrees and signs the consent document, the data
collection process can begin.
Each participant will be measured individually, twice with the Tremorometer and twice
with the Leap Motion Controller. First, the participant will have the accelerometer from
the Tremorometer taped to the index finger of the hand that they believe to exhibit the
most symptomatic tremor. The participant will rest their hand on a small slanted box and
be asked to relax their fingers and hands. The acceleration of their index finger will then
be recorded for 30 seconds, while the participant counts down from 100. After the first
Tremorometer recording, the subject will be asked to re-adjust their hand on the slanted
box and again relax their fingers. The participant will again be asked to count down from
100 while the 30-second recording takes place for the second time. Once the second
recording is complete, the accelerometer will be removed. The participant will then be
asked to place the same hand on the small slanted box with their fingers relaxed, this
time in front of the Leap Motion Controller. The position of each finger on the testing
hand will then be recorded for 30 seconds, while the participant counts down from 100.
After the first recording with the Leap Motion Controller, the subject will be asked to readjust their hand and again place it on the slanted box with their fingers relaxed. The
second 30-second recording with the Leap Motion Controller will then take place, while
the subject again counts down from 100. Once complete, the data collection for that
participant will be over and the participant will be finished with the study and thanked for
their time. It is estimated that the time commitment for each participant will be
approximately 10 minutes.
Once the data for all subjects has been collected, the data analysis can begin. For the
first part of the data analysis, the data from the Leap Motion and Tremorometer will be
analyzed to compare several important characteristic features, such as peak frequency
and amplitude of the tremor. To do this, the position data from the Leap Motion
Controller will be converted to acceleration data to compare it to the acceleration data
from the Tremorometer. Tremor statistics, such as peak frequency and amplitude, from
the Leap Motion Controller and the Tremorometer will be calculated and compared. For
the second portion of the data analysis, the position data from the Leap Motion
Controller will be used to identify characteristic features that could be used to
differentiate the Parkinson subjects from the other subjects. To do this, characteristic
features will be selected that differentiate the Parkinson subjects from the normal healthy
subjects. From there, the same features, and possibly more, will be used in an attempt
to differentiate the Parkinson subjects from the Essential Tremor subjects since it is
expected that it will be harder to differentiate Parkinson tremor from Essential tremor,
based on past time-frequency analyses of tremor.8 These features will then be used in
an attempt to classify, as accurately as possible, all subjects from the study as either
Parkinson or non-Parkinson.
6
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D2 Subject Selection and Withdrawal
2.a

Inclusion Criteria
1) 10 patients diagnosed with Parkinsonism with tremor
a. age greater than or equal to 18
b. male or female
c. any race or ethnicity
d. physician confirmed Parkinsonism, with tremor as a symptom, based
on diagnostic criteria6
e. ability to give informed consent
2) 10 patients diagnosed with Essential Tremor
a. age greater than or equal to 18
b. male or female
c. any race or ethnicity
d. physician confirmed essential tremor based on diagnostic criteria7
e. ability to give informed consent
3) 10 normal control subjects
a. age greater than or equal to 18
b. male or female
c. any race or ethnicity
d. ability to give informed consent

2.a

Exclusion Criteria
1) 10 patients diagnosed with Parkinsonism with tremor
a. History of stroke, seizure, cerebral palsy, or additional neurological
diagnosis
b. Severe upper limb tremor
c. Any serious medical or psychiatric condition
d. Age less than 18
e. Cognitive impairment (Mini-Mental State Score <19)
2) 10 patients diagnosed with Essential Tremor
a. History of stroke, seizure, cerebral palsy, or other major psychiatric
illness
b. Severe upper limb tremor
c. Any serious medical or psychiatric condition
d. Age less than 18
e. Cognitive impairment (Mini-Mental State Score <19)
3) 10 normal control subjects
a. History of stroke, seizure, cerebral palsy, or other major psychiatric
illness
b. Severe upper limb tremor
c. Any serious medical or psychiatric condition
d. Age less than 18
e. Cognitive impairment (Mini-Mental State Score <19)
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2.b

Ethical Considerations

Each participant will be an adult equal to or greater than 18 years of age and will have
the ability to give informed consent. To ensure that the participant can give informed
consent, they must not have a Mini-Mental State Score less than 19 or any serious
medical or psychiatric condition. Only study team members will have access to the
medical record of any potential and/or enrolled subjects. These records are password
protected in the clinical movement disorders database (MARS), which is HIPAA
compliant. Any data that will be collected will not contain any identifiers. The collected
data will only be stored on a LOK-IT Secure Flash Drive, which is automatically
encrypted with military-grade 256-bit AES hardware encryption and is HIPAA compliant.

2.c

Subject Recruitment Plans and Consent Process

10 subjects with clinical diagnostic criteria for Parkinsonism, 10 subjects with clinical
diagnostic criteria for Essential Tremor, and 10 normal control subjects will be enrolled in
this study. The Washington University Movement Disorders electronic medical record
(MARS) clinical database is the clinical database for which clinical information is entered
for all patients seen in the movement disorders division of neurology. The database
follows a large number of patients with Parkinsonism with tremor as a symptom as well
as patients with Essential Tremor. Therefore, the 10 subjects with Parkinsonism with
tremor and the 10 subjects with Essential Tremor will be recruited from this database.
The 10 healthy control subjects will be recruited among their spouses or from the
Volunteer for Health initiative of Barnes-Jewish Hospital, an affiliate of the Washington
University School of Medicine with a pool of over 8000 volunteers. The study team will
identify potential participants from this database and participants will be recruited in
person in the movement disorder clinic at Washington University School of Medicine
during clinic visits with their physician or nurse. The study team member will determine
the capacity of the potential participant to consent for her/himself during initial contact
and ask screening questions to determine if the potential participant fits the
inclusion/exclusion criteria for the study. If the subject expresses interest in the study
and is deemed to fit all inclusion/exclusion criteria, informed consent materials will be
provided to the subject. A study team member will review the document and the study
with the potential participant to answer any questions or explain any unclear points.
Potential participants will be given time to read the document in its entirety, ask
questions, and speak with friends/family members if they so desire. If the potential
participant agrees, the participant will sign the informed consent and will be offered a
signed copy of the consent after both parties sign the document.

2.d

Randomization Method and Blinding

The participants will not be randomized and this study is not blinded.

2.e

Risks and Benefits

The only potential risks for the participants are mild and considered unlikely. These risks
include:
1. Attempting to hold one hand still in one position may be uncomfortable.
2. Participants may become uncomfortable, frustrated, or bored during the
recording.
3. Participants may become stressed if they exhibit too severe of upper limb
tremor to record the data.
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To reduce any potential risk to the subjects, a physician will be present throughout all
studies. Confidentiality will also be maintained in accordance with applicable state and
federal laws and all study data will be identified only by a code number. Personally
identifying data will not be recorded or collected.
The two devices being used, the Leap Motion Controller and the Tremorometer, meet
the FDA definition of a Non-Significant Risk Device (NSR) because:
1. Neither is an implant
2. Neither will be used in supporting or sustaining human life
3. Neither will be of substantial importance in diagnosing, curing, mitigating, or
treating disease, or otherwise preventing impairment of human health
4. Neither presents a potential for serious risk to the health, safety, or welfare of
a subject
The Leap Motion Controller is a consumer three-dimensional camera and will be used in
accordance with its purpose: to measure and record hand and finger motions. The
Tremorometer has 510k clearance for measuring and quantifying tremor in human
participants, which will be its only use in this study.
While there are no direct benefits to participants, this study may provide potential
benefits to society by possibly providing a better understanding of the characteristic
features of rest tremor in Parkinsonism. It may also provide a better alternative method
to record and measure rest tremor that may aid in the differentiation of Parkinsonism
from Essential Tremor.

2.f

Early Withdrawal of Subjects

Potential participants will be informed that they may withdraw from the study at any point
and that they will not be penalized or lose any benefits that they would otherwise qualify
for.

2.g

When and How to Withdraw Subjects

If a participant decides to withdraw, they may inform the study team member during the
recording. In this case, the recordings will end and the data collected from the participant
will be deleted and not used in the study. Participants may also be withdrawn from the
study if they exhibit upper limb tremor too severe to be recorded or cannot spread their
fingers enough to be detected by the Leap Controller. This withdrawal will be based on
the judgment of the study team member at the time of recording. If the participant
decides to withdraw from the study or if they are withdrawn due to severe upper limb
tremor, the participant will be escorted out of the examination room and thanked for their
time.

2.h

Data Collection and Follow-up for Withdrawn Subjects

Any data collected by a subject who has decided to withdraw or is withdrawn during the
recording will not be used and deleted. There will be no follow-up for withdrawn subjects.
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E Study Procedures
E1 Screening for Eligibility
The Washington University Movement Disorders electronic medical record (MARS)
clinical database will be used to recruit and screen potential participants for eligibility.
This is the clinical database for which clinical information is entered for all patients seen
in the movement disorders division of neurology. The Washington University School of
Medicine Research Participant Registry powered by the Volunteer for Health may also
be used to recruit normal control subjects. The study team members will review patient
records in the Washington University Movement Disorders electronic medical record
clinical database (MARS) will be reviewed to identify potential participants. The patient
records will be used to screen for eligibility by reviewing the existence of a definite
diagnosis of Parkinsonism or Essential Tremor, the Mini-Mental Status Exam, and
information regarding examination findings with regards to tremor (i.e. whether present,
the degree of severity, etc.) This information is critical inclusion/exclusion criteria that
must be confirmed from the medical record. Without confirming the definite diagnosis
and medical history of a patient, it is not possible to identify appropriate participants to
recruit based on specific inclusion criteria.

E2 Schedule of Measurements
Once both parties sign the consent form, the study can begin that same day. All
participants, including the control participants, will follow the same procedure. Each
participant will be measured twice and be measured individually. First, the participant will
be asked to allow a study member to affix with tape the accelerometer (from the
Tremorometer system) to the index finger on the hand that they believe to exhibit the
most symptomatic tremor. The participant will then be asked to place said hand on a
small slanted box and asked to spread their fingers so that no fingers are touching
another finger. The participant will again be asked to allow their fingers to relax and
drape over the edge of the box, still ensuring that their fingers are not touching each
other. Once the participant has their hand in a comfortable position, they will be verbally
alerted that the measurement will start and be asked to silently countdown from 100.
After 30 seconds, the participant will be verbally alerted that the measurement is over
and the subject will be asked to readjust their hand and the recording will be repeated
following the same procedure. Once the second recording using the Tremorometer is
complete, the accelerometer will be removed. The participant will then be asked to again
place the same hand on the small slanted box, this time in front of the Leap Motion
Controller. The participant will again be asked to attempt to spread their fingers so that
no fingers are touching another finger and then allow their fingers to relax and drape
over the edge of the box, ensuring that their fingers are still not touching one another.
Once the participant has their hand in a comfortable position, they will be verbally alerted
that the measurement will start and be asked to silently countdown from 100. After 30
seconds, the participant will be alerted that the measurement is over. The participant will
then be asked to readjust their hand and fingers and the second recording of the data
using the Leap Motion Controller will then occur using the same procedure. Once
complete, the participant will be finished and thanked for their time. It is estimated that
the time commitment for each individual visit will be approximately 10 minutes, which
includes a short explanation of the study along with recordings of the individual
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participant. There will be no attempt at a long-term follow-up. Each participant will be
given an option to be contacted with the results of the study, once the study is complete.

E3 Study Outcome Measurements and Ascertainment
The study outcome measurements will consist of the position and acceleration
measurements from the Leap Motion and from the Tremorometer. These measurements
will be used to calculate tremor statistics to compare the measurements from the two
devices. The positional measurements from the Leap Motion Controller will then be used
to determine characteristic features that will classify subjects in the study as either
Parkinson subjects or non-Parkinson subjects. The positional data from the Leap Motion
Controller will be obtained using Java code and the Leap Motion SDK and saved as a
tab-delimited .txt file. The data would be recorded at a rate of approximately 150 frames
per second, with each frame consisting of a timestamp and the three dimensional
position of each of the five fingers of the hand being recorded. The acceleration data
from the Tremorometer would be obtained using the program TremTest, a part of the
Tremorometer package, which would collect data at 100 frames per second and save
the three-dimensional acceleration every 10 milliseconds. The data will be saved to a
LOK-IT Secure Flash Drive, which is automatically encrypted with military-grade 256-bit
AES hardware encryption, which is HIPAA compliant.

F Statistical Plan
F1

Sample Size Determination and Power

In a previous study entitled the Effect of deep brain stimulation on amplitude and
frequency characteristics of rest tremor in Parkinson's disease by Beuter et al (2001), 8
Parkinsons subjects were used to determine some of the same characteristics that will
also be calculated in this study.9 In a similar study, 8 Parkinsons subjects and 8 healthy
subjects were used to again obtain the time and frequency structure of tremor.10 Also, in
a study that used a 3D motion analysis system to measure tremor, 6 Parkinson subjects
were used.11 Based on these similar studies, we will recruit 10 healthy subjects, 10
Parkinson subjects, and 10 Essential Tremor subjects. We expect that the number of
participants will provide enough data to adequately examine tremor and to provide
enough characteristic features involved in the rest tremor of Parkinsonism to classify
subjects with Parkinsons differently than healthy subjects and subjects with Essential
Tremor.
Each subject will be recorded twice for 30 seconds using the Leap Motion Controller and
twice for 30 seconds using the Tremorometer. The Leap Motion Controller records data
at an approximate rate of 150 times per second, while the Tremorometer records data at
a rate of 100 times per second. Therefore, each subject will provide approximately 9,000
position measurements and 6,000 acceleration measurements from the Leap Motion
and Tremorometer, respectively. Given that there will be 10 subjects per group, this will
result in approximately 90,000 position measurements and 60,000 acceleration
measurements per group.
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F2

Analysis Plan

The primary aim of the study is to determine whether the Leap Motion Controller can be
used to obtain similar tremor statistics as those obtained from a triaxial accelerometer
(Tremorometer). To do this, the three-dimensional positional data from the Leap Motion
Controller will be used to derive three-dimensional acceleration data in order to compare
it to the acceleration data obtained from the Tremorometer. To compare the data, certain
tremor statistics will be calculated and compared in MATLAB. These tremor statistics
consist of parameters obtained from a power distribution of the tremor within a certain
frequency band, some of which include the peak tremor intensity and the peak tremor
frequency along with other statistics used in previous studies.9,10,11
The secondary aim of this study is to determine whether subjects with Parkinson disease
can be classified differently from healthy patients and patients with Essential Tremor by
using positional data collected by the Leap Motion Controller. To do this, positional data
collected by the Leap Motion Controller will be imported using Java and the LeapSDK
and analyzed in MATLAB. A variety of tremor statistics will be calculated and used to
determine characteristic features that identify each group of subjects. These
characteristic features will again stem from a power distribution of the tremor and be
chosen based on how well they differentiate the different groups of subjects.

F3

Statistical Methods

The position data from the Leap Motion Controller will be converted into acceleration
data. The tremor parameters from the Tremorometer and the Leap Motion Controller will
then be obtained from the power distribution of the tremor within a certain frequency
band. The tremor parameters, such as peak frequency and amplitude, from the
Tremorometer will be compared against the tremor parameters from the Leap Motion
Controller using a Bland-Altman plot as well as a paired t-test. The position data from the
Leap Motion Controller will also be used to identify different tremor statistics that can be
used to classify subjects as Parkinson or non-Parkinson subject.

F4

Missing Outcome Data

Missing outcome data will be approached using listwise deletion, also known as
complete case analysis. If one sample of a recording does not return an acceleration or
position, that sample will be deleted from the recording. This will have virtually no effect
on the data due to the high sampling rate of the devices.

G Data Handling and Record Keeping
G1 Confidentiality and Security
Only study team members will have access to the medical record of any potential and/or
enrolled subjects. These records are password protected in the clinical movement
disorders database (MARS), which is HIPAA compliant. Any data that will be collected
will not contain any identifiers. This collected data will only be collected to and stored on
a LOK-IT Secure Flash Drive, which is automatically encrypted with military-grade 256bit AES hardware encryption, which is HIPAA compliant.
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H Study Administration
H1 Organization and Participating Centers
The coordinating site will be the Movement Disorders Clinic at the Washington University
School of Medicine with the lead PI being Matthew Johnson.

H2

Study Timetable
Portion of Study
Subject Recruitment/Data Collection
Data Analysis/Study Report
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I

Attachments

I1

Informed consent documents

FOR IRB USE ONLY
$STAMP_IRB_ID
$STAMP_APPRV_DT
$STAMP_REL_DT
$STAMP_EXP_DT

INFORMED CONSENT DOCUMENT
Project Title:

Detection of Parkinson Disease Rest Tremor

Principal Investigator:

Matthew Johnson

Research Team Contact:

Matthew Johnson: (561) 906-1671

This consent form describes the research study and helps you decide if you want to participate. It
provides important information about what you will be asked to do during the study, about the risks and
benefits of the study, and about your rights as a research participant. By signing this form you are
agreeing to participate in this study.
• If you have any questions about anything in this form, you should ask the research team for
more information.
• You may also wish to talk to your family or friends about your participation in this study.
• Do not agree to participate in this study unless the research team has answered your
questions and you decide that you want to be part of this study.
WHAT IS THE PURPOSE OF THIS STUDY?
This is a research study. We invite you to participate in this research study because you: have been
diagnosed with Parkinson Disease and have tremor as a symptom, have been diagnosed with Essential
Tremor, or are healthy with no symptoms of tremor.
The purpose of this research study is to create an algorithm that will predict, with reasonable accuracy, if
a patient has Parkinson Disease based on their rest tremor. To create this algorithm, rest tremor data will
be collected by recording the three-dimensional position and acceleration of the index finger using two
different devices. The first device, the Tremorometer, uses a three-dimensional accelerometer (a device
that measures changes in acceleration) and is cleared by the FDA to measure and quantify tremor by
measuring acceleration and calculating tremor statistics in human patients. The second device, the Leap
Motion Controller, is a three-dimensional camera that can obtain position data. The data collected and
analyzed by the Tremorometer will be compared to that of the Leap Motion Controller to determine
whether the Leap Motion Controller can be used to obtain similar results as the Tremorometer. The data
from the Leap Motion Controller will be analyzed and used to create an algorithm that can predict
whether a patient has Parkinson Disease. It is hypothesized that the Leap Motion Controller will provide
similar results as the Tremorometer and that the data from the Leap Motion Controller can be used to
create a reasonably accurate algorithm that can identify a patient with Parkinson Disease from a patient
with Essential Tremor or a healthy patient.
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FOR IRB USE ONLY
$STAMP_IRB_ID
$STAMP_APPRV_DT
$STAMP_REL_DT
$STAMP_EXP_DT

WHAT WILL HAPPEN DURING THIS STUDY?
The study will occur in an examination room behind closed doors in the movement disorders clinic
within the Washington University School of Medicine. The data that will be recorded will consist of the
position and acceleration of your fingers over time and whether you have Parkinson Disease, Essential
Tremor, or are healthy with no symptoms of tremor.
You will first be asked to allow a study member to tape a small sensor (the accelerometer from the
Tremorometer system) to your index finger on the hand that you exhibit the most symptomatic tremor.
You will then be asked to place said hand on a small slanted box and be asked to spread your fingers so
that no fingers are touching another finger. You will then be asked to allow your fingers to relax and
drape over the edge of the box, still ensuring that your fingers are not touching. Once your hand is in a
comfortable position, you will be warned that the recording will start and be asked to silently countdown
from 100. After 30 seconds, you will be told that the recording is over and the sensor will be removed.
You will then be asked to place the same hand on the small slanted box in front of the Leap Motion
Controller (a small three-dimensional camera that tracks hand and finger movements and has not yet
been used to measure hand or finger tremors.) You will again be asked to allow your fingers to relax and
drape over the edge of the box, still ensuring that no fingers are touching another finger. Once your hand
is in a comfortable position, you will be told that the recording will begin and be asked to silently
countdown from 100. After 30 seconds, you will be told that the recording is over and the you will be
finished with your participation in the study.
Will you save my samples or research data to use in future research studies?
As part of this study, we are obtaining tremor data (in the form of position and acceleration over time)
from you. By agreeing to be part of this study you give up any property rights you may have in the
tremor data. We would like to use your tremor data for other research projects in the future. These future
studies may provide additional information that will be helpful in understanding Parkinson's Disease,
but it is unlikely that what we learn from these studies will have a direct benefit to you. It is possible that
your tremor data might be used to develop tests, treatments or cures. There are no plans to provide
financial compensation to you should this occur. If you agree, this means we will store your tremor data
and may use it for studies going on right now as well as studies that are conducted in the future.
I would also like your permission to share your tremor data with other investigators doing research in
similar fields such as other diseases where tremor is a common symptom. These investigators may be at
Washington University or at other research centers. We may also share you research data with large
data repositories (a repository is a database of information) for broad sharing with the research
community. If your individual research data is placed in one of these repositories only qualified
researchers, who have received prior approval from individuals that monitor the use of the data, will be
able to look at your information.
Your tremor data will be stored without your name or any other kind of link that would enable us to
identify which data are yours. Therefore, if you give permission to store and use your tremor data, it
will be available for use in future research studies indefinitely and cannot be removed.
Version # [insert version number]
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Please place your initials in the blank next to Yes or No for each of the questions below:
My tremor data may be stored and used for future research as described above.
_____ Yes
Initials

_____ No
Initials

My tremor data may be shared with other investigators and used by these investigators for the
future research as described above.
_____ Yes
Initials

_____ No
Initials

HOW MANY PEOPLE WILL PARTICIPATE?
Approximately 30 people will take part in this study conducted by investigators at Washington
University.
HOW LONG WILL I BE IN THIS STUDY?
If you agree to take part in this study, your involvement will last for approximately 10 minutes.
WHAT ARE THE RISKS OF THIS STUDY?
You may experience one or more of the risks indicated below from being in this study. In addition to
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this
study.
Less Likely / Less Common
Mild
•
•
•

Risk 1: Attempting to hold one hand still in one position may be physically uncomfortable.
Risk 2: Become fatigued, frustrated, or bored during the recording.
Risk 3: Become stressed if you exhibit too severe of upper limb tremor to record the data.

One risk of participating in this study is that confidential information about you may be accidentally
disclosed. We will use our best efforts to keep the information about you secure, and we think the risk
of accidental disclosure is very small. Please see the section in this consent form titled “How will you
keep my information confidential?” for more information.

Version # [insert version number]
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WHAT ARE THE BENEFITS OF THIS STUDY?
You will not benefit from being in this study.
However, we hope that, in the future, other people might benefit from this study because the study may
help provide a better understanding of the characteristic features of rest tremor in Parkinsonism as well
as provide a better alternative to record and measure rest tremor that may aid in the differentiation of
Parkinsonism from Essential Tremor.
WILL IT COST ME ANYTHING TO BE IN THIS STUDY?
You will not have any additional costs for being in this research study. You and/or your
medical/hospital insurance provider will remain responsible for your regular medical care expenses.
WILL I BE PAID FOR PARTICIPATING?
You will not be paid for being in this research study.
WHO IS FUNDING THIS STUDY?
This study is not being funded.
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY?
Washington University investigators and staff will try to reduce, control, and treat any complications
from this research. If you feel you are injured because of the study, please contact the investigator at
(561) 906-1671 and/or the Human Research Protection Office at (314) 633-7400 or 1-(800)-438-0445.
Decisions about payment for medical treatment for injuries relating to your participation in research will
be made by Washington University. If you need to seek medical care for a research-related injury, please
notify the investigator as soon as possible.
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL?
We will keep your participation in this research study confidential to the extent permitted by law.
However, it is possible that other people such as those indicated below may become aware of your
participation in this study and may inspect and copy records pertaining to this research. Some of these
records could contain information that personally identifies you.
• Government representatives, (including the Office for Human Research Protections) to complete
federal or state responsibilities
• People who use the Washington University School of Medicine's Research Participant Registry
or the clinical movement disorders database (MARS)
• Hospital or University representatives, to complete Hospital or University responsibilities
• Information about your participation in this study may be documented in your health care records
Version # [insert version number]
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and be available to your health care providers who are not part of the research team.
Washington University’s Institutional Review Board (a committee that oversees the conduct of
research involving human participants.) The Institutional Review Board has reviewed and
approved this study.

To help protect your confidentiality, we will have you escorted into a separate examination room with
closed doors in the clinic, after seeing your physician. The data that will be recorded will be fully deidentified and will not include your name, date of birth, clinic number, or any other identifiable
information. The only data that will be recorded will be the positional and acceleration data of your
finger and whether or not you have Parkinson Disease. This data will only be saved on a LOK-IT Secure
Flash Drive, which is automatically encrypted with military-grade 256-bit AES hardware encryption.
This level of encryption is HIPAA compliant and ensures that the data is unreadable if the flash memory
were to be physically accessed. If we write a report or article about this study or share the study data set
with others, we will do so in such a way that you cannot be directly identified.
Are there additional protections for my health information?
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this
research, you must give the research team permission to use and disclose (share) your PHI for the study
as explained in this consent form. The research team will follow state and federal laws and may share
your health information with the agencies and people listed under the previous section titled, “How will
you keep my information confidential?”.
Once your health information is shared with someone outside of the research team, it may no longer be
protected by HIPAA.
The research team will only use and share your information as talked about in this form. When possible,
the research team will make sure information cannot be linked to you (de-identified). Once information
is de-identified, it may be used and shared for other purposes not discussed in this consent form. If you
have questions or concerns about your privacy and the use of your PHI, please contact the University’s
Privacy Officer at 866-747-4975.
Although you will not be allowed to see the study information, you may be given access to your health
care records by contacting your health care provider.
If you decide not to sign this form, it will not affect
• your treatment or the care given by your health provider.
• your insurance payment or enrollment in any health plans.
• any benefits to which you are entitled.
However, it will not be possible for you to take part in the study.
If you sign this form:
• You authorize the use of your PHI for this research
• Your signature and this form will not expire as long as you wish to participate.
Version # [insert version number]

Page 5 of 7

18

121

______________________________________________________________________________________

FOR IRB USE ONLY
$STAMP_IRB_ID
$STAMP_APPRV_DT
$STAMP_REL_DT
$STAMP_EXP_DT

•

You may later change your mind and not let the research team use or share your information
(you may revoke your authorization).
• To revoke your authorization, complete the withdrawal letter, found in the Participant section
of the Human Research Protection Office website at http://hrpo.wustl.edu (or use the direct
link: http://hrpohome.wustl.edu/participants/WithdrawalTemplate.rtf) or you may request
that the Investigator send you a copy of the letter.
o If you revoke your authorization:
! The research team may only use and share information already collected for
the study.
! Your information may still be used and shared if necessary for safety reasons.
! You will not be allowed to continue to participate in the study.

IS BEING IN THIS STUDY VOLUNTARY?
Taking part in this research study is completely voluntary. You may choose not to take part at all. If
you decide to be in this study, you may stop participating at any time. If you decide not to be in this
study, or if you stop participating at any time, you won’t be penalized or lose any benefits for which you
otherwise qualify.
What if I decide to withdraw from the study?
You may withdraw by telling the study team you are no longer interested in participating in the study or
you may send in a withdrawal letter. A sample withdrawal letter can be found at http://hrpo.wustl.edu
under Information for Research Participants.
Will I receive new information about the study while participating?
If we obtain any new information during this study that might affect your willingness to continue
participating in the study, we’ll promptly provide you with that information.
Can someone else end my participation in this study?
Under certain circumstances, the researchers might decide to end your participation in this research
study earlier than planned. This might happen because in our judgement you are exhibiting upper limb
tremor too severe to be recorded or if you have too much trouble keeping your fingers separated during
the recording.
WHAT IF I HAVE QUESTIONS?
We encourage you to ask questions. If you have any questions about the research study itself, please
contact: Matthew Johnson, (561) 906-1671. If you experience a research-related injury, please contact:
Dr. Arye Nehorai, (314) 935-5565.
If you have questions, concerns, or complaints about your rights as a research participant, please contact
the Human Research Protection Office, 660 South Euclid Avenue, Campus Box 8089, St. Louis, MO
63110, (314) 633-7400, or 1-(800)-438-0445 or email hrpo@wusm.wustl.edu. General information
about being a research participant can be found by clicking “Participants” on the Human Research
Version # [insert version number]
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Protection Office web site, http://hrpohome.wustl.edu. To offer input about your experiences as a
research subject or to speak to someone other than the research staff, call the Human Research
Protection Office at the number above.

This consent form is not a contract. It is a written explanation of what will happen during the study if
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study.
Your signature indicates that this research study has been explained to you, that your questions have
been answered, and that you agree to take part in this study. You will receive a signed and dated copy
of this form.

Do not sign this form if today’s date is after $STAMP_EXP_DT.
__________________________________________
(Signature of Participant)

_______________________________
(Date)

____________________________________________
(Participant's name – printed)

Statement of Person Who Obtained Consent
The information in this document has been discussed with the participant or, where appropriate, with the
participant’s legally authorized representative. The participant has indicated that he or she understands
the risks, benefits, and procedures involved with participation in this research study.
__________________________________________
(Signature of Person who Obtained Consent)

_______________________________
(Date)

___________________________________________
(Name of Person who Obtained Consent - printed)
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Device Documentation
The Leap Motion Controller
EU Declaration of Conformity
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Safety and Compliance

This Important Information Guide contains safety, handling,
disposal, recycling and regulatory information, as well as the
limited hardware warranty for your Leap Motion Controller.
Read all safety information and operating instructions
below before using your Leap Motion Controller to
avoid injury. For user instructions for the Leap Motion
Controller and the latest version of this Important
Information Guide visit: leapmotion.com/support

Important Safety and Handling Information
High-risk activities
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO
LIFE OR PROPERTY.
Operating environment
Operating your Leap Motion Controller outside these ranges
may affect performance:
Operating temperature: 32° to 113° F (0° to 45° C)
Storage temperature: 14 to 122° F (-10° to 50° C)
Relative humidity: 5% to 85% (non-condensing)
Operating altitude: 0 to 10,000 feet (0 to 3048 meters)
Operating your Leap Motion Controller in bright sunlight, or
where bright light sources or reflective surfaces (including
exposed metal vents) are above the device, will impact
performance. In order to improve performance, move to a less
bright or reflective environment.
For best performance, maintain a clear field of view between
your Leap Motion Controller and your hands and fingers. Loose
sleeves, large or loose jewelry, and non-transparent objects or
materials that are near the device, or between the device and
your hands, or right above your hands, may impact
performance. In addition, avoid wearing dark gloves, or using
dark or transparent instruments to use the controller.
Cleaning your Leap Motion Controller
Dust, dirt and fingerprints on the top of the device may
degrade the performance of your Leap Motion Controller.
When cleaning the outside of the device, first unplug the cable.
Then use a dry cloth to wipe the surface. Do not use
detergents, abrasive cleaners or other cleaners, which may
scratch the surface, and harm performance. Do not allow the
device to become wet.

Leap Motion Controller
Important Information Guide
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Proper handling
The surface of your Leap Motion Controller may become warm
during normal use. The Leap Motion Controller complies with
the user-accessible surface temperature limits defined by the
International Standard for Safety of Information Technology
Equipment (IEC 60950-1).
Ergonomics
When using your Leap Motion Controller, locate it so that it is
comfortable to use. Center your controller in front of your
keyboard or laptop. Adjust your chair or work surface so that
your elbows are near your side and your forearms are roughly
parallel to the floor. Your chair may need to be slightly higher
or your work surface slightly lower than usual.
You should sit at such a height so that your forearms extend at
roughly a right angle from your body to a position slightly
above your Leap Motion Controller, with your wrist and hands
in roughly a straight line. Your hands should be just above the
device, and your shoulders should be relaxed. You can rest your
forearms on your work surface, but do not rest on a sharp edge.
If you have discomfort, take a break, and when using the
controller again, change your arm posture. If you have
persistent or recurrent discomfort after use, stop use and see a
physician.
Disposal and Recycling Information
This symbol on the product (and on its packaging) is in
accordance with the European Union's Waste Electrical and
Electronic Equipment (WEEE) Directive. The symbol indicates
that this product must be recycled/disposed of separately from
other household waste. It is the end user’s responsibility to
dispose of this product by taking it to a designated WEEE
collection facility for the proper collection and recycling of the
waste equipment. The separate collection and recycling of
waste equipment will help to conserve natural resources and
protect human health and the environment. For more
information about recycling, please contact your local
environmental office, an electrical/electronic waste disposal
company or the store where you purchased the product.
Device Information
To get information about your Leap Motion Controller, use the
“About” box in your Leap Motion software. It shows you what
software is installed, the serial number, and more.
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This Important Information Guide contains safety, handling,
disposal, recycling and regulatory information, as well as the
limited hardware warranty for your Leap Motion Controller.
Read all safety information and operating instructions
below before using your Leap Motion Controller to
avoid injury. For user instructions for the Leap Motion
Controller and the latest version of this Important
Information Guide visit: leapmotion.com/support

Important Safety and Handling Information
High-risk activities
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO
LIFE OR PROPERTY.
Operating environment
Operating your Leap Motion Controller outside these ranges
may affect performance:
Operating temperature: 32° to 113° F (0° to 45° C)
Storage temperature: 14 to 122° F (-10° to 50° C)
Relative humidity: 5% to 85% (non-condensing)
Operating altitude: 0 to 10,000 feet (0 to 3048 meters)
Operating your Leap Motion Controller in bright sunlight, or
where bright light sources or reflective surfaces (including
exposed metal vents) are above the device, will impact
performance. In order to improve performance, move to a less
bright or reflective environment.
For best performance, maintain a clear field of view between
your Leap Motion Controller and your hands and fingers. Loose
sleeves, large or loose jewelry, and non-transparent objects or
materials that are near the device, or between the device and
your hands, or right above your hands, may impact
performance. In addition, avoid wearing dark gloves, or using
dark or transparent instruments to use the controller.
Cleaning your Leap Motion Controller
Dust, dirt and fingerprints on the top of the device may
degrade the performance of your Leap Motion Controller.
When cleaning the outside of the device, first unplug the cable.
Then use a dry cloth to wipe the surface. Do not use
detergents, abrasive cleaners or other cleaners, which may
scratch the surface, and harm performance. Do not allow the
device to become wet.

Proper handling
The surface of your Leap Motion Controller may become warm
during normal use. The Leap Motion Controller complies with
the user-accessible surface temperature limits defined by the
International Standard for Safety of Information Technology
Equipment (IEC 60950-1).
Ergonomics
When using your Leap Motion Controller, locate it so that it is
comfortable to use. Center your controller in front of your
keyboard or laptop. Adjust your chair or work surface so that
your elbows are near your side and your forearms are roughly
parallel to the floor. Your chair may need to be slightly higher
or your work surface slightly lower than usual.

Compliance

Software License Agreement

FCC Compliance Statement
Tested to comply with FCC standards. FOR HOME OR OFFICE
USE.

Use of the Leap Motion Controller constitutes acceptance of
the Leap Motion and third-party software license terms found
at: www.leapmotion.com/legal

This device complies with Part 15 of the FCC Rules. Operation is
subject to the following two conditions: 1) this device may not
cause harmful interference, and 2) this device must accept any
interference received, including interference that may cause
undesired operation.

Leap Motion Hardware Limited Warranty

This equipment has been tested and found to comply with the
limits for a Class B digital device, pursuant to part 15 of the FCC
Rules. These limits are designed to provide reasonable
protection against harmful interference in a residential
installation. This equipment generates, uses and can radiate
radio frequency energy. And, if not installed and used in
accordance with the instructions, may cause harmful
interference to radio communications. However, there is no
guarantee that interference will not occur in a particular
installation. If this equipment does cause harmful interference
to radio or television reception, which can be determined by
turning the equipment off and on, the user is encouraged to try
to correct the interference by one or more of the following
measures:

You should sit at such a height so that your forearms extend at
roughly a right angle from your body to a position slightly
above your Leap Motion Controller, with your wrist and hands
in roughly a straight line. Your hands should be just above the
device, and your shoulders should be relaxed. You can rest your
forearms on your work surface, but do not rest on a sharp edge.
If you have discomfort, take a break, and when using the
controller again, change your arm posture. If you have
persistent or recurrent discomfort after use, stop use and see a
physician.

-- Reorient or relocate the receiving antenna.
-- Increase the separation between the equipment and receiver.
-- Connect the equipment into an outlet on a circuit different
from that to which the receiver is connected.
-- Consult the dealer or an experienced radio/TV technician for
help.

Disposal and Recycling Information
This symbol on the product (and on its packaging) is in
accordance with the European Union's Waste Electrical and
Electronic Equipment (WEEE) Directive. The symbol indicates
that this product must be recycled/disposed of separately from
other household waste. It is the end user’s responsibility to
dispose of this product by taking it to a designated WEEE
collection facility for the proper collection and recycling of the
waste equipment. The separate collection and recycling of
waste equipment will help to conserve natural resources and
protect human health and the environment. For more
information about recycling, please contact your local
environmental office, an electrical/electronic waste disposal
company or the store where you purchased the product.

Warning: Where shielded interface cables or accessories have
been provided with the product or specified additional
components or accessories elsewhere defined to be used with
the installation of the product, they must be used in order to
ensure compliance with FCC limits. Changes or modifications to
the product not expressly approved by Leap Motion, Inc. could
void your right to use or operate your product.
Canada Compliance Statement
CAN ICES-3 (B)/NMB-3(B)
IC Statement: This Class B digital apparatus complies with
Canadian ICES – 003.
Déclaration IC: Cet appareil numérique de catégorie B est
conforme à la norme canadienne NMB-003.

Device Information
To get information about your Leap Motion Controller, use the
“About” box in your Leap Motion software. It shows you what
software is installed, the serial number, and more.

European Compliance Statement
A copy of the EU Declaration of Conformity is available at:
www.leapmotion.com/legal
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Leap Motion, Inc. (“Leap Motion” or “we”) warrants this Leap
Motion hardware product against material defects in materials
and workmanship for a period of one year from the date of
purchase (“Warranty Period”) by the original end user
purchaser (“you”). Except where prohibited by applicable law,
this warranty is nontransferable and is limited to the original
purchaser. This warranty gives you specific legal rights, and you
may also have other rights that vary under local laws.
Software distributed by Leap Motion with or without the Leap
Motion brand name (including, but not limited to, the software
that interacts with or that is pre-installed in the product) is not
covered under this limited warranty. Refer to the licensing
agreement accompanying the software for details of your
rights with respect to its use. Leap Motion does not warrant
that the operation of the product will be uninterrupted or
error-free. Leap Motion is not responsible for damage arising
from failure to follow instructions relating to the product’s use.
Remedies
If the product is determined to be materially defective during
the Warranty Period, Leap Motion will (at its option) (1) repair or
replace the product, or (2) refund the price paid, provided that
the product is returned to the point of purchase or such other
place as Leap Motion may direct with a copy of the sales receipt
or dated itemized receipt. Shipping and handling charges may
apply except where prohibited by applicable law. Leap Motion
may, at its option, use new or refurbished or used parts in good
working condition to repair or replace any product. Any
replacement product will be warranted for the remainder of the
original warranty period or thirty (30) days, whichever is longer
or for any additional period of time that may be applicable in
your jurisdiction.
This warranty does not cover problems or damage resulting
from (1) accident, abuse, misapplication, or any unauthorized
repair, modification or disassembly; (2) improper operation or
maintenance, usage not in accordance with product
instructions or connection to improper voltage supply; (3) use
of cables or other equipment not supplied by Leap Motion; or
(4) other causes that are not defects in material and
workmanship except where such restriction is prohibited by
applicable law. This warranty additionally does not cover
products marked as “sample” or sold “AS IS”.
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Compliance

Software License Agreement

FCC Compliance Statement
Tested to comply with FCC standards. FOR HOME OR OFFICE
USE.

Use of the Leap Motion Controller constitutes acceptance of
the Leap Motion and third-party software license terms found
at: www.leapmotion.com/legal

This device complies with Part 15 of the FCC Rules. Operation is
subject to the following two conditions: 1) this device may not
cause harmful interference, and 2) this device must accept any
interference received, including interference that may cause
undesired operation.

Leap Motion Hardware Limited Warranty

This equipment has been tested and found to comply with the
limits for a Class B digital device, pursuant to part 15 of the FCC
Rules. These limits are designed to provide reasonable
protection against harmful interference in a residential
installation. This equipment generates, uses and can radiate
radio frequency energy. And, if not installed and used in
accordance with the instructions, may cause harmful
interference to radio communications. However, there is no
guarantee that interference will not occur in a particular
installation. If this equipment does cause harmful interference
to radio or television reception, which can be determined by
turning the equipment off and on, the user is encouraged to try
to correct the interference by one or more of the following
measures:
-- Reorient or relocate the receiving antenna.
-- Increase the separation between the equipment and receiver.
-- Connect the equipment into an outlet on a circuit different
from that to which the receiver is connected.
-- Consult the dealer or an experienced radio/TV technician for
help.
Warning: Where shielded interface cables or accessories have
been provided with the product or specified additional
components or accessories elsewhere defined to be used with
the installation of the product, they must be used in order to
ensure compliance with FCC limits. Changes or modifications to
the product not expressly approved by Leap Motion, Inc. could
void your right to use or operate your product.
Canada Compliance Statement
CAN ICES-3 (B)/NMB-3(B)
IC Statement: This Class B digital apparatus complies with
Canadian ICES – 003.
Déclaration IC: Cet appareil numérique de catégorie B est
conforme à la norme canadienne NMB-003.
European Compliance Statement
A copy of the EU Declaration of Conformity is available at:
www.leapmotion.com/legal

How to Obtain Warranty Support
Before submitting a warranty claim, we recommend you visit
the support section at www.leapmotion.com for technical
assistance. Valid warranty claims are generally processed
through the point of purchase during the first 30 days after
purchase; however, this period of time may vary depending on
where you purchased your product – please check with Leap
Motion or the retailer where you purchased your product for
details. Warranty claims that cannot be processed through the
point of purchase and any other product related questions
should be addressed directly to Leap Motion. The addresses
and customer service contact information for Leap Motion can
be found in the documentation accompanying your product
and on the web at: www.leapmotion.com/support

Leap Motion, Inc. (“Leap Motion” or “we”) warrants this Leap
Motion hardware product against material defects in materials
and workmanship for a period of one year from the date of
purchase (“Warranty Period”) by the original end user
purchaser (“you”). Except where prohibited by applicable law,
this warranty is nontransferable and is limited to the original
purchaser. This warranty gives you specific legal rights, and you
may also have other rights that vary under local laws.

Limitation of Liability
LEAP MOTION WILL NOT BE LIABLE FOR ANY SPECIAL, DIRECT,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES
WHATSOEVER ARISING FROM THE USE OR SERVICE OF THE
PRODUCT. IN ADDITION, LEAP MOTION WILL NOT BE LIABLE
FOR ANY LOSS OF PROFITS, REVENUE OR DATA (WHETHER
DIRECT OR INDIRECT) OR COMMERCIAL LOSS FOR BREACH OF
ANY EXPRESS OR IMPLIED WARRANTY ON YOUR PRODUCT
EVEN IF LEAP MOTION HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES. EXCEPT WHERE PROHIBITED BY LAW, THE
WARRANTY AND REMEDIES DESCRIBED ARE EXCLUSIVE AND IN
LIEU OF ALL OTHER WARRANTIES, REMEDIES, AND
CONDITIONS, WHETHER ORAL, WRITTEN, EXPRESS, STATUTORY
OR IMPLIED. Any recovery is limited to repair, replacement, or
refund as described above. Some jurisdictions do not allow the
exclusion or limitation of special, indirect, incidental or
consequential damages, so the above limitation or exclusion
may not apply to you.
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO
LIFE OR PROPERTY. THIS WARRANTY WILL NOT APPLY IF THE
PRODUCT IS USED IN SUCH A MANNER. ANY SUCH USE IS
ENTIRELY AT THE USER’S DISCRETION AND RISK. ANY SUCH
USER WILL BE SOLELY RESPONSIBLE FOR (AND LEAP MOTION
DISCLAIMS) ANY AND ALL LOSS, LIABILITY, OR DAMAGES
RESULTING FROM SUCH USE.

Software distributed by Leap Motion with or without the Leap
Motion brand name (including, but not limited to, the software
that interacts with or that is pre-installed in the product) is not
covered under this limited warranty. Refer to the licensing
agreement accompanying the software for details of your
rights with respect to its use. Leap Motion does not warrant
that the operation of the product will be uninterrupted or
error-free. Leap Motion is not responsible for damage arising
from failure to follow instructions relating to the product’s use.
Remedies
If the product is determined to be materially defective during
the Warranty Period, Leap Motion will (at its option) (1) repair or
replace the product, or (2) refund the price paid, provided that
the product is returned to the point of purchase or such other
place as Leap Motion may direct with a copy of the sales receipt
or dated itemized receipt. Shipping and handling charges may
apply except where prohibited by applicable law. Leap Motion
may, at its option, use new or refurbished or used parts in good
working condition to repair or replace any product. Any
replacement product will be warranted for the remainder of the
original warranty period or thirty (30) days, whichever is longer
or for any additional period of time that may be applicable in
your jurisdiction.
This warranty does not cover problems or damage resulting
from (1) accident, abuse, misapplication, or any unauthorized
repair, modification or disassembly; (2) improper operation or
maintenance, usage not in accordance with product
instructions or connection to improper voltage supply; (3) use
of cables or other equipment not supplied by Leap Motion; or
(4) other causes that are not defects in material and
workmanship except where such restriction is prohibited by
applicable law. This warranty additionally does not cover
products marked as “sample” or sold “AS IS”.

Duration of Implied Warranties
EXCEPT TO THE EXTENT PROHIBITED BY APPLICABLE LAW, LEAP
MOTION DISCLAIMS ALL IMPLIED AND STATUTORY
WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY
AND FITNESS FOR A PARTICULAR PURPOSE. ANY IMPLIED
WARRANTY OR CONDITION OF MERCHANTABILITY OR FITNESS
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FOR A PARTICULAR PURPOSE ON THE PRODUCT IS LIMITED IN
DURATION TO THE DURATION OF THE WARRANTY PERIOD
ABOVE. Some jurisdictions do not allow limitations on how
long an implied warranty lasts, or do not allow exclusions or
limitations on certain damages, including damages for death or
personal injury caused by negligence, so the above limitation
may not apply to you.
National Statutory Rights
Consumers in some jurisdictions may have legal rights
under applicable national legislation governing the sale of
consumer goods. These rights are not affected by the
warranties in this limited warranty.
No Other Warranties
No Leap Motion dealer, agent, or employee is authorized to
make any modification, extension, or addition to this warranty.
Your seller is solely responsible for any other warranties.

Service and Support
Your Leap Motion Controller does not contain any
user-serviceable parts. If you need service, contact Leap Motion
at one of the numbers below. Helpful information is also
available on our website at:
www.leapmotion.com/support
Within the United States: 1-866-745-4609 (toll-free).
Outside the United States: +1-415-692-3860 (carrier charges
apply - please contact your telecom service provider for
details).
The hours our customer support is available may be found at:
www.leapmotion.com/support
Leap Motion Address
Leap Motion, Inc.
333 Bryant Street, Ste LL 150
San Francisco CA 94107
USA
EU fiscal representative office:
CTPark BrnoTuřanka 110 627 00 Brno-Slatina
Czech Republic

46-0006
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How to Obtain Warranty Support
Before submitting a warranty claim, we recommend you visit
the support section at www.leapmotion.com for technical
assistance. Valid warranty claims are generally processed
through the point of purchase during the first 30 days after
purchase; however, this period of time may vary depending on
where you purchased your product – please check with Leap
Motion or the retailer where you purchased your product for
details. Warranty claims that cannot be processed through the
point of purchase and any other product related questions
should be addressed directly to Leap Motion. The addresses
and customer service contact information for Leap Motion can
be found in the documentation accompanying your product
and on the web at: www.leapmotion.com/support
Limitation of Liability
LEAP MOTION WILL NOT BE LIABLE FOR ANY SPECIAL, DIRECT,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES
WHATSOEVER ARISING FROM THE USE OR SERVICE OF THE
PRODUCT. IN ADDITION, LEAP MOTION WILL NOT BE LIABLE
FOR ANY LOSS OF PROFITS, REVENUE OR DATA (WHETHER
DIRECT OR INDIRECT) OR COMMERCIAL LOSS FOR BREACH OF
ANY EXPRESS OR IMPLIED WARRANTY ON YOUR PRODUCT
EVEN IF LEAP MOTION HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES. EXCEPT WHERE PROHIBITED BY LAW, THE
WARRANTY AND REMEDIES DESCRIBED ARE EXCLUSIVE AND IN
LIEU OF ALL OTHER WARRANTIES, REMEDIES, AND
CONDITIONS, WHETHER ORAL, WRITTEN, EXPRESS, STATUTORY
OR IMPLIED. Any recovery is limited to repair, replacement, or
refund as described above. Some jurisdictions do not allow the
exclusion or limitation of special, indirect, incidental or
consequential damages, so the above limitation or exclusion
may not apply to you.
THE PRODUCT IS NOT INTENDED FOR CONTROL, WHETHER
DIRECT OR INDIRECT, OF OR USE WITH INDUSTRIAL OR
MEDICAL EQUIPMENT OF ANY TYPE, AND IS NOT INTENDED
FOR ANY USE WHERE FAILURE OR FAULT OF THE PRODUCT
COULD DIRECTLY OR INDIRECTLY CAUSE RISK OR DAMAGE TO
LIFE OR PROPERTY. THIS WARRANTY WILL NOT APPLY IF THE
PRODUCT IS USED IN SUCH A MANNER. ANY SUCH USE IS
ENTIRELY AT THE USER’S DISCRETION AND RISK. ANY SUCH
USER WILL BE SOLELY RESPONSIBLE FOR (AND LEAP MOTION
DISCLAIMS) ANY AND ALL LOSS, LIABILITY, OR DAMAGES
RESULTING FROM SUCH USE.

FOR A PARTICULAR PURPOSE ON THE PRODUCT IS LIMITED IN
DURATION TO THE DURATION OF THE WARRANTY PERIOD
ABOVE. Some jurisdictions do not allow limitations on how
long an implied warranty lasts, or do not allow exclusions or
limitations on certain damages, including damages for death or
personal injury caused by negligence, so the above limitation
may not apply to you.
National Statutory Rights
Consumers in some jurisdictions may have legal rights
under applicable national legislation governing the sale of
consumer goods. These rights are not affected by the
warranties in this limited warranty.
No Other Warranties
No Leap Motion dealer, agent, or employee is authorized to
make any modification, extension, or addition to this warranty.
Your seller is solely responsible for any other warranties.

Service and Support
Your Leap Motion Controller does not contain any
user-serviceable parts. If you need service, contact Leap Motion
at one of the numbers below. Helpful information is also
available on our website at:
www.leapmotion.com/support
Within the United States: 1-866-745-4609 (toll-free).
Outside the United States: +1-415-692-3860 (carrier charges
apply - please contact your telecom service provider for
details).
The hours our customer support is available may be found at:
www.leapmotion.com/support
Leap Motion Address
Leap Motion, Inc.
333 Bryant Street, Ste LL 150
San Francisco CA 94107
USA
EU fiscal representative office:
CTPark BrnoTuřanka 110 627 00 Brno-Slatina
Czech Republic

Duration of Implied Warranties
EXCEPT TO THE EXTENT PROHIBITED BY APPLICABLE LAW, LEAP
MOTION DISCLAIMS ALL IMPLIED AND STATUTORY
WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY
AND FITNESS FOR A PARTICULAR PURPOSE. ANY IMPLIED
WARRANTY OR CONDITION OF MERCHANTABILITY OR FITNESS

46-0006
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Tremorometer 510(k) Summary
510k Summary
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I3
3.a

Device Tracking Forms
Leap Motion
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3.b

Tremorometer
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I4

Miscellaneous

4.a

Mini-Mental Status Exam

Mini-Mental State Examination (MMSE)
Patient’s Name:

Date:

Instructions: Score one point for each correct response within each question or activity.
Maximum
Score

Patient’s
Score

Questions

5

“What is the year? Season? Date? Day? Month?”

5

“Where are we now? State? County? Town/city? Hospital? Floor?”

3

The examiner names three unrelated objects clearly and slowly, then
the instructor asks the patient to name all three of them. The patient’s
response is used for scoring. The examiner repeats them until patient
learns all of them, if possible.

5

“I would like you to count backward from 100 by sevens.” (93, 86, 79,
72, 65, …)
Alternative: “Spell WORLD backwards.” (D-L-R-O-W)

3

“Earlier I told you the names of three things. Can you tell me what
those were?”

2

Show the patient two simple objects, such as a wristwatch and a pencil,
and ask the patient to name them.

1

“Repeat the phrase: ‘No ifs, ands, or buts.’”

3

“Take the paper in your right hand, fold it in half, and put it on the floor.”
(The examiner gives the patient a piece of blank paper.)

1

“Please read this and do what it says.” (Written instruction is “Close
your eyes.”)

1

“Make up and write a sentence about anything.” (This sentence must
contain a noun and a verb.)
“Please copy this picture.” (The examiner gives the patient a blank
piece of paper and asks him/her to draw the symbol below. All 10
angles must be present and two must intersect.)

1

30

TOTAL

33
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Interpretation of the MMSE:
Method

Score

Single Cutoff

<24

Abnormal

<21

Increased odds of dementia

>25

Decreased odds of dementia

21

Abnormal for 8th grade education

<23

Abnormal for high school education

<24

Abnormal for college education

Range

Education

Severity

Interpretation

24-30

No cognitive impairment

18-23

Mild cognitive impairment

0-17

Severe cognitive impairment

Interpretation of MMSE Scores:
Score

Degree of
Impairment

Formal Psychometric
Assessment

Day-to-Day Functioning

25-30

Questionably
significant

If clinical signs of cognitive impairment
are present, formal assessment of
cognition may be valuable.

May have clinically significant but mild
deficits. Likely to affect only most
demanding activities of daily living.

20-25

Mild

Formal assessment may be helpful to
better determine pattern and extent of
deficits.

Significant effect. May require some
supervision, support and assistance.

10-20

Moderate

Formal assessment may be helpful if
there are specific clinical indications.

Clear impairment. May require 24-hour
supervision.

0-10

Severe

Patient not likely to be testable.

Marked impairment. Likely to require
24-hour supervision and assistance
with ADL.

Source:
•

Folstein MF, Folstein SE, McHugh PR: “Mini-mental state: A practical method for grading the cognitive
state of patients for the clinician.” J Psychiatr Res 1975;12:189-198.
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